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Globally over 2.8 million children aged between 0-18 years were living with HIV 
in 2019. ART substantially reduces mortality but the pre-requisite step for 
accessing treatment is HIV diagnosis. Coverage of HIV treatment in children has 
lagged behind when compared to adults largely because of delayed diagnosis. 
Children experience unique challenges to access HIV testing. Existing strategies 
for paediatric HIV testing, which largely are similar to those used for adults, have 
not been effective in addressing the HIV diagnosis gap in children. Index-linked 
HIV testing (HIV testing offered to household members and sexual contacts of 
individuals living with HIV) for children and adolescents may improve HIV 
testing uptake and have high HIV yield. Offering index-linked HIV testing for 
children and adolescents in both facility and community settings may be an 
effective strategy to help bridge the HIV testing gap. The aim of this research was 
to evaluate facility and community-based approaches for index-linked HIV 
testing for children and adolescents aged 2-18 years in Zimbabwe.  
This PhD combined mixed methods research in the city of Bulawayo and in 
Matabeleland South province between January 2018 and May 2019. Overall, 
2870 index patients had 6062 children who were eligible for HIV testing in their 
households. Indexes were offered a choice of facility-based or community-based 
HIV testing (either home-based HIV testing by a health provider or an oral 
mucosal transudate (OMT) HIV test kit given to a caregiver to test their 
child(ren)). HIV testing was accepted for 5326 (87.9%) children, and 3638 
children were tested (60.0% HIV testing uptake). The HIV prevalence and yield 
were 1.1% and 0.6% respectively. Older children and adolescents were less likely 
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to be tested when compared to children aged 2-5 years. Children had increased 
odds of being tested if community-based HIV testing was chosen over facility-
based HIV testing. There was inadequate emphasis on paediatric HIV in routine 
HIV care which had a negative impact on subsequent uptake of HIV testing for 
children. Once the decision to test had been made, access to facilities was 
sometimes challenging and alleviated by community-based HIV testing. 
OMT tests, although previously validated for HIV testing in adults and widely 
used in HIVST for adults had not been validated for HIV testing in children <12 
years. In this research, OMT sensitivity was 100% [97.5% CI: 94.9% to 100%]) 
and specificity was 99.9% [95% CI: 99.6% to 100.0%] among children aged 2-18 
years when compared to national HIV testing algorithms. A further application of 
OMT testing evaluated as part of this research was caregiver’s ability to test their 
children for HIV and interpret test results. Overall, most caregivers correctly 
collected oral fluid (87.1% without provider demonstrations and 96.8% with 
demonstrations from a provider, p=0.002).  
The HIV yield was low when compared with blanket HIV testing approaches in 
similar settings. There is a need to improve messaging on the importance of HIV 
testing for children and adolescents and to provide support to caregivers and 
their families in order to increase HIV testing uptake. Addressing access barriers 
through the provision of community-based HIV testing can optimise index-linked 
HIV testing. Caregiver-provided testing using OMTs is a feasible and accurate HIV 
testing strategy for children and can also be used to improve uptake of HIV 
testing for children.  
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1. Introduction  
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1.1 Background  
Globally over 2.8 million children aged between 0-18 years were living with HIV 
in 2019.1 Prevention of Mother-to-Child Transmission (PMTCT) programmes 
have been rapidly scaled up over the last decade.2 PMTCT programmes include 
HIV testing for pregnant mothers, provision of antiretroviral therapy (ART) and 
HIV testing for HIV exposed infants (early infant diagnosis (EID)). In 2010 global 
coverage of pregnant mothers receiving ART was only 46%, but this had 
increased to 92% by 2018.2   
Although PMTCT programmes have been successful in reducing mother to child 
transmission of HIV (MTCT) there is geographical heterogeneity in PMTCT 
coverage; for example in 2018 within the Eastern and Southern Africa region ART 
coverage among HIV positive pregnant mothers in Angola was only 38% while 
coverage in Botswana was >95%.2 Poor access and adherence to ART among 
pregnant and breastfeeding mothers results in continued MTCT. 
Gaps in EID are substantial and result in many children with HIV not being 
diagnosed and starting ART until later childhood. In 2018 only 68% of infants 
born to mothers living with HIV were tested within 6 weeks of birth globally.2 In 
2019 global ART coverage among children aged (0-14 years) was only 53%.3 HIV 
testing is the critical first step to accessing HIV treatment and the low coverage 
of ART among children is primarily due to delayed HIV diagnosis.  
A key HIV testing strategy recommended by the World Health Organization 
(WHO) since 2007 is provider-initiated testing and counselling (PITC) whereby 
HIV testing is offered to all individuals presenting to health facilities regardless 
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of the reason for presentation.4 However, this strategy has been challenging to 
implement. One study in Zimbabwe where the approach of PITC was optimised 
by moving from an opt-in to an opt-out approach, with the use of additional staff 
and maintaining test kit supply chains, showed 35% of children living with HIV 
were still undiagnosed in a community prevalence survey conducted after two 
years of providing PITC in the study facilities.5 
A limitation of PITC in children is that caregivers and providers often perceive 
children to be at low risk of being HIV-infected if they have survived infancy. This 
is likely to be due to the very high rates of mortality among infants observed in 
the pre-ART which led to the assumption that survival beyond early childhood 
with HIV was exceptional. Therefore HIV testing of children who survive infancy 
has often not been prioritised by paediatric HIV programmes.6-8 Furthermore, 
the lower HIV prevalence and subsequently the low HIV yield among children 
means blanket HIV testing approaches such as PITC may not be the most efficient 
nor cost-effective, particularly in resource-constrained settings.6-8 Health 
facilities are often inaccessible to children due to opening hours that compete 
with school times and in addition, HIV testing for children also requires parental 
consent which is often difficult to navigate for health providers in settings where 
many children are orphaned and present to facilities with caregivers who are not 
their biological parents.6-8 These limitations and challenges with facility-based 
PITC for children highlight the need for HIV testing strategies that are tailored 
for this population group. 
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1.2 Research starting points  
Index-linked HIV testing (HIV testing offered to household members and sexual 
contacts of individuals living with HIV) was recommended by WHO in 2015 as an 
HIV testing strategy to identify sexual partners and children of people living with 
HIV with undiagnosed HIV.9 For sexual contacts this targeted strategy has been 
proven to have higher yields of undiagnosed HIV and is more cost effective when 
compared to blanket HIV testing approaches.10-12 Although evaluated for sexual 
contacts, there was scarce data on the uptake and yield of index-linked HIV 
testing for children and adolescents.11,13 
 In addition to index-linked HIV testing WHO also recommended the use of 
community-based HIV testing strategies to expand HIV testing access and 
identify more individuals living with undiagnosed HIV in high prevalence 
settings.9 These community strategies include door-to-door HIV testing to reach 
all people in a geographical area, mobile clinics, events based HIV testing, 
workplace HIV testing and HIV testing campaigns.14  Key among community-
based HIV testing strategies is HIV self-testing (HIVST) whereby adults can use 
oral mucosal transudate tests (OMTs) to perform HIV testing on themselves.15 
These strategies have been shown to increase awareness of HIV testing and also 
increase the rates of people who test for the first time.16 Notably, OMT tests were 
not validated for children <12 years.  
1.3 Rationale of the study  
Diagnosing HIV and starting ART early in children has been shown to 
significantly improve morbidity and mortality.17,18 The CHER trial which was 
conducted in South Africa showed that early HIV diagnosis and initiation on ART 
  5
reduced early infant mortality by 76%.17 However, a 2018 cohort analysis of data 
from 25 countries in SSA found the median age to start ART among children born 
between 1994-2005 was 7.8 years in LMIC and 7.3 years in upper-middle income 
countries within the region.19 
HIV testing is the first step in the HIV cascade.2 Children living with undiagnosed 
HIV continue to be missed by the current HIV testing strategies. The development 
and evaluation of novel and effective HIV testing strategies to optimise the 
identification of children with undiagnosed HIV is the first step to successful 
control of HIV.  
Index-linked HIV testing for children and adolescents may improve HIV testing 
uptake and have high HIV yield. Offering index-linked HIV testing for children 
and adolescents in both facility and community settings may be an effective 
strategy to help bridge the HIV testing gap. Furthermore, investigating the 
barriers and facilitators of index-linked HIV testing for children and adolescents 
can support in improving implementation and operationalization of this strategy. 
1.4 Research aims and objectives  
The aim of this research was to evaluate approaches for index-linked HIV testing 
for children and adolescents (aged 2-18 years), through a mixed methods 
research.  
The study objectives were to:  
1. Evaluate the acceptability, uptake and yield of an index-linked HIV testing 
strategy (HIV testing offered to children living in households with an 
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individual living with HIV) offered in facility and community-based 
settings. 
2. Explore provider and caregiver perceptions and experiences of index-
linked HIV testing for children and adolescents. 
3. Evaluate the diagnostic accuracy of the oral mucosal transudate HIV test 
for children and adolescents.  
4. Assess the feasibility and accuracy of caregiver provided HIV testing for 
children and adolescents. 
The research was conducted as part of the Bridging the Gap in HIV testing and 
care for children in Zimbabwe (B-GAP) project, which aimed to evaluating index-
linked HIV testing for children as well as a community-based support 
intervention for children who test HIV positive. This thesis is based on the HIV 
testing component of the B-GAP project.  
1.5 Thesis outline  
This thesis follows the “research paper style” in accordance with the London 
School of Hygiene and Tropical Medicine (LSHTM) guidelines. As such the thesis 
is made up of six manuscripts that have been published. The outline of the 
chapters is as follows:  
Chapter 1 (this chapter) contains an overview of the research background, gaps 
in knowledge, study rationale, the research aim and objectives and the outline of 
the thesis.  
Chapter 2 provides a review of the literature on HIV, the epidemiology of 
paediatric HIV, the evolution of PMTCT programming and the barriers to HIV 
testing for children and adolescents. This chapter includes Research Paper 1, a 
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review published by Current Opinion in HIV and AIDS in 2018 summarising the 
barriers and strategies for HIV testing for adolescents in Sub-Saharan Africa.20 
The title of the paper is “Barriers to, and emerging strategies for, HIV testing 
among adolescents in sub-Saharan Africa”. In addition, this chapter also provides 
an overview of the HIV epidemic in Zimbabwe.  
Citation (Research Paper 1): Chikwari CD, Dringus S, Ferrand RA. Barriers to, 
and emerging strategies for, HIV testing among adolescents in sub-Saharan 
Africa. Curr Opin HIV AIDS 2018; 13(3): 257-64.  
Chapter 3 is a published protocol paper describing the methods used in this 
research. The paper is titled “Evaluating the effectiveness and cost-effectiveness of 
health facility-based and community-based index-linked HIV testing strategies for 
children: protocol for the B-GAP study” and was published by BMJ Open.21 In 
addition to this chapter the methods specific to individual studies are described 
in the respective chapters in which each study is included.  
Citation (Research Paper 2): Dziva Chikwari C, Simms V, Dringus S, Kranzer K, 
Bandason T, Vasantharoopan A, Chikodzore R, Sibanda E, Mutseta M, Webb K, 
Engelsmann B, Ncube G, Mujuru H, Apollo T, Weiss HA, Ferrand R. Evaluating the 
effectiveness and cost-effectiveness of health facility-based and community-
based index-linked HIV testing strategies for children: protocol for the B-GAP 
study in Zimbabwe. BMJ Open 2019;9: e029428. doi: 10.1136/bmjopen-2019-
029428  
Chapter 4 is a published research paper comparing uptake of facility vs 
community-based index-linked HIV testing strategies and the overall uptake and 
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yield of index-linked HIV testing for children and adolescents. The paper is titled 
“Comparison of Index-linked HIV testing for children and adolescents in health 
facility and community-based settings in Zimbabwe: Findings from the 
interventional B-GAP study” and was published in the Lancet HIV.22  
Citation (Research Paper 3): Dziva Chikwari C, Simms V, Kranzer K, Dringus S, 
Chikodzore R, Sibanda E, Webb K, Engelsmann B, Redzo N, Bandason T, Mujuru 
H, Apollo T, Ncube G, Hatzold K, Weiss HA, Ferrand RA. Comparison of index-
linked HIV testing for children and adolescents in health facility and community 
settings in Zimbabwe: findings from the interventional B-GAP study. Lancet HIV. 
2020. 
Chapter 5 is a published research paper in Implementation Science 
Communications. This manuscript evaluates the provider and caregiver 
perspectives of index-linked HIV testing in order to identify barriers to uptake 
and ways through which implementation of index-linked HIV testing can be 
improved. It is titled “Addressing the challenges and relational aspects of index-
linked HIV testing for children and adolescents: insights from the B-GAP study in 
Zimbabwe”.23  
Citation (Research Paper 4): Dziva Chikwari C, Bernays S, Dringus S, Simms V, 
Weiss HA, Sibanda E, Kranzer K, Ncube G, Chikodzore R, Webb K, Chirimambowa 
T, Sithole K, Ndondo N, Apollo T, Mutseta M, Ferrand RA: Addressing the 
challenges and relational aspects of index-linked HIV testing for children and 
adolescents: insights from the B-GAP study in Zimbabwe. Implementation 
Science Communications 2020, 1:99 
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Chapter 6 is a brief report titled “Diagnostic Accuracy of Oral Mucosal Transudate 
Tests Compared with Blood-Based Rapid Tests for HIV Among Children Aged 18 
Months to 18 Years in Kenya and Zimbabwe”.24 This report was published in the 
Journal of Acquired Immune Deficiency Syndromes (JAIDS) and assesses the 
sensitivity and specificity of the oral HIV test in children and adolescents when 
compared to the national HIV testing algorithms.  
Citation (Research Paper 5): Dziva Chikwari C, Njuguna IN, Neary J, Rainer C, 
Chihota B, Slyker JA, Katz DA, Wamalwa DC, Oyiengo L, Bandason T, McHugh G, 
Dauya E, Mujuru H, Stewart KA, John-Stewart GC, Ferrand RA, Wagner AD. Brief 
Report: Diagnostic Accuracy of Oral Mucosal Transudate Tests Compared with 
Blood-Based Rapid Tests for HIV Among Children Aged 18 Months to 18 Years in 
Kenya and Zimbabwe. Journal of acquired immune deficiency syndromes (1999) 
2019; 82(4): 368-72.  
Chapter 7 is a manuscript also published in JAIDS and is titled, “Feasibility and 
Accuracy of HIV testing of children by caregivers using oral mucosal transudate HIV 
tests.” The manuscript evaluates caregiver’s ability to accurately perform oral 
HIV testing on their children and caregiver’s ability interpret the oral HIV test 
results either with or without prior provider demonstrations. 
Citation (Research Paper 6): Dziva Chikwari C, Simms V, Kranzer K, Dringus S, 
Chikodzore R, Sibanda E, Webb K, Redzo N, Mujuru H, Apollo T, Ncube G, Hatzold 
K, Bernays S, Weiss HA, Ferrand RA. Feasibility and Accuracy of HIV testing of 
children by caregivers using oral mucosal transudate HIV tests. Journal of 
acquired immune deficiency syndromes (in Press).  
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Chapter 8 is a discussion of all the study findings, strengths and limitations of 
the research, the implications of this research, conclusions and 
recommendations for future research for the implementation of index-linked HIV 
testing for children and adolescents.  
1.6 Contribution of the author  
I was responsible for the development of the study protocol based on a 4-page 
grant proposal prepared by Professor Ferrand. Under the supervision of 
Professor Ferrand and Dr Simms, I designed the study methods, outcomes, data 
collection tools, topic guides and standard operating procedures. I applied for all 
the ethical approvals for the study in Zimbabwe and at LSHTM.  
I recruited, trained and supervised all the research assistants that enrolled 
participants into the study and collected both the quantitative and qualitative 
data. The study database was managed by Tsitsi Bandason and Nicol Redzo who 
also did the data cleaning. I prepared the analytical plans and performed the data 
analysis for all the publications in this thesis with support from Dr Simms 
(quantitative analysis) and Dr Bernays (qualitative analysis).  
I wrote the complete drafts of all the research papers included in this thesis, was 
responsible for submission to the journals and responding to the reviewer 
comments.  
1.7 Funding  
The B-GAP project was funded by the UK Medical Research Council and I was 
supported by the LSHTM Capacity Strengthening Research Degrees scheme in 
collaboration with the Biomedical Research and Training Institute in Zimbabwe.  
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2.1 Introduction  
The following chapter presents a narrative review of HIV among children and 
adolescents including HIV transmission among children, HIV testing methods, 
gaps and barriers to HIV testing for children and adolescents as well as a 
narrative of the setting in which this research was conducted, Zimbabwe. A 
narrative review was selected instead of a systematic literature review as it used 
as a background to the overall doctoral project.  Chapters 2-7 of this thesis are 
published manuscripts and as such focus on specific components of index-linked 
HIV testing in relation to the research question addressed by the respective 
manuscript. The aim of this chapter and the narrative review which is embedded 
in it is to provide an overall background to the thesis. The specific aim of the 
narrative review is to understand the current landscape for HIV diagnosis of 
children and adolescents and what strategies have been used to address 
HIV testing gaps for this age group. Given that the review was conducted to 
describe the broad landscape around paediatric HIV testing, a systematic review 
approach (which would have focused on a specific outcome) was not used.  The 
methods used in developing this narrative review included a breakdown of the 
review into relevant sections (subtopics) and a search of relevant literature in 
each subtopic on PubMed and Google Scholar. Two critical limitations of this 
strategy were that the search was conducted only by me, and this literature 
search was conducted in a non-systematic manner, which may have missed some 
key publications.  
  15
2.2 HIV infection  
The HIV epidemic was identified in the United States in 1981. A cluster of cases 
of unusual tumours and opportunistic infections (Kaposi’s sarcoma and 
Pneumocystis pneumonia) in previously well homosexual men was subsequently 
recognised as being due to a new form of acquired immune deficiency syndrome 
(AIDS).1,2  
Epidemiological investigations indicated that the disease was sexually 
transmitted and could also be acquired from administration of infected blood 
products and exposure to contaminated needles.3,4  HIV was identified as being 
the cause of AIDS in 1983, and the development of a serological test to identify 
HIV infection in 1984 was followed by the discovery that AIDS was not only a 
“western” disease but also occurring in the heterosexual population of central 
African countries.5  In Kinshasa, Democratic Republic of Congo (DRC), the annual 
number of cases of Kaposi’s sarcoma diagnosed in a large public sector hospital 
tripled from 1970 to 1984, and epidemic increases in the wasting syndrome 
(termed “Slim disease”), a sentinel marker of AIDS, were noted in the late 1970s 
in Uganda and DRC.6,7  HIV is now recognised to have originated in Africa, which 
remains the worst affected continent.  
HIV causes depletion of CD4+ T-cells, the central mediators of the human 
immune response, by entering and replicating within the CD4+ T-cells and 
consequently causing CD4+ T-cell destruction and depletion.8,9 The depletion of 
CD4+ T-cells results in immune deficiency causing an increased frequency of 
opportunistic infections among those infected.32 If untreated, HIV leads to AIDS, 
a syndrome of advanced HIV infection and ultimately results in death.10 
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The epidemiology of HIV infection is heterogeneous with substantial local, 
national and regional variations. Some parts of the world have experienced 
concentrated HIV epidemics (general population HIV prevalence <1% but HIV 
prevalence >5% in at least one high risk sub-population e.g., sex workers or men 
who have sex with men) such as in Latin America, the Middle East and Europe. 
Other regions such as within parts of southern and eastern Africa have 
experienced generalised HIV epidemics  (general population HIV prevalence 
>1%).11 Sub-Saharan Africa (SSA) is the epicentre of the HIV pandemic and in 
2019 over 70% of the total number of people with HIV globally were living in 
SSA.8,12 Additionally, in the 2017 Global Burden of Disease study, HIV was the 
leading cause of morbidity and mortality in SSA among children and adults.13 
Within the southern African region, in 2018 Eswatini had the highest HIV 
prevalence (27.4%) among adults aged 15-49 years.14  
HIV transmission occurs in three ways; through unprotected sexual (vaginal or 
anal) intercourse, from blood products or from an infected mother to her child.15 
In part the disproportionally high HIV prevalence in SSA has been attributed to 
high prevalence of ulcerative sexually transmitted infections (STIs) and multiple 
concurrent sexual partnerships.16,17 Heterosexual transmission is the 
predominant mode of transmission in SSA with an associated epidemic in 
children as result of vertical (mother-to-child) transmission in countries with 
generalised HIV epidemics.16,18  
2.3 HIV diagnosis 
There are two types of HIV diagnostic approaches -either using viral detection or 
antibody detection methods. The first HIV antibody tests were available in 1985, 
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which were laboratory based. Subsequently, rapid, point-of-care blood-based 
tests were developed with results available within 20 minutes, enabling HIV 
testing to be done in lower-level health facilities and in community-based 
settings.19,20 The sensitivity of these tests may be improved by combining HIV 
antibody detection with detection of the p24 antigen, a viral protein. The p24 
antigen appears in blood sooner than antibodies after infection thus resulting in 
a shorter window period (time after HIV infection but before it can be picked up 
by an HIV test).21 These tests require a fingerprick blood sample and have mostly 
been performed by trained health providers. HIV antibodies can also be found in 
saliva, leading to the development or oral mucosal transudate (OMT) tests for 
HIV testing.22 In order to optimise HIV diagnosis by balancing specific test 
sensitivity and specificity, HIV testing algorithms that use two or more tests for 
diagnosis confirmation are routinely used.23  
Viral detection methods involve detection of viral nucleic acid using polymerase 
chain reaction (PCR).19 PCR testing requires laboratory infrastructure and is 
mainly used for early infant diagnosis (EID) of HIV, where HIV antibody tests 
cannot be used due to the passive transfer of maternal antibodies to the infant.19  
2.4 Treatment of HIV infection  
HIV remains an incurable infection, but antiretroviral therapy (ART) given in 
combination (highly active ART (HAART) or combination ART (cART)) of three 
or more drugs can durably suppress viral replication.24 Durable suppression of 
viral replication enables immune reconstitution, thus reducing the risk of 
infections and death.10 Viral load measured in blood gives an indicator of the 
response to ART in an individual, with an undetectable viral load (depending on 
  18
the threshold of the viral load measurement assay) demonstrating successful 
treatment.10  
Early initiation of ART, before severe immune deficiency, has substantial benefits 
such as reduction in HIV associated clinical events, HIV morbidity and 
mortality.25,26 Treatment guidelines have evolved over time in terms of the 
definition of “early treatment” with initial guidance recommending treatment 
initiation based on WHO clinical stage (3 or 4) and also on CD4 count (<350 
cells/mm3). Evidence from three key randomised controlled trials and 
observational studies showed initiating ART at higher CD4 counts (>550 
cells/mm3) reduced the risk of disease progression to AIDS.  Findings from the 
TEMPRANO trial conducted in the Ivory Coast showed among adults the risk of 
death and severe HIV related illness was lower for those who had initiated ART 
with a baseline CD4+ count >500 cells/mm3 when compared to those with 
delayed initiation.27 A multicontinental randomised controlled trial conducted by 
the HIV Prevention Trials Network (HPTN 052) also showed early treatment 
initiation (with CD4+ counts between 350-500 cells/mm3) when compared to 
initiation after CD4+ count <350 cells/mm3  was associated with a 41% reduction 
in HIV related clinical events.28 Furthermore initiating ART as soon as possible 
after diagnosis vs after having two or more clinic visits was shown not to cause 
attrition in care nor detract from viral suppression.29 Based on findings from 
these and other studies a “treat all” policy, regardless of clinical stage and CD4 
cell count, was recommended by WHO for all individuals living with HIV from 
2016.26  Despite the lack of similar data on the impact on mortality in older 
children, the approach of universal treatment regardless of disease and 
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immunological stage was extended to all age-groups for standardising delivery 
programmes and on the premise that earlier treatment could facilitate better 
immune constitution and reduce risk of comorbidities in children such as growth 
failure, neurocognitive disease and organ damage.30-32   
2.5 Mother to child transmission of HIV  
While initially recognised predominantly as an adult infection primarily 
contracted through unprotected sexual intercourse, HIV can be transmitted from 
mother to child.33 HIV transmission from mother to child can occur in utero, 
intra-partum (during labour or delivery) or via post-natal transmission through 
breastfeeding.34 In utero transmission of HIV can occur from as early as 8 weeks 
gestation.33 Intra-partum transmission is largely due to exposure of the baby to 
cervico-vaginal secretions.33,35 
The generalised adult HIV epidemic in SSA was therefore followed by an 
epidemic of HIV in children, mirroring the adult HIV epidemic.36 Approximately 
90% of HIV infections in children occur as a result of  mother to child 
transmission (MTCT).33 In 2005 a survey comparing ANC and population-based 
HIV prevalence conducted in rural South Africa found over 38% of pregnant 
women attending antenatal care (ANC) clinics were HIV positive.37 The HIV 
prevalence among pregnant women attending ANC clinics was much higher than 
among all women in the sampled general population (25%). This higher 
prevalence was likely due to the fact that women attending ANC are sexually 
active and not using contraceptives.37 Higher prevalence of HIV among ANC 
attendees is consistent in many countries with generalised HIV epidemics.38 In 
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2019 the global MTCT of HIV including both perinatal and postnatal HIV 
transmission was 9.1%.36 
Factors that affect MTCT of HIV can be categorised as viral, maternal, obstetrical, 
foetal and infant.33 High maternal viral load, prolonged rapture of membranes 
during labour, prematurity of pregnancy and prolonged/mixed breastfeeding 
have been shown to increase the risk of HIV transmissions from mother to 
child.33,39,40 Elective caesarean sections were shown to decrease the risk of HIV 
transmission by up to 50% likely due to the fact that an elective caesarean occurs 
prior to the rapture of membranes and reduces contact of the foetus with 
secretions or blood from the mother during labour contractions and in the genital 
tract.41 However, the decreased risk of HIV transmission conferred by elective 
caesarean section was offset by the increased risks associated with surgery and 
challenges with implementation in resource limited settings.42  
The presence of HIV in cell-free and cellular portions of breast milk is responsible 
for postnatal transmissions through breastfeeding.33 In SSA breastfeeding 
contributes significantly to perinatal HIV transmissions.33 In a randomised 
controlled trial conducted in Kenya from 1992-1998 there was significantly 
higher HIV infection in the arm where children were breastfed (36.7%) when 
compared to those who were formula fed (20.5%) in the first two years of life.39 
A cohort study conducted in South Africa from 2001-2005 comparing HIV 
transmission among infants breastfed exclusively and those who received mixed 
feeding showed increased HIV transmission risk among those who received 
mixed breastfeeding.43 While avoidance of breastfeeding was initially proposed 
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as a strategy to prevent MTCT it is not often feasible in low- and middle-income 
settings where clean and safe drinking water is often not accessible.42 
2.6 Prevention of mother to child transmission of HIV  
2.6.1 ART for the prevention of mother to child HIV transmission  
Over the last 20 years there have been a number of approaches developed for 
prevention of mother-to-child HIV transmission (PMTCT).44 Key among the 
PMTCT strategies adopted is the use of ART for pregnant mothers.36 A landmark 
study conducted by the Paediatric AIDS Clinical Trials 076 Study Group in 1994 
showed that HIV transmission rates at 18 months post-delivery were 
significantly lower when zidovudine prophylaxis was given to the mother and 
her child (8.3% compared to 25.5% among recipients of placebo).44,45 Despite 
this, the zidovudine regimen was not widely implemented in resource-
constrained settings due to the requirement for early engagement with care and 
early treatment initiation for pregnant women as well as the intravenous 
administration of zidovudine during labour which would not be practical in many 
LMIC settings.44 Drug regimens subsequently were simplified and shortened to 
mitigate against these challenges e.g. the introduction of single dose nevirapine 
(NVP). In an HIV Prevention Trials Network randomised controlled trial (HIVNET 
012) conducted in Uganda published in 2003 the prevalence of HIV at 6-8 weeks 
among infants who had received single dose NVP was 11.8% while that among 
infants receiving zidovudine was 20.0%.44 This regimen was simple, cheap and 
effective, however, concerns about NVP resistance soon surfaced, and cART was 
recommended as a strategy for PMTCT since 2006.44 
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 Current WHO guidance is that all pregnant women are to be initiated on 
treatment at the point of diagnosis regardless of their CD4 count in order to 
reduce the likelihood of HIV transmission to children.46 This was recommended 
after evidence from multiple cohorts showed treatment started before 
pregnancy together with having an undetectable viral load can result in zero risk 
of HIV transmission to children.47  
With few alternatives to breastfeeding in LMIC settings additional PMTCT 
strategies aimed at reducing post-natal transmission through breastfeeding were 
evaluated, namely the use of ART as prophylaxis for infants during the 
breastfeeding period.42 Current treatment regimens recommend prophylaxis 
using either NVP or zidovudine among breastfed or non-breastfed infants for a 
duration of 4-6 weeks post-delivery with room for extension of up to 12 weeks.44 
The extension up to 12 weeks is for scenarios where the mother was diagnosed 
during labour or after delivery and intends to breastfeed or if the infant was 
identified as HIV exposed after delivery and is breastfeeding.64 WHO 
recommends exclusive breastfeeding for six months.44  
2.6.2 Coverage of the prevention of mother to child transmission of 
HIV programmes   
The coverage of pregnant women living with HIV accessing ART has increased 
significantly over time. In 2010 global coverage was 17%, however, by 2019 
global coverage had reached 85%.36 However, there is substantial heterogeneity 
in coverage with some regions such as in West and Central Africa having under 
60% coverage while some regions, such as Eastern and Southern Africa, have 
successfully and consistently reached almost all pregnant women with 95% 
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coverage in 2019.36  Importantly, the gaps in coverage of ART within PMTCT 
programmes mean that new infections in children continue to occur. 
2.6.3 Gaps in the prevention of mother to child transmission of HIV 
programmes 
Firstly, some women do not register for ANC which means they do not access HIV 
testing as part of PMTCT programmes and are therefore unable to access and 
initiate treatment early.36,48 HIV testing while initially offered by request in ANC, 
evolved into an opt-in and subsequently to an opt-out (HIV testing performed on 
women presenting for ANC unless they actively decline) approach which 
increased uptake.36,49 In addition, women who test negative remain at risk of HIV 
infection, necessitating repeat HIV testing  during pregnancy and breastfeeding. 
The early stage HIV infection is associated with a very high viral load and a 
particularly high risk of MTCT.50 Uptake of HIV retesting among initially HIV 
negative pregnant women can be low. A study conducted in Tanzania from 2015-
2016 found only 30% of pregnant women where were HIV negative at first ANC 
contact retested for HIV up until the postpartum period. 51 
Late or no registration for ANC has been attributed to structural barriers such as 
costs to access facilities, limited access to facilities due to long distances needed 
to be travelled to access health facilities and also long waiting times at facilities. 
52,53 Furthermore, individual barriers exist such as lack of knowledge about the 
need to register for ANC early to access PMTCT as well as lack of partner 
involvement in ANC.52,53 HIV associated barriers also exist such as HIV stigma and 
discrimination in the community which stops women from accessing HIV testing 
and subsequently HIV treatment. 52,53    
  24
Secondly, once tested and initiated on treatment further challenges among 
pregnant women still prevail including poor adherence to ART during pregnancy 
and breastfeeding and loss to follow up (Figure 1).50 Disrupted or poor ART 
adherence increases risk of MTCT of HIV and has been attributed to non-
disclosure of HIV status by pregnant mothers to their partners and limited 
partner involvement to support with HIV treatment.52,53 
To optimise PMTCT widespread coverage of HIV testing and ART among 
pregnant women together with interventions to monitor and maintain viral 
suppression are required.54 Possible solutions include community sensitisation 
on the importance of HIV testing  and treatment for pregnant mothers, improved 
access to HIV testing, ANC services and ART through decentralisation of services 
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2.6.4 Early Infant Diagnosis  
Infants born to HIV positive mothers are recommended to have an HIV test 
within 4 – 6 weeks of birth. However, according to UNAIDS, in 2019 only 60% of 
children eligible for HIV testing at birth had received an HIV test within 6 weeks 
globally.36,56 Rapid antibody tests (tests that detect HIV antibodies in blood or 
oral fluid) which can be done at the POC produce results within 20 minutes but 
cannot be used for testing infants due to the passive transfer of maternal 
antibodies resulting in false positive tests.57 
Therefore, up until 18 months of age, diagnosis of HIV requires viral detection 
(rather than antibody detection) methods such as DNA PCR.40,58,59 Virological 
tests detecting DNA PCR are costly and require much more infrastructure and 
sophisticated laboratory capacity, resulting in HIV testing being restricted to 
central laboratories. Turnaround of test results (from laboratory to the health 
facility or to the patient) can often take several months meaning delayed 
diagnosis for infants who do return for results but also many infant-mother pairs 
are lost to follow up.58 In an observational study of eight African countries 98.3% 
of infants who had POC tests in 2017 received their results within 30 days. In 
comparison only 18.7% of infants receiving virological HIV testing from 2014-
2017 had received their results within 30 days.60 
As such, strategies that have been used to try and improve uptake of EID include 
alignment of HIV testing with routine child health visits, use of SMS reminders 
and community follow up of infants who are lost to follow up.58 
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More recently, several POC HIV testing platforms for EID have been evaluated, 
demonstrated to be feasible and to improve rates of results return and ART 
initiation rates but have not been implemented widely to date.58,61 This may be 
due to the costs associated with roll out of the POC EID testing platforms or their 
more recent introduction into the market whereby only two EID POC tests had 
been prequalified by WHO by January 2019.59 In an observational study of eight 
African countries, over 92.3% of HIV positive infants who received POC HIV 
testing  were initiated on ART within 60 days while only 43.3% of infants 
receiving conventional EID were initiated.60 Current WHO guidance is that HIV 
exposed infants should also be tested for HIV again at nine months. However, 
often children do not return for repeat HIV testing.23  
The suboptimal coverage of PMTCT and EID mean HIV infections in children 
continue to occur and those infected are not identified timely (Figure 1).   
2.7 Paediatric HIV infection 
HIV in children is associated with rapid disease progression and high mortality, 
with a 50% mortality by age two years recorded in African cohorts in the pre-
ART era.62 However, there is variation in disease progression among children 
with perinatal HIV infection. Some children with HIV have much slower 
progressing disease, and survive to older childhood even without ART.63 A 
French paediatric cohort of HIV infected children published in 2007 showed that 
2% of children infected in the perinatal period had no clinical nor immune 
disease progression by 10 years of age.64 An Italian study from 1994 found that 
among 182 HIV infected children who survived beyond 5 years of age 15% had 
no disease symptoms.65 
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It is estimated that a third of children with perinatally-acquired HIV have slow-
progressing disease, with a median survival of at least 16 years (no upward 
estimates available).66 A study conducted between 2007-2008 in Zimbabwe 
found that 46% of the 301 adolescents aged 10-18 years admitted at two general 
hospitals for any reason were HIV positive, of whom only 38% were previously 
undiagnosed.67 These adolescents presented with a spectrum of opportunistic 
infections as well as chronic co-morbidities showing evidence of long term 
survival with perinatally-acquired HIV.67 
In the last twenty years, as HIV epidemics have matured in Africa, large numbers 
of children have been presenting to clinical services with advanced HIV infection 
in older childhood and adolescence. The reasons for these differences in disease 
progression among perinatally infected children are multi-faceted and may 
include clinical factors such as low CD4 count and high viral load and disease 
stage, of the mother, viral factors (e.g., viral subtype) or immune factors (e.g., HLA 
type).68   
It is important to note that slow progression does not imply that children 
growing up with HIV are asymptomatic.69 The majority commonly have 
recurrent minor infections such as skin and upper respiratory tract infections 
that are also common in children without HIV, and therefore may not prompt HIV 
testing because they may not be automatically associated with HIV infection.70 
HIV infection is also associated with growth failure, pubertal delay and other 
comorbidities such as chronic cardiorespiratory, neurocognitive disease and skin 
disease.66,67,71-74 Importantly, once established, these conditions may not be 
reversible with ART.73,75 In infants (aged 6-12 weeks) enrolled in the CHER trial, 
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immediate initiation of treatment following diagnosis reduced mortality by  76% 
which prompted WHO guidelines for ART in infants regardless of disease or 
immunological stage.76 Such a big reduction in mortality has not been observed 
in other age groups, however, several studies have shown that earlier treatment 
is associated with faster CD4 count recovery in the first 3 months on ART and a 
sustained higher CD4 count.30,76 Furthermore, ART is associated with improved 
growth but children who start ART later may not achieve their full growth 
potential.73,77  
Many children who were born with HIV before PMTCT programmes were scaled 
up or continue to be infected despite availability of PMTCT programmes are 
presenting and will continue to present in later childhood due to the gaps in 
PMTCT and EID programmes discussed above. Delayed initiation on ART 
increases the risk of disease progression, additional end organ complication and 
also reduces grown potential.66 Earlier access to treatment can prevent these 
complications. 
There is a need to continue strengthening PMTCT programmes including EID to 
facilitate timely initiation of ART in infants who test HIV positive. However, as 
the HIV epidemic has aged, it is apparent that there is a need to focus on timely 
diagnosis of children and adolescents who have been missed by PMTCT 
programmes. 
2.8 Global HIV testing models and trends  
HIV testing is the entry point for access HIV treatment and care as well as for 
accessing HIV prevention interventions. UNAIDS has set specific targets aimed at 
  30
ending the HIV epidemic, namely the 95-95-95 targets with 95% of people living 
with HIV aware of their status, 95% of those aware of their status on ART and 
95% of those on ART virally supressed by 2030.78 The first target highlights the 
importance of HIV testing  in both improving clinical outcomes (as people are 
able to access HIV treatment once diagnosed) and in being a key pilar for 
epidemic control.78  
2.8.1 HIV testing coverage 
Coverage of HIV testing uptake globally has increased over time with an 
estimated 70% of people living with HIV in 2015 knowing their HIV status and 
79% in 2018. In 2019, an estimated 7.1 million people with HIV were 
undiagnosed.78 There is significant heterogeneity among population groups, for 
example there is lower uptake of HIV testing among adolescents.79 In a 2016 
survey among adolescents and young adults (aged 15-24 years) in Nigeria only 
24% had ever tested for HIV.80 There is also geographic variation of HIV testing 
coverage with only 52% of people in the Middle East and North Africa living with 
HIV knowing their HIV status in 2019 while in the same year 70% of people living 
with HIV  in eastern Europe and central Asia knew their HIV status.78 There is 
therefore a need to bridge these HIV testing gaps in order to improve HIV 
morbidity and mortality through access to HIV treatment.  
2.8.2 HIV testing models 
Successes in HIV testing coverage and knowledge of HIV status have been 
attributed to the availability of timely and low-cost rapid diagnostic tests, and 
policy changes to facilitate increasing numbers of testers though lay workers and 
more recently HIV testing in community-based settings.81  
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HIV testing models have evolved over time: Voluntary counselling and testing 
(VCT) was one of the earliest HIV testing approaches used, whereby HIV testing 
was made available in different settings but was client-initiated and relied on 
individuals deciding to undergo HIV testing and attending VCT services. Uptake 
of HIV testing through VCT was low 23 In 2008 study from Tanzania VCT uptake 
among men and women was 12% and 7% respectively.82 Similarly a cohort study 
published in 2007 among adults in Zimbabwe showed lifetime VCT uptake of 
only 11%.83 These findings were consistent in SSA and low VCT uptake was 
largely attributed to individuals believing they are at low-risk for HIV infection 
and lack of awareness about the availability and need for HIV testing.20,84 VCT 
relies largely on the individuals initiative and often results in late diagnosis.   
In 2007 WHO recommended that provider-initiated testing and counselling 
(PITC) be offered to all patients attending health facilities in settings with 
generalised HIV epidemics.20,85 PITC places the onus of HIV testing on the health 
provider, and requires that the provider offers HIV testing to all clients 
irrespective of symptoms or clinical diagnosis.85 One application of PITC was HIV 
testing in ANC setting for pregnant mothers as part of PMTCT programmes,  
particularly to facilitate delivery of ART for reducing the risk of MTCT.20 In a 
study conducted in Botswana ANC patients who knew their HIV status increased 
from 47% to 78% after the introduction of PITC.86 PITC removed some barriers 
to HIV testing such as the need for personal motivation to test. While PITC has 
helped improve HIV testing uptake PITC coverage has been suboptimal in some 
groups such as among children where HIV testing is not offered consistently by 
providers.87  
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Challenges with implementation of PITC include lack of staff and overworked  
health providers who are then not able to  prioritise HIV testing, unstable supply 
chains of HIV test kit supplies, lack of space to conduct HIV testing; difficulty in 
navigating ethical issues such as consent and confidentiality.88,89 Client level 
barriers to HIV testing include lack of personal motivation to seek testing, fears 
of HIV positive diagnosis, fear of HIV related stigma and discrimination and not 
feeling ready to test.90,91 A key limitation of PITC is that it requires individuals to 
present to health facilities in order to access HIV testing; for those who are living 
with HIV this may translate to delayed HIV diagnosis which would only occur at 
the onset of symptoms and therefore advanced disease stage.  
Innovative HIV testing strategies are therefore needed to bridge gaps in uptake 
of facility-based HIV testing. HIV testing outside health facility settings including 
workplace-based testing, home-based testing, mobile outreach, and school-
based testing have been aimed at reaching individuals who otherwise would not 
access health facilities. They have broadly been effective in reaching population 
groups where HIV testing has historically been low such as men and young 
people.23,92 A systematic review of strategies to engage with HIV testing services 
in SSA found mobile and home-based HIV testing significantly increased HIV 
testing by males when compared to VCT.93 There are several advantages to 
community-based HIV testing strategies such as being able to reach groups that 
traditionally do not engage with health facilities (e.g. men, young people, 
marginalised groups such as PWID, LGBQTI etc) and reduction of stigma by 
normalising HIV testing. However, there are several concerns associated with 
these approaches including lower HIV yield and therefore potentially being less 
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cost-effective, the requirement for additional human and infrastructural 
resources, concerns about privacy and confidentiality in the different test 
locations and onward linkage to care for those who test HIV positive.23  
2.8.3 HIV self-testing 
HIV self-testing (HIVST) is a novel HIV strategy whereby individuals are able to 
test themselves for HIV.22 Individuals collect the test specimens, perform the test 
and interpret the test results without assistance from a provider. While routine 
HIV testing mainly uses rapid blood-based testing the HIVST is usually performed 
using an OMT test using a salivary sample. In four studies conducted between 
2003-2004 where OMT tests were compared to enzyme immunoassays and 
western blot tests, OMT tests had a sensitivity of 99.1% and a specificity of 
99.6%.94 In a meta-analysis assessing the diagnostic performance of the Oraquick 
advance rapid HIV-1/2 (OraSure Technologies Inc, PA, USA) test, the pooled 
sensitivity was 98.0% for oral specimens and 99.7% for blood based specimens.95 
In this analysis pooled specificity was 99.7% for oral specimens while that of 
blood specimens was 98.5%.95 While OMT testing is highly sensitive and specific 
neither study included  children and OMT testing had not been validated for use 
in children younger than 12 years at the time of conducing this research.96  
Current WHO guidelines are that any positive/reactive HIVST result must be 
confirmed by subsequent blood based tests at a health facility in order to confirm 
an HIV diagnosis.22,23 This has successfully been implemented in many high HIV 
prevalence setting such as Malawi, Zimbabwe and Zambia.22 High HIVST uptake 
has been reported among key population groups such as sex workers, men who 
have sex with men and also among older adolescents.97,98 In a community-based 
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study conducted among adults >16 years in Malawi the crude uptake of HIVST 
was over 83%, however, adolescents aged 16-18 years were more likely to test.98 
HIVST has been shown to be highly acceptable to first time testers and some 
population groups for several reasons including non- reliance on trained health 
providers. HIVST is convenient and allows testers to have autonomy about when 
or where HIV testing occurs and also allows them to perform the test in private. 
The non-invasive nature of OMT tests also makes them more accessible when 
compared to blood-based test.99,100 Some potential concerns about HIVST were 
low literacy to read and follow instructions, concerns about being able to 
accurately perform the test, concerns about social harms after tests have been 
performed in the absence of a provider (e.g. in the community) and the costs of 
buying a self-test kit.101,102 The unit cost of an OMT test is higher than that of a 
blood-based rapid antibody test.103 
Successes in HIV testing coverage and knowledge of HIV status have been 
attributed to the availability of timely and low-cost rapid diagnostic tests and 
policy changes to facilitate increasing numbers of testers though lay workers and 
HIV testing in community-based settings.81 Gaps in coverage and challenges with 
HIV testing uptake persist leaving a requirement for innovative strategies to 
improve HIV testing uptake and coverage.  
2.8.4 HIV testing for children and adolescents  
 Globally HIV testing rates among children and adolescents are much lower when 
compared to those in adults.104 In 2019 only 53% children <14 years living with 
HIV were aware of their HIV status and on treatment compared to 63% among 
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older adolescents and adults (>15 years).78 Children living with HIV who are not 
identified in infancy are subsequently often identified when they present with 
advanced disease or AIDS-indicator conditions.70,105  
HIV testing strategies for children have largely been the same as those used for 
adult populations.56 As described above, PITC has been recommended by WHO 
since 2007.106 Despite this, HIV testing uptake among children and adolescents 
also remains low. In Zimbabwe, after two years of implementing PITC for 
children in primary health facilities, a community prevalence survey in 2016 
found 37.7% of children (8-17 years) with HIV were still undiagnosed.107 This 
reflects the inadequacies of facility-based HIV testing strategies for reaching 
children with HIV as well as scope for the inclusion of children in community-
based HIV testing approaches. 
There are a number of issues that need to be considered when considering HIV 
testing in children and adolescents: 
1. Lower HIV prevalence in children 
In comparison to adults children and adolescents have a lower HIV 
prevalence which may result in lower HIV yield with universal HIV 
testing strategies when compared to adults.108 As such the resources 
required to identify one child living with undiagnosed HIV are higher 
which makes blanket HIV testing approaches less suitable.  
2. Guardians act as intermediaries 
In many countries within SSA all children under the age of 16 years 
require guardian consent in order to access HIV testing services.109 The 
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legal requirement for parental consent, which does not exist for adults, 
adds a layer of logistical complications to be navigated for HIV testing 
children who are sometimes orphaned and have frequent changes in 
guardianship in settings with generalised HIV epidemics.109-111 In 
addition, the requirement for caregiver support and approval for the HIV 
testing of children and adolescents means children and adolescents have 
to navigate further social barriers such as caregiver fears surrounding 
HIV stigma, discrimination and fears of disclosing their own HIV status 
to the child or the status of the child to the child.  
3. Low perception of HIV risk 
There is a historic assumption the children with perinatal HIV infection 
do not survive beyond infancy.87 As such often older children and 
adolescents are believed to not have perinatal HIV infection as they have 
lived undiagnosed and untreated till adolescence. This impacts HIV 
testing as carers are less likely to suspect HIV infection in children 
despite the children having recurring illness.87 Furthermore it creates 
institutional barriers where providers also have low perceived HIV risk 
and as such children and adolescents are perceived to be of lower 
priority and providers do not routinely offer HIV testing for children as 
suggested by PITC strategies.87 
4. Children living with HIV have a sexually transmitted disease acquired 
perinatally 
A study from Zimbabwe found that providers often felt ill-equipped for 
navigating counselling and disclosure issues when HIV testing children 
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and adolescents.87,112 The fact that children living with HIV have a 
diseases predominantly acquired through sexual intercourse means that 
the HIV testing process, in particular counselling for HIV testing is a 
process that requires the provision of additional information as well as 
provider skills in navigating the complexities of this.112 
5. Availability of  HIV tests 
For younger children (<18 months) the presence of maternal HIV 
antibodies means routinely used rapid blood-based HIV tests cannot be 
used in this age group.87,113 For children <12 years the OMT tests which 
are increasingly being used have not yet been validated for use in this 
population.87,113 The smaller pool of available HIV tests for children 
limits HIV testing access in this group when compared to adults.   
The review paper at the end of this chapter (Research Paper 1) describes in detail 
the barriers and emerging strategies for HIV testing among adolescents.  
2.8.5 Targeted HIV testing strategies and Index-linked HIV testing  
 Targeted HIV testing strategies often focus on high-risk groups such as sex 
workers and men who have sex with men as well as hard to reach groups who 
don’t usually engage with health facilities and HIV testing such as men and 
adolescents.22,114 They can also  reduce the number of tests required to identify 
one HIV positive case and therefore may be more efficient and cost-effective.114 
Targeted HIV testing strategies that have been rolled out include mobile HIV 
testing in known hotspots, home based HIV testing, social network HIV testing 
and partner notification services or index-linked HIV testing.23,114 Some of these 
have been highly successful such as index case HIV testing for sexual partners 
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which when compared to routine HIV testing services such as passive referral in 
a study conducted in 2009 in Malawi had significantly higher uptake (24% vs 
51% respectively).115  
Among children and adolescents, a simple four item screening tool to identify 
those at risk of being HIV infected and who can subsequently be targeted for HIV 
testing reduced the number need to test to identify one HIV-positive child by up 
to 50%.116,117 In a study conducted in Zimbabwe a screening tool with four 
questions to identify older children (10-19 years) living with HIV in health 
facilities had a sensitivity of 80.4% and specificity of 66.3% to identify HIV.116 
Another targeted strategy is index-linked HIV testing whereby children of 
individuals living with HIV are specifically targeted for HIV testing.23 At the time 
of conducting the research for this thesis index-linked HIV testing for children 
had been evaluated in one study in Kenya among 2–12-year-olds and had an HIV 
prevalence of 7.4% which was much higher than the general population 
prevalence of 1%.118 
2.9 Zimbabwe 
2.9.1 The HIV epidemic in Zimbabwe  
Zimbabwe has had an early onset generalised HIV epidemic, with adult HIV 
prevalence peaking at 29% in 1997.119 In 2020 the HIV prevalence in Zimbabwe 
still remained one of the highest in Sub-Saharan Africa at 12.9% among 
individuals >15 years.120 There have been minor fluctuations in prevalence in the 
last five years due to the widespread roll out of ART and people living longer with 
HIV infection. Zimbabwe is one of the few countries where HIV incidence (0.38% 
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in 2020 compared to 5% in 2000) has dropped.121 An earlier drop in HIV 
incidence was attributed to the intensified roll out of prevention measures such 
as condoms distributed freely nationwide and more recently nationwide 
voluntary medical male circumcision campaigns, treatment as prevention and 
other behavioural interventions.121  
HIV testing and treatment services in Zimbabwe are largely facility-based. 
Additionally, community-based HIV testing strategies such as events-based HIV 
testing, and mobile outreach HIV testing have been implemented though the 
MoHCC and partner organisations but are often not sustained. In 2016, among 
adults (15-64 years) 73.7% had been tested before, however, this proportion was 
much lower in young adults (15-24 years) at 50.4% in the same year.122 
The early onset sustained HIV epidemic in Zimbabwe led to an associated 
epidemic of HIV infection among children prior to the advent and scale up of 
PMTCT programmes, with large numbers presenting for the first time in older 
childhood and adolescence as HIV epidemics matured.  
In 2010 PMTCT coverage in Zimbabwe was only 29%, increasing to 94% in 
2019.14 However, MTCT continues to occur due to the gaps in PMTCT 
programmes and suboptimal coverage of EID means that children continue to 
present beyond infancy with undiagnosed HIV.123 In 2018 Zimbabwe recorded 
4800 new HIV infections among children aged 0-14 years.14 According to a 
national population based survey (ZIMPHIA) the HIV prevalence among children 
and adolescents (0-14 years) was 1.6% in 2016.122  
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2.9.2 The economy, public health system and HIV response in 
Zimbabwe  
Over the last 30 years the Zimbabwe has been faced with a weakened economic 
and political environment. This decline over time has negatively impacted the 
delivery of and funding for health services.124 However, HIV programming has 
remained one of the top health priorities, and over 1.1 million Zimbabweans 
were accessing ART in 2018.14 Funding for HIV services in Zimbabwe is largely 
though international donors such as PEPFAR and the Global Fund as well as 
domestic funding through the national AIDS Levy which was introduced by the 
Zimbabwean government in 1991.14,125 The HIV response in Zimbabwe is 
coordinated by the National AIDS Council (NAC) in collaboration with the 
Ministry of Health and Child Care (MoHCC).125 
HIV testing and treatment services are largely decentralised and provided in 
nurse-led primary care health facilities. HIV programmes also include primary 
care counsellors (who mainly provide HIV testing services) and community or 
village health workers who follow up clients defaulting on HIV or TB treatment, 
and refer clients from the community to the facility.126 Primary care counsellors 
go through a 6-week training programme while village/community health 
workers go through an 8-week training programme with the opportunity of 
refresher training.127  
It is within this landscape that my PhD project was conducted.  
2.10 Summary 
Early diagnosis of HIV and initiation on treatment improves morbidity and 
mortality. Although PMTCT programmes have been rapidly scaled up, MTCT of 
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HIV continues to occur, with many children only diagnosed when they present 
with advance disease in later childhood, and coverage of ART in children lagging 
behind that in adults because of the delay in diagnosis.  
Children and adolescents are faced with unique barriers to access HIV testing and 
there is an urgent need to develop and evaluate interventions suitable for this 
group. This thesis will focus on the evaluation of index-linked HIV testing for 
children and adolescents in Zimbabwe, a country with sustained severe 
generalised HIV epidemic.  
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 CURRENTOPINION Barriers to, and emerging strategies for, HIV
testing among adolescents in sub-Saharan Africa
Chido D. Chikwaria,b, Stefanie Dringusc, and Rashida A. Ferranda,b
Purpose of review
HIV/AIDS is one of the leading causes of death among adolescents in sub-Saharan Africa and 40% of
new HIV infections worldwide occur in this group. HIV testing and counselling (HTC) is the critical first step
to accessing HIV treatment. The prevalence of undiagnosed HIV infection is substantially higher in
adolescents compared with adults. We review barriers to HTC for adolescents and emerging HTC
strategies appropriate to adolescents in sub-Saharan Africa.
Recent findings
There are substantial individual, health system and legal barriers to HTC among adolescents, and stigma
by providers and communities remains an important obstacle. There has been progress made in recent
years in developing strategies that address some of these barriers, increase uptake of HTC and yield of
HIV. These include targeted approaches focused on provision of HTC among those higher risk of being
infected, for example, index-linked HTC and use of screening tools to identify those at risk of HIV.
Community-based HIV-testing approaches including HIV self-testing and incentives have also been shown to
increase uptake of HTC.
Summary
In implementing HTC strategies, consideration must be given to scalability and cost-effectiveness. HTC
approaches must be coupled with linkage to appropriate care and prevention services.
Keywords
adolescents, barriers, HIV, strategies, testing
INTRODUCTION
HIV testing and counselling (HTC) is the critical first
step to accessing HIV treatment and is an opportu-
nity to promote healthy sexual behaviour through
counselling and linkage to HIV prevention and
sexual reproductive health services [1,2
&&
,3]. The
prevalence of undiagnosed HIV infection is substan-
tially higher in adolescents compared with adults
[4]. Population HIV Impact Assessments (PHIA) sur-
veys conducted in Malawi, Zambia and Zimbabwe
between 2015 and 2016 showed that less than 50%
of young people aged between 15 and 24 years living
with HIV were aware of their HIV status [5
&
,6,7].
Adolescents with HIV include those who have
acquired HIV vertically as well as horizontally
[2
&&
]. In sub-Saharan Africa (SSA), which bears
74% of the global burden of HIV infection, large
numbers of adolescents, infected vertically before
interventions to prevent mother-to-child transmis-
sion were scaled up have been presenting to health
services with undiagnosed HIV in recent years [8]. In
addition, 40% of new HIV infections worldwide
occur in adolescence and HIV infection rates in this
age-group are projected to rise [5
&
,9]. Delayed diag-
nosis is associated with an increased risk of mortality
as well as onward HIV transmission [5
&
]. We review
barriers to HIV testing for adolescents and emerging
HTC strategies appropriate to adolescents in SSA.
BARRIERS TO HIV TESTING AND
COUNSELLING AMONG ADOLESCENTS
Barriers to HTC among adolescents occur at indi-
vidual, health service provider and policy levels
(Table 1).
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Studies have reported a lack of comprehensive
HIV knowledge and of inaccurate perception of
personal risk, with some adolescents considering
HTC to be neither necessary nor important [19].
Other barriers to HTC reported by adolescents are
fear of the consequences of having a positive test
result, and stigma from peers and providers [10
&
].
Adolescents, particularly younger adolescents who
are more likely to be vertically infected, rely on their
caregivers for accessing HTC. Many are orphaned
and have changing caregivers. In addition, care-
givers may have more urgent competing priorities,
which mean that they only consider having their
child tested whenever the child gets sick and likely
develops advanced disease [13,14]. Although many
caregivers suspect their adolescent may have HIV
either because of the parent having died or because
of chronic ill-health, there is a misplaced desire to
protect their child from the stigma she or he may
face in the community [13]. In the case of a verti-
cally infected adolescent, a positive HIV test deduc-
tively discloses the HIV status of the mother (and
possibly the father) and the guilt and the fear of
blame from their child has been shown to be a
reason why caregivers may not have their children
tested [13,15,16].
Since 2007, the World Health Organization
(WHO) has recommended provider-initiated HIV
testing and counselling (PITC) in high HIV-preva-
lence settings, whereby HIV testing is offered proac-
tively to all clients attending a healthcare facility
regardless of the reason for attendance [20]. This
relies on clients attending the facility and a health-
care worker (HCW) then offering HTC. Distance
from health facilities, transportation costs and
KEY POINTS
 The prevalence of undiagnosed HIV infection is higher
in adolescents compared with other age-groups.
 Barriers to HTC among adolescents include need for
guardian consent, negative attitudes and lack of
training among healthcare workers, stigma and
distance from facilities, inconvenient opening hours of
facilities and long waiting times.
 Several strategies have improved uptake and yield of
HTC in adolescents including HIV testing targeted at
adolescents at high risk of being infected, community-
based testing (campaigns, mobile testing, home-based
testing), use of incentives and HIV self-testing.
 HTC strategies for adolescents must be evaluated for
their potential for scalability and cost-effectiveness and
should ensure linkage to appropriate treatment and
prevention services after testing.
Table 1. Summary of barriers to HIV testing and counselling in adolescents
Individual and societal
Individual Fear of HIV-positive status and stigma [10&,11–13]
Lack of comprehensive HIV knowledge [11]
Perception of low risk [14,15]
Family/community Stigma and sanctioning of sexual activity in adolescents [10&,13,16]
Caregiver noninvolvement [10&]
Parental fear of disclosure of own HIV status [15,16]
Desire to protect children from stigma [16]
Competing priorities among caregivers [11]
Lack of HIV knowledge [11]
Health service provider
Staff Healthcare worker judgemental attitudes [10&,12]
Lack of confidentiality (healthcare provider disclosure of HIV status to caregivers) [10&,12]
Lack of HIV knowledge [14]
Insufficient training of healthcare workers in discussing HIV, ethicolegal issues [14]
Concern about unavailability of support services for adolescents with HIV [14]
Health facilities Lack of staff and testing kits [14]
Priority for HIV testing within facilities given to other services, for example, PMTCT [14]
Accessibility of facilities; location and unsuitable working hours [12]
Health policy and legal
Legal age of consent [11,14,17&]
Discrepancies in national HIV-testing guidelines [14,18]
Adolescents and HIV
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inconvenient opening hours are barriers for access-
ing health services by adolescents. Common reasons
adolescents report for not accessing HTC are the
stigmatizing and judgemental attitudes of health-





In a 2013 study evaluating PITC among children
aged 6–15 years attending primary healthcare clin-
ics (PHCs) in Zimbabwe, only 54% underwent HTC,
the primary reason for the low coverage being that
HCWs did not offer HTC [14]. Notably, being aged
more than 11 years was associated with lower odds
of being offered HIV testing. From a provider per-
spective, inadequate knowledge and training of
healthcare providers in addressing the complexities
of HIV in adolescents such as ethicolegal issues,
disclosure and the ‘language’ to discuss HIV serve
as barriers to offering HTC [14]. Other barriers
include lack of adequate staff, and prioritization
driven by donor funding [e.g. prioritization of pre-
vention of mother-to-child transmission (PMTCT]),
concern about the availability of appropriate sup-
port services for those who test HIV-positive, and
the perception of adolescents as a low-risk group
(particularly younger adolescents who would not be
expected to be sexually active) [8,14].
Most countries require consent from a guardian
for minors to access HTC [17
&
]. Many adolescents in
Africa do not live with their parents but within
extended family structures, either because they
are orphaned or because parents migrate for work
[13]. Caregiving arrangements are, therefore, unsta-
ble and guardianship is often not legally defined,
leaving healthcare providers to make a difficult
decision about whether the accompanying care-
giver is ‘suitable’ to give consent [17
&
,18]. In five
SSA countries, the legal age of consent for HTC is
18 years or above [17
&
]. There have been policy
changes in some countries, for example, in South
Africa, whereby a child above the age of 12 years can
consent for an HIV test independently [21]. How-
ever, the legislation also stipulates that it is an
offence to have consensual sex below the age of
16 years, a legal barrier for sexually active adoles-
cents at high risk of HIV infection to seek HTC
[17
&
,18,21]. Policies do make provision for health-
care providers to give consent on behalf of the
minor whenever a guardian is unavailable, if HTC
is ‘within the best interests of the minor,’ or provi-
sion to consent independently by those deemed to
be ‘mature minors’ [17
&
]. However, these conditions
are often subjective and rely on providers having to
make decisions, which they are not always trained
to do. The practical implications of legislature
around consent has posed challenges for healthcare
providers in terms of the conflict between main-
taining confidentiality versus disclosing test results
to caregivers to ensure that adolescents are sup-
ported [22].
HIV TESTING AND COUNSELLING
STRATEGIES FOR ADOLESCENTS
HTC strategies have evolved over the last 10 years
from client-initiated approaches such as voluntary
counselling and testing (VCT) to provider-initiated
testing and counselling approaches (PITC) offered
routinely in health facilities, and more recently
implementation of community-based strategies
[7]. These have largely focused on adults and not
been tailored to the needs of adolescents [23
&
].
Recognizing the need to prioritize adolescents as a
key population for HIV prevention and care, the
WHO developed specific HTC guidelines for adoles-
cents in 2013 [24]. Most of the WHO recommenda-
tions were based on low-quality evidence, and the
guidelines highlighted the need to establish com-
parative effectiveness of interventions to improve
access to HTC in this age-group [24]. In this section,
we discuss recent approaches to HTC tailored for
adolescents in SSA. These strategies are summarized
in Table 2 and relevant studies are detailed in
Table 3.
PITC has been shown to have a high yield (pro-
portion of individuals who test HIV positive of those
eligible for testing), but as discussed above relies on
providers offering HTC to clients [34]. A study in
Table 2. Summary of HIV testing strategies for adolescents








Targeted testing Index-linked testing
Use of screening tools
Facility modifications Extended hours
Youth friendly services
Routine opt-out testing
Community-based testing Door-to-door testing
Mobile testing
Campaign testing
Use of social events
Youth centres
School based
Technology and edutainment Telephone-based counselling
Simulated processes
HIV testing among adolescents in SSA Chikwari et al.
1746-630X Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved. www.co-hivandaids.com 3
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 www.co-hivandaids.com Volume 13  Number 00  Month 2018
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: ; COH/130305; Total nos of Pages: 8;
COH 130305
Zimbabwe that compared routine opt-out testing
(ROOT), whereby clients are tested unless they
actively declined to test, to standard PITC among
children aged 6–15 years attending in six PHCs in
Zimbabwe, showed that implementation of ROOT
increased the proportion of individuals who under-
went HTC and the yield of undiagnosed HIV [33].
An opt-out strategy transforms HIV testing into a
routine, default clinical action, which removes some
decision-making from the providers and guardians. A
potential concern of such an approach is that it may
result in coercion of the client and reduce client
autonomy, a concern that has been debated within
PMTCT of HIV programmes wherever such an
approach is widely used [35]. Such a concern needs
to be weighed against the right to and also benefit of
access to effective and life-saving treatment, and the
reliance of adolescents on others to give consent on
their behalf to access HTC. More recently, implemen-
tation and scale-up of HIV-prevention programmes
such as voluntary medical male circumcision
(VMMC) and preexposure prophylaxis (PreP) include
opt-out HIV testing and serve as an opportunity for
adolescents to know their HIV status [36–38].
A potential concern about blanket HTC
approaches such as PITC in adolescents is that it
is an inefficient strategy, given the relatively low-
HIV prevalence in this age group compared with
adults [33]. Thus, targeted approaches that identify
those at higher risk of being HIV-infected have been
proposed as potentially more cost-effective and sus-
tainable [34]. Two studies conducted in Malawi and
Kenya between 2013 to 2015 showed that 45 and
42% of adults in care, respectively, had children and
adolescents of unknown HIV status [25
&&
,39]. Nota-
bly, in the Kenya study, of adults who had children
of unknown HIV status, 82% reported their child
being more than 13 years, suggesting that adoles-
cents are much more likely to be undiagnosed than
younger children [39]. Actively testing children of
HIV-infected parents, an approach referred to as
index-linked testing, showed a four-fold increase
in HIV-testing rates as well as a high yield of HIV
(7–15%) compared with yield in studies that have
offered ‘unselected’ HTC [39]. Similarly, in the
Malawi study, index-linked testing of children (1–
15 years) and young persons (aged 15–24 years),
coupled with home-based testing and tracked fol-
low-up was highly acceptable and resulted in high
uptake (94%) and yield of HIV (4%) [25
&&
].
A screening tool consisting of five items [client-
reported orphan hood, past hospitalization, skin
problems, a sexually transmitted infection (STI)
and poor functional ability] developed in 2011 to
identify adolescents (10–18 years) at risk of being
HIV-positive who could then be targeted for HIV
testing, reduced the numbers needed to test to
identify an HIV-infected adolescent by 60% in
Zimbabwe [40]. In a follow-up study in 2015 that
field-tested a modified tool (four items, STI
removed) in older children and adolescents (6–15
years) attending PHCs, the sensitivity and specificity
in detecting HIV infection were 80.4 and 66.3%,
respectively [31]. In a similar study in Zambia
among 10–14 year olds, the odds of being HIV-
infected was 4.3 higher among those classified at
risk by the tool compared with those classified as not
at risk [26]. Although both targeted approaches
increase yield, they are more likely to identify verti-
cally rather than horizontally infected adolescents.
Community-based HTC strategies including
door-to-door, mobile and campaign HTC may be
able to diagnose individuals at an earlier stage of
infection by being more accessible and not relying
on providers’ discretion or on a client visiting a
health facility [41]. The latter is particularly relevant
as health facility usage rates among adolescents are
low [42]. A prevalence survey in Zimbabwe showed
that although health facility-based HTC resulted in
high yield of HIV, it was insufficient to reduce
community-level burden of undiagnosed HIV [43].
Nearly 40% of adolescents (8–17 years) with HIV in
the community-based survey were found to be undi-
agnosed despite implementation of optimized PITC
over 2 years in the seven study communities [43].
In Zambia, the PopART trial showed an 81%
uptake of HTC among adolescents aged 15–19 years
using a community-based door-to-door approach.
However, within households enumerated, contact
was not made with 25% of adolescents and one of
the major challenges cited in this study was diffi-
culty in obtaining consent from parents for their
adolescents to undergo HTC [30]. The yield in this
study was 3% among women and 1% among men. A
study from Kenya and Uganda that used mobile
community health campaigns wherever HTC was
offered over 2 weeks, followed by door-to-door HTC
reported 88% uptake of HTC among adolescents and
young people aged 10–24 years [44]. This was a
significant increase in HTC uptake as only 28% of
respondents reported prior HIV testing [44].
Although there was high coverage of HTC, the
number needed to test to identify one HIV-positive
adolescent was 88 in Uganda and 23 in Kenya. A
cross-sectional study in South Africa conducted
between 2014 and 2015, evaluating index-linked
HIV testing, campaign HTC and door-to-door test-
ing among adolescents (10–19 years) reported
uptake of 99% among adolescents who had received
counselling. However, yield of HIV was highest
through campaign testing (9%) followed by index-
linked testing (6%) and door-to-door testing had the
HIV testing among adolescents in SSA Chikwari et al.
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lowest yield (5.9%) [32]. The HPTN043 multicoun-
try trial (Project ACCEPT) conducted in Zimbabwe,
South Africa, Tanzania and Swaziland, which com-
bined community mobilization and mobile HTC
with posttest support services for adults (18 years),
improved rates of HIV testing by 25%, which were
sustained over 36 months of continued evaluation,
setting this intervention apart from traditional one-
off community-based HIV-testing campaigns [45].
The increase in proportion of testers was especially
pronounced in men (45% increase). However, over-
all incidence of HIV among young people [18–22,
23
&
,24] was the same in intervention and noninter-
vention communities [intervention effect 0.98 con-
fidence interval (CI) 0.80–1.22; P¼0.86][45].
Although community-based HTC strategies
appear to have high acceptance, reduced barriers
to access, and may identify those who are otherwise
hard-to-reach and are asymptomatic and would,
therefore, not attend health facilities, they have a
low yield of HIV, and require considerable resources
[30]. The cost effectiveness of these strategies must
be assessed to inform the feasibility of scalability and
long-term sustainability [46,47]. In addition, ensur-
ing linkage to care may be more challenging with
community-based HTC.
A study conducted among 16–24 years olds in
South Africa to evaluate self-testing using a rapid
blood test demonstrated that 96.4% completed the
test correctly and were able to interpret the test
results [48], and only 3% of participants failed to
prick their finger [48]. In recent years, HIV self-
testing using oral mucosal transudate (OMT) HIV
tests has been shown to be highly acceptable and
accurately performed by adults in SSA [37,49]. Fol-
lowing a large-scale evaluation of HIV self-testing in
SSA, there has been a rapid scale-up of this strategy
with a consequent reduction in the cost of OMT
tests [50]. Self-testing provides individuals the flexi-
bility to choose where and when to perform an HIV
test without fear of judgement from a provider [51],
and has the potential to bridge the gap that cur-
rently exists in access to HTC among adolescents
[52]. A community-based study in Malawi that eval-
uated self-testing found that the highest uptake was
among 16–19-year olds. [49]. This approach may,
however, not be appropriate for younger adoles-
cents [17
&
,21], and an alternative may be to train
guardians to test their own children.
The use of incentives may be one approach to
increase uptake of HTC [53]. A recent randomized
controlled trial conducted in Zimbabwe comparing a
fixed incentive (US$ 2)or lotteryparticipation (to win
US$ 5 or US$ 10), both given to caregivers of 8–17-
year olds, showed 3.67 and 2.66 higher odds, respec-
tively, of adolescents accessing HTC compared with
the control arm (no incentive) [28]. A pilot random-
ized trial in Kenya also found higher uptake of HTC in
children aged 0–12 years whenever an incentive of
cash or mobile money transfer (KSH500, KSH1000
and KSH1500) was offered to their female caregiver
whenever compared with a similar cohort that did
not offer incentives (72 versus 14%) [29]. In this
study, 25% of caregivers had children of unknown
HIV status who were more than 12 years and, there-
fore, ineligible. Concerns have been raised about the
potential for scalability, the cost-effectiveness and
the potential for coercion from caregivers to adoles-
cents to test [28,29]. However, the risk of coercion is
unlikely to be significant, given the small amounts of
incentives given. In both studies incentives were
given to caregivers suggesting that this strategy
would likely be more sustainable for younger adoles-
cents in the context of vertical HIV infection and
repeated HTC would not be required until sexual
debut. Further research is required to assess effective-
ness of incentives offered to adolescents themselves
on HTC uptake.
Organized social events (sports events and cam-
paigns) that incorporate sexual and reproductive
health services and HTC have been used to reach
adolescents. ‘One-stop shop’ services that incorpo-
rate HTC among a broader package of health services
(e.g. nutritional counselling) could decrease the
stigma associated with HIV testing and be more
acceptable to adolescents. Such an approach has
been used in South Africa delivered through mobile
services and at youth centres [54]. Grassroots Soccer,
a nongovernmental organization, through their
SKILLZ Street program for girls aged between 12
and 16 years in South Africa from 2011 to 2012
found that as part of their soccer-based program,
69% of girls had tested for HIV [55].
Use of mobile technology coupled with edutain-
ment has been used to improve HTC uptake and
intention to test among adolescents [27,56]. The
Shout-It-Now program in South Africa used a step-
wise process with a combination of technology, tele-
phone counselling and social marketing with reports
of testing uptake of 98.5% through their school pro-
gram [27]. More research is required to evaluate the
yield and effectiveness of this approach.
CONCLUSION
HIV testing is the critical first step to accessing HIV
treatment and prevention services. In recent years,
there has been progress made towards developing
HTC strategies appropriate for adolescents. It is vital
to consider not only the feasibility, acceptability
and yield of strategies but also their potential for
scalability and cost-effectiveness. Finally, linkage to
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appropriate care and prevention services must be
coupled with HTC approaches.
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3. Evaluating the effectiveness of health facility-and 
community-based index-linked HIV testing strategies for 




3.1 Introduction  
As detailed in the previous chapter children face significant barriers in accessing 
HIV testing and often reach adolescence with undiagnosed HIV infection.6,85,88 As 
such, effective strategies are needed to identify children and adolescents living 
with undiagnosed HIV.  
The aim of the B-GAP project was to evaluate the effectiveness of index-linked 
HIV testing in identifying children with HIV aged 2–18 years in Zimbabwe. As 
part of the B-GAP project people living with HIV were offered index-linked HIV 
testing for household members aged 2-18 years via a choice of three HIV testing 
methods, namely facility-based testing by a provider, community-based testing 
by a lay worker and provision of an HIV self-test kit to the caregiver to test their 
children at home.  
This chapter presents the published protocol of the main B-GAP study. The paper 
provides a description of the formative work conducted, study setting and study 
procedures. Although all components of this thesis are covered in this protocol 
paper the hypothesis that underpinned this PhD was that “Providing 
differentiated HIV-testing through the gateway of index testing is an 
effective and acceptable way to identify undiagnosed HIV in children".  
The methods used in the final research for this thesis are founded on the methods 
outlined in the protocol paper and on formative work conducted as part of the 
study. However, some operational adaptations were made throughout the 
implementation of the study and as such methodology for some components 
evolved. To add to information provided in this manuscript; Table 1 below 
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summarizes the key objectives and methods finally used in answering the 
research questions presented in this thesis. In addition, detailed methods are 
described in each subsequent chapter.  
Table 1: Overview of Research Objectives and Methods used in thesis    
Objective Methods 
1. Evaluate the acceptability, 
uptake, and yield of an index-
linked HIV testing strategy (HIV 
testing offered to children living 
in households with an individual 
living with HIV) offered in facility 
and community-based settings. 
Quantitative Study 
 Clinic based screening of potential indexes 
by research staff  
 Follow up and testing of children and 
adolescents by research staff  
 Quantitative data collection on tablet-based 
questionnaires administered and completed 
by research staff  
2. Explore provider and caregiver 
perceptions and experiences of 
index-linked HIV testing for 
children and adolescents. 
Qualitative Study 
 Focus Group Discussions (FDGs) with health 
providers and caregivers  
 FDGs conducted by external research staff 
not involved in implementation of the main 
study  
3. Evaluate the diagnostic accuracy 
of the oral mucosal transudate 
HIV test for children and 
adolescents.  
Quantitative Study 
 Facility based screening and testing of 
children and adolescents by research staff  
 Quantitative data collection on tablet-based 
questionnaires administered and completed 
by research staff 
4. Assess the feasibility and 
accuracy of caregiver provided 
HIV testing for children and 
adolescents. 
Quantitative Study 
 Facility based screening and community-
based observations of caregivers testing their 
children by research staff  
 Quantitative data collection on tablet-based 
questionnaires administered and completed 
by research staff 
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AbstrACt 
Introduction The number of new paediatric infections per 
year has declined in sub-Saharan Africa due to prevention-
of-mother-to-child HIV transmission programmes; 
many children and adolescents living with HIV remain 
undiagnosed. In this protocol paper, we describe the 
methodology for evaluating an index-linked HIV testing 
approach for children aged 2–18 years in health facility 
and community settings in Zimbabwe.
Methods and analysis Individuals attending for HIV 
care at selected primary healthcare clinics (PHCs) will 
be asked if they have any children aged 2–18 years in 
their households who have not been tested for HIV. Three 
options for HIV testing for these children will be offered: 
testing at the PHC; home-based testing performed by 
community workers; or an oral mucosal HIV test given 
to the caregiver to test the children at home. All eligible 
children will be followed-up to ascertain whether HIV 
testing occurred. For those who did not test, reasons 
will be determined, and for those who tested, the HIV 
test result will be recorded. The primary outcome will be 
uptake of HIV testing. The secondary outcomes will be 
preferred HIV testing method, HIV yield, prevalence and 
proportion of those testing positive linking to care and 
having an undetectable viral load at 12 months. HIV test 
results will be stratified by sex and age group, and factors 
associated with uptake of HIV testing and choice of HIV 
testing method will be investigated.
Ethics and dissemination Ethical approval for this 
study was granted by the Medical Research Council of 
Zimbabwe, the London School of Hygiene and Tropical 
Medicine and the Institutional Review Board of the 
Biomedical Research and Training Institute. Study results 
will be presented at national policy meetings and national 
and international research conferences. Results will also 
be published in international peer-reviewed scientific 
journals and disseminated to study communities at the 
end of study.
IntroduCtIon
HIV testing is the critical first step to accessing 
life-saving antiretroviral therapy (ART).1 
Despite this, many children living with HIV 
in sub-Saharan Africa, which was home to 
approximately 92% of the 3.2 million chil-
dren below 15 years with HIV globally in 
2014, remain undiagnosed.2–4 
Children infected through mother-to-
child transmission who are not diagnosed 
in infancy often remain undiagnosed until 
strengths and limitations of this study
 ► Our study will provide evidence for the effective-
ness of index-linked HIV testing in facilities and 
communities. The strategy has the potential to be a 
cost-effective and efficient strategy for HIV testing in 
children, given the relatively low prevalence in this 
age group.
 ► Our intervention is relevant to policy questions for 
the implementation of HIV testing for children. This 
study will provide evidence for use of lower level 
cadres to offer and perform HIV testing as advocated 
by the WHO in both rural and urban settings.
 ► Other HIV testing interventions will be implemented 
by other stakeholders in the study areas during the 
study period. This may affect the impact  assess-
ment of this study.
 ► Potential challenges include low uptake of the inter-
vention, lost-to-follow-up of clients once they have 
agreed to have their child tested and finding clients 
who have opted for home-based testing.
 ► Due to relatively low HIV prevalence (<4%), analysis 
of linkage to care will be limited to a purely descrip-
tive analysis of the proportion of children linking to 
care and virologically suppressed at 12 months.
 on D
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they present with symptomatic HIV infection in later 
childhood.5 Coverage of early infant diagnosis is subop-
timal and therefore a substantial proportion of children 
infected through mother-to-child transmission are not 
diagnosed timely in infancy and are only identified in 
later childhood when they develop advanced disease.6 
In 2017, only 63% of HIV-exposed infants in eastern 
and southern Africa received an HIV test within 8 weeks 
of age as recommended.6 In a study that implemented 
provider-initiated HIV testing and counselling (PITC) 
among children aged 6–16 years in primary care clinics 
in Zimbabwe from 2013 to 2015, the median age of HIV 
diagnosis was 11 years and those aged >13 years were 
less likely than younger children to be diagnosed.7 8 The 
high proportion of undiagnosed HIV among children in 
sub-Saharan Africa, together with low paediatric treat-
ment coverage, continues to be key in sustaining the 
epidemic.
Barriers to HIV testing of children and adolescents 
include the need for guardian consent in most countries 
in sub-Saharan Africa for children younger than 16 years, 
negative attitudes and lack of training among healthcare 
workers, stigma and long distances between homes and 
healthcare facilities where testing is provided, inconve-
nient opening hours of facilities and long waiting times.1
A 2011 study from Zambia assessing reasons for non-up-
take of HIV testing among children aged below 15 
years found that the majority (76%) with confirmed or 
suspected HIV infection had a primary caregiver who was 
also living with HIV.9 A study from Zimbabwe testing chil-
dren aged 6–16 years conducted in 2014 found that 95% 
of those who tested HIV positive were perinatally infected. 
More importantly, 65% had a caregiver or sibling known 
to be HIV positive or taking ART, and 20% of the accom-
panying caregivers also tested HIV positive.10 Similarly, 
in a Malawian study including patients (15–49 years) on 
ART at a large ART clinic in 2006–2007, 81% of their 
children (0–16 years) had reportedly not been tested.11 
These studies show that children living with HIV-infected 
adults are at high risk for being HIV positive themselves; 
however, in most instances, these children have not been 
provided with HIV testing.
The WHO has recommended index-linked HIV testing, 
whereby household members, sexual contacts or children 
of a known HIV-infected person are offered an HIV test, 
as one of the approaches for addressing the gap in HIV 
testing.12 Two studies that have implemented such an 
approach among children in Malawi and Kenya found 
that more than 40% of adults in HIV care were living in 
households with children of unknown HIV status and 
the prevalence of HIV in children tested through this 
approach was significantly higher than from other ‘unse-
lective’ HIV testing approaches within Africa.13 14
The Bridging the GAP in HIV testing and care for Chil-
dren in Zimbabwe (B-GAP) study aims to investigate the 
effectiveness of index-linked HIV testing among children 
aged 2–18 years in Zimbabwe. Testing will use both facil-
ity-based and community-based approaches to address 
the barriers described above. Notably, as well as offering 
facility-based and home-based HIV testing for untested 
children of index adults with HIV, this study will also inves-
tigate a novel approach whereby caregivers can test their 
children using an oral mucosal HIV test. We elaborate on 
the formative research that informed the approaches to 
index-linked HIV testing, study design and methodology, 
analysis and intended study impact. In addition, the study 
will also evaluate the cost-effectiveness and conduct a 
process evaluation to inform factors that will influence 
scalability of this approach in programmatic settings. 
This study speaks strongly to the WHO recommendations 
to develop innovative feasible strategies to reduce the 
burden of undiagnosed HIV among children.12
MEthods
study objectives
The aim of the study was to evaluate the effectiveness of 
index-linked HIV testing in identifying children with HIV 
aged 2–18 years in Zimbabwe. The objectives are to
1. Evaluate the acceptability, uptake and yield of an in-
dex-linked HIV testing strategy for children and ado-
lescents in facility-based and community-based settings.
2. Investigate factors associated with uptake of in-
dex-linked HIV testing and with choice of a certain 
method (clinic-based, community-based provider-de-
livered and community-based caregiver-delivered test-
ing).
3. Investigate linkage to care, retention in care and viro-
logical suppression among children living with HIV 
who are offered community health worker (CHW) 
delivered support in addition to clinic-based care (the 
standard of care).
4. Estimate the cost and calculate the cost-effectiveness of 
index-linked HIV testing for children and adolescents, 
compared with current standard of care.
5. Conduct a process evaluation of the intervention’s im-
plementation, mechanisms of impact and local context 
to inform the components required for sustainability 
and scalability.
Patient and public involvement
Formative research and key considerations for study design
Between May and December 2017, we conducted exten-
sive stakeholder engagement and a situational analysis to 
inform the intervention design with regard to the testing 
strategy. The specific objectives were first to understand 
HIV testing pathways within public healthcare facilities 
and their partnerships with non-governmental stake-
holders; to inform selection of study sites and healthcare 
worker cadres to implement the intervention; and second 
to elicit key stakeholder views on preferences, potential 
limitations and foreseeable obstacles for delivery of index-
linked HIV testing. Results were used to inform the inter-
vention design and preparedness for implementation, as 
well as development of standard operating procedures.
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Interviews were conducted with Ministry of Health and 
Child Care (MoHCC) officials and key informants from 
MoHCC partner organisations that were implementing 
HIV programmes in Zimbabwe. In total, 25 field observa-
tions, 19 site assessments at healthcare facilities across 2 
provinces and 53 in-depth interviews (IDIs) with health-
care providers, community-based organisations, adults 
and adolescents living with HIV and CHWs were under-
taken. These findings will be reported in detail elsewhere; 
however, a summary of how findings informed design is 
shown in table 1.
Formative work was also conducted to inform the 
community-based support intervention for children 
living with HIV delivered by CHW. The research find-
ings, development and design of the community-based 
support intervention will be presented in a separate 
manuscript.
study sites
Zimbabwe has the sixth highest adult HIV prevalence 
globally and approximately 1.3 million people were living 
with HIV in 2017.6 15 The study will be conducted in six 
primary healthcare clinics (PHCs) in Bulawayo (urban) 
and three PHCs in Mangwe district (rural) in Zimbabwe. 
In 2016, Bulawayo had the highest adult HIV prevalence 
(18.7%) in an urban setting, while Mangwe in Matabele-
land South Province has the highest national HIV preva-
lence (22.3%).15 Clinics were purposively selected based 
on (1) the size of the facility so that the target sample size 
could be reached, and (2) their geographical locations 
to allow good accessibility by the study team in rural sites 
(figure 1). HIV clinics in hospitals were excluded due to 
their larger and less well-defined catchment area which 
would make community-based testing and follow-up 
difficult.
Participant recruitment: inclusion and exclusion criteria
All individuals with HIV attending for care at study clinics 
will be screened daily to identify attendees with children 
aged 2–18 living in their household (index). If the index 
attendee is <18 years, they will need to be accompanied by 
a parent or caregiver aged >18 years to provide consent. 
Indices who have children with unknown status or chil-
dren who previously tested HIV negative more than 
6 months ago will be offered HIV testing for their chil-
dren. Being tested more than 6 months ago was included 
as a criterion for offering testing to account for older 
children who may have been horizontally infected. If 
the index consents to having the child or children in the 
household tested, three testing options will be offered: 
(1) testing at the clinic by a healthcare provider, (2) 
home-based testing performed by a healthcare provider 
or (3) at home by the caregiver using a self-test kit.
Table 1 Summary of how formative research informed intervention design
Finding Intervention design
Prevalence of undiagnosed HIV among children is 
heterogeneous across settings and regions.
Study sites were chosen based on an anticipated high prevalence of 
undiagnosed HIV.
Index-linked testing has not been fully implemented due 
to staff shortage at health facilities.
Research staff were hired to support implementation of intervention 
in facilities.
HIV testing services are provided by multiple 
stakeholders across the country with poor coordination 
between stakeholders. This results in duplication of 
services and failure to link individuals accessing services 
through community partners with health facilities.
A collaborative agreement between the research team and the 
MoHCC and its implementing partners conducting HIV testing in 
facilities and communities was established. HIV test kits will be 
provided by the MoHCC and all HIV testing data reported to the 
MoHCC.
User fees are in place for health service provision at the 
urban facilities including HIV testing (US$5 and US$3 
depending on age of child).
For the purpose of this study, user fees will be dropped for all 
children and adolescents undergoing HIV testing in selected 
healthcare facilities
Individuals have to travel long distances to access 
healthcare facilities particularly in rural settings.
A novel HIV testing strategy will be introduced whereby caregivers 
will be given the option to test their children at home using an HIV 
self-test kit, thus eliminating the requirement for caregivers to bring 
children to the healthcare facility for testing.
MoHCC, Ministry of Health and Child Care.  
Figure 1 Map of the selected Bridging the GAP in HIV 
testing and care for children in Zimbabwe sites.
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Demographic details of the index and the children 
will be recorded electronically on tablets by the research 
assistants using Open Data Kit.16 Locator details of the 
household including mobile phone numbers and phys-
ical addresses will be collected for all consenting index 
cases and particularly for community-based HIV testing 
and to ascertain HIV test outcomes among those who opt 
to test their children using a self-test kit. All participants 
will be given a study helpline number to call for further 
information, counselling referrals or support.
hIV testing procedures
HIV testing will be carried out according to national 
guidelines using a serial testing algorithm.17
Clinic-based HIV testing
Caregivers who opt for clinic-based HIV testing of 
their children will be given referral cards on the day 
of screening by a research assistant. HIV testing will be 
performed by routine clinic staff. Research assistants will 
use locator information to follow-up participants who 
have consented to have their child(ren) tested in the 
clinic but have not presented to the clinic within 7 days 
of recruitment. They will make up to three attempts to 
locate the index via telephone or home visit at day 7, 14 
and 21 postscreening.
Community-based HIV testing by a healthcare provider
Caregivers who opt for community-based testing will 
indicate a suitable date for HIV testing on the day of 
screening. A MoHCC implementing partner for commu-
nity-based testing will visit the household to conduct an 
HIV test. If no contact is made on the scheduled visit date, 
the provider will conduct a further two visits to perform 
HIV testing. A test outcome will be recorded once three 
attempts have been made within 30 days of screening.
Community-based HIV testing by the caregiver
Caregivers who opt to use an HIV oral mucosal test 
(OMT) to test their children at home will undergo an 
assessment of guardianship status for each child. Only 
indices who are parents or legal guardians of eligible chil-
dren will be eligible to take an OMT kit. Detailed instruc-
tions on performing an oral HIV test and interpreting the 
test result will be given by research assistants in the clinic 
using an OMT, an instruction pamphlet from the manu-
facturer translated to local languages and demonstration 
videos. The research assistant will complete a brief compe-
tency assessment including a demonstration of how to 
perform the test and how to interpret a set of results 
displayed on pictures by the caregiver. If the caregiver 
fails the competency assessment, they will be asked to take 
up either of the other two testing options. Caregivers who 
successfully complete the competency assessment will be 
provided with a test kit for each eligible child and will be 
instructed to conduct the test within 5 days of screening 
and to keep the used OMT kit. They will be instructed to 
bring each child who tests OMT reactive for HIV to the 
clinic for confirmatory HIV testing as recommended by 
WHO guidelines.18 Written information about confirma-
tory HIV testing services will be provided. Caregivers will 
be followed up to ascertain HIV test outcome either by 
telephone call or home visit within 7 days and their used/
unused OMT test kits will be collected within 21 days of 
screening.
The first 10–15 index cases who select caregiver testing 
in each clinic will undergo supervised caregiver self-
testing to evaluate if there are any problems with care-
givers’ understanding. The parent/guardian will conduct 
the test while a research assistant is present at the home 
on the selected testing date and in parallel the research 
assistant will conduct a rapid blood test as per the 
national HIV testing algorithm.17 During the assessment, 
the research assistant will note any challenges the care-
giver had with completing the test and whether or not 
the caregiver requested assistance from the research assis-
tant. Appropriate changes will be made to the training 
and demonstration practices if necessary.
Linkage to care if HIV positive
Children and adolescents will be told their HIV status 
according to their level of understanding and maturity 
as described by the national HIV testing and counselling 
guidelines.17 All caregivers and children who test HIV 
positive will receive post-test counselling and a written 
referral to their nearest healthcare facility for confirma-
tory HIV testing and linkage to HIV care. For clinic-based 
testing, referrals will be made to the clinic staff respon-
sible for initiating care on the day of testing. For commu-
nity-based testing and caregiver testing, written referrals 
will be made to the nearest/preferred healthcare facility 
and all participants will be followed up by study staff to 
ascertain linkage to HIV care. Study staff will share all 
HIV testing records with the relevant healthcare facility. 
Caregivers of and children who test HIV positive (or are 
identified as known HIV positive but not linked to care) 
will be offered support visits from a CHW at home or at a 
community-based location of their choice conducted at 1, 
3 and 6 months postdiagnosis.
In addition to the above-described testing procedures, 
partners of index cases will be offered HIV testing. This 
will not contribute to study outcomes but will be imple-
mented to ensure the intervention complies with current 
standard of care and WHO recommendations.
outcomes
The primary outcome will be uptake of HIV testing, 
defined as an eligible child having completed an HIV 
test and the caregiver knowing the test result within 30 
days of the HIV test being offered. The HIV test result or 
reasons why a test is not done will be recorded. Secondary 
outcomes for the study will include the preferred HIV 
testing method, HIV yield and prevalence. HIV preva-
lence and yield will be stratified by age group (0–5, 6–10 
and 10–18 years). Additional secondary outcomes will 
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Cost-effectiveness analysis
The cost-effectiveness analysis aims to determine whether 
index-linked testing in children is a cost-effective strategy 
compared with current standard of care in Zimbabwe; 
passive provider-initiated testing at healthcare facilities. 
Both the full costs of delivering the intervention and 
the incremental costs will be estimated using a provider 
perspective through mixed methods involving a combina-
tion of primarily bottom-up micro-costing, with the use of 
top-down costing when necessary. Costs will be presented 
as follows: (1) Cost per child tested via each of the index-
linked testing modalities; (2) Cost per HIV-positive child 
detected through each of the index-linked testing modal-
ities; and (3) cost per new HIV initiate. The base case 
Cost-Effectiveness Analysis (CEA) will be conducted over 
a lifetime time horizon, annually discounted at the stan-
dard rate of 3%,19 to reflect future costs and effects at 
current value, to estimate the incremental cost effective-
ness ratio, as cost per disability-adjusted life year (DALY) 
averted. A dynamic transmission model will be used to 
estimate the DALYs averted, derived from a combination 
of accessing treatment and the HIV infections averted, 
using parameters extracted from the literature. A sensi-
tivity analysis will be conducted to explore the impact of 
key variables on the results including HIV prevalence and 
geographical location. As there is much debate and uncer-
tainty surrounding recommended C-E threshold values 
for different settings,20 a cost-effectiveness acceptability 
curve will be constructed. The resulting Incremental 
Cost-Effectiveness Ratio (ICER) will be compared against 
different threshold values that are likely to be appropriate 
to the Zimbabwe setting. This analysis will help inform 
MoHCC policy around alternate forms of HIV testing and 
counselling.
Process evaluation
A detailed mixed-methods process evaluation will be 
conducted alongside the delivery of the intervention. The 
process evaluation will be based on the Medical Research 
Council Process Evaluation Framework and will explore 
three core evaluation functions: implementation, mecha-
nisms of impact and context to evaluate the delivery and 
receipt of the intervention, in order to better understand 
what components of the intervention work, for whom and 
under what circumstances.21 The process evaluation data 
will be analysed and written up in order to contribute 
to understanding the study results and to provide guid-
ance for sustainable and scalable implementation of the 
intervention by local health authorities should it prove 
successful. Quantitative indicators for the process evalua-
tion will include staff turnover, record of shortage of test 
kits and supplies and incident reports about facility-based 
and community-based testing from research assistants 
and the project coordinator. Descriptive statistics of these 
indicators will be used to help assess aspects of the inter-
vention’s fidelity, feasibility and acceptability, and to iden-
tify lessons important in informing the replication and 
scale-up of this approach to testing.
Focus group discussions (FGDs) with research assistants 
and FGDs and IDIs with a purposively selected sample of 
indices will be conducted to elicit provider and caregiver 
perceptions and experiences of index-linked HIV testing 
for children at baseline and end line. Sampling for FGDs 
will include a group of caregivers representing index age 
(older vs younger) and sex, HIV testing option, HIV test 
uptake (accepted vs did not accept testing; and whether 
child tested or not) and study site (rural vs urban). We will 
also conduct IDIs with caregivers who had a child test HIV 
positive through index-linked HIV testing at end line.
As testing by caregivers is a novel intervention, the 
acceptability of this method will be explored from 
providers’ and caregivers’ perspectives. IDIs will be held 
with caregivers who selected this option to understand 
how messaging and training for caregiver testing used 
in the competency and accuracy assessments can be 
improved, as well as how testing is performed by care-
givers on their children in their homes. Interviews will 
also be held with index participants who did not select his 
method to understand their concerns.
sample size estimates
Sample size estimations are based on precision of esti-
mates of uptake of index-linked HIV testing. We will 
recruit participants from nine clinics, with an average 
daily adult attendance of 32 per clinic (excluding repeat 
attenders). Over 12 weeks per clinic, we expect to screen 
a total of 5184 HIV-positive index cases at nine clinics with 
children aged 2–18 years (assuming 5 working days a week 
and 30% of adults with HIV have children and adoles-
cents living in the household). Assuming an index refusal 
rate of 35%, and an average of 2 children per house-
hold, we would screen approximately 6739 children and 
adolescents. This sample size provides ±1% precision for 
an estimate of 80% of screened children and adolescents 
taking up HIV testing, with a 95% CI of 79.0%–81.0%. 
Sample sizes for qualitative work will be determined on 
an ongoing basis by study staff until thematic saturation 
has been reached.
Assuming HIV prevalence of 4%, this would yield 215 
children living with HIV eligible for linkage-to-care. This 
sample size provides good precision of ±6% around an 
estimated 80% linking-to-care (n=172) and precision of 
±9% around an estimated 70% with viral suppression at 
12 months out of 85% retained in care (n=102/146).
data analysis
A study flowchart showing total number of index cases 
screened, eligibility of index cases and children in their 
household, proportions of index cases providing consent 
for collection of additional data about themselves and 
the children living in their households will be presented 
(figure 2). Demographic characteristics of index partici-
pants and children and adolescents living in their house-
holds will be summarised using proportions, means and 
SD. The uptake of HIV testing and HIV prevalence strati-
fied by age group (0–5, 6–10 and 10–18 years) and sex will 
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be calculated, and factors associated with uptake of index-
linked HIV testing will be assessed using univariate anal-
ysis. A multivariate logistic regression will be conducted 
to assess factors predictive of uptake/non-uptake of HIV 
testing adjusted for clustering by index case. We will eval-
uate factors associated with the uptake of the preferred 
HIV testing method using multinomial logistic regres-
sion. The proportion of children who tested positive and 
linked to HIV care and the proportion with virological 
suppression will be calculated at 12 months.
study status
The study began recruitment of study participants in 
January 2018. Recruitment is ongoing.
dIsCussIon
There has been a remarkable scale-up of prevention of 
mother-to-child HIV transmission (PMTCT) programmes 
resulting in a decline in numbers of perinatally acquired 
HIV infections.2 However, many children and adoles-
cents with HIV, acquired before PMTCT programmes 
were scaled-up, remain undiagnosed, with diagnosis only 
occurring when they present with advanced disease.6 In 
addition, suboptimal coverage of early infant diagnosis 
within PMTCT programmes results in many HIV-exposed 
children not being identified.2 6 Those who acquire HIV 
postnatally through breastfeeding may also present later 
in childhood. HIV testing is the critical step to accessing 
HIV treatment and high rates of undiagnosed HIV partly 
explain the lower coverage of HIV treatment in children 
and adolescents compared with adults.22
PITC has been recommended by the WHO since 
2007.23 However, this relies on an individual attending 
a health facility. Also, PITC may not be as cost-effective 
a strategy in children as in adults given the lower HIV 
prevalence among children compared with adults. Index-
linked testing is a targeted strategy focusing on testing of 
children at higher risk of HIV infection. If effective, this 
strategy has the potential to be a more cost-effective and 
efficient HIV testing strategy in resource-limited settings. 
Our study will implement both community-based and 
health facility-based HIV testing for children and investi-
gate a novel approach of caregivers testing their own chil-
dren to increase accessibility and uptake of HIV testing.
We believe that community-based strategies in our 
study have the potential to eliminate many of the barriers 
to HIV testing for children and adolescents.14 In a study 
conducted in Malawi, index-linked testing offered to chil-
dren and young people (1–24 years) had higher uptake 
for community (95.5%) when compared with facili-
ty-based (4.5%) testing.14 Enabling caregivers to test their 
children may reduce the burden of client-associated costs 
such as time spent in and getting to facilities for testing 
by clients, provider time, and maintenance and upkeep of 
health facilities. However, most importantly, it allows the 
caregivers to perform the test in the comfort and privacy 
of their homes and empowers them to take responsibility 
for the testing. Another innovation is the use of CHWs to 
perform HIV testing in the community. While a similar 
cadre termed ‘primary care counsellor’ is widely used 
to provide HIV testing in health facilities, HIV testing in 
communities is largely provided by nurses. The CHWs will 
complete a 2-week training in ethics and rapid HIV testing 
as well as on study procedures. If effective, our study 
will provide evidence for use of lower level cadres such 
as community health workers to offer and perform HIV 
testing as advocated by the WHO.12 There is evidence to 
show that the use of lower level cadres can reduce cost of 
staffing for the government and may improve cost-effec-
tiveness of community-based approaches when compared 
with traditional facility-based HIV testing.24
Furthermore, the study also addresses linkage to care, 
initiation of ART and adherence through a commu-
nity-based support intervention. It is crucial that any 
HIV testing intervention addresses these steps in the 
continuum of HIV care to ensure maximum benefits (ie, 
reduced morbidity and onward transmission).
Potential challenges include low uptake of the inter-
vention, lost-to-follow-up of clients once they have agreed 
to have their child tested and finding clients who have 
opted for home-based testing. Within our study, user fees 
for HIV testing were dropped. This has implications for 
the generalisability of our findings in settings where user 
fees are in place and may act as a barrier to uptake of HIV 
testing services. Similarly, our study findings may not be 
generalisable to other settings as contextual factors may 
affect uptake of the intervention. It is important to note 
that in parallel to evaluation of uptake and yield of index-
linked HIV testing, we will conduct a detailed process 
evaluation to explore the implementation, mechanisms 
of impact and contextual factors affecting the delivery 
and acceptability of this intervention, which will help 
Figure 2 Index-linked HIV testing participant flow.
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inform sustainability and scale-up should it prove effec-
tive. Another limitation is that other HIV testing inter-
ventions will be implemented in our study settings at the 
same time. However, detailed recording of other HIV 
testing interventions will be part of the process evalua-
tion. This will help with understanding how other HIV 
testing interventions interact with each other and index-
linked testing.
Ethics and dissemination
Ethical approval was sought and granted by the Medical 
Research Council of Zimbabwe (MRCZ), the London 
School of Hygiene and Tropical Medicine ethics 
committee and the Institutional Review Board of the 
Biomedical Research and Training Institute.
Study progress and findings will be reported annually 
to MRCZ and feedback meetings will be held quarterly 
with the health directorates of the two study sites. Results 
of interim data analysis will be presented at national and 
international research meetings and conferences. Results 
will also be prepared for publication in international 
peer-reviewed scientific journals and disseminated to 
study communities at the end of study. A detailed dissem-
ination plan to inform scale-up will be developed for 
implementation.
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4.1 Introduction   
The aim of this chapter is to compare the uptake and yield of community and 
facility-based delivery of index-linked HIV testing for children and adolescents in 
urban and rural settings in Zimbabwe, a country with a sustained, severe 
generalised HIV epidemic. Indexes (defined as HIV positive individuals who had 
children in their households eligible for HIV testing i.e. children who had not 
previously been tested or had tested HIV-negative more than six months ago) 
were offered a choice of  i) bringing the child(ren) for HIV testing at the health 
facility, ii) the child(ren) receiving home-based testing performed by a health 
provider or iii) taking an OMT test kit to test their children in the home.  
The study showed that facility-based HIV testing was most frequently chosen by 
indexes, but children were more likely to be tested if the index chose either of the 
community-based HIV testing methods. Additionally, older adolescents were less 
likely to be tested compared to younger children, and boys were less likely to be 
tested than girls. In this study the yield of HIV was low when compared to other 
studies in similar settings.  
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Articles
Comparison of index-linked HIV testing for children and 
adolescents in health facility and community settings in 
Zimbabwe: findings from the interventional B-GAP study
Chido Dziva Chikwari, Victoria Simms, Katharina Kranzer, Stefanie Dringus, Rudo Chikodzore, Edwin Sibanda, Karen Webb, Barbara Engelsmann, 
Nicol Redzo, Tsitsi Bandason, Hilda Mujuru, Tsitsi Apollo, Getrude Ncube, Karen Hatzold, Helen A Weiss, Rashida A Ferrand
Summary
Background Index-linked HIV testing, whereby children of individuals with HIV are targeted for testing, increases 
HIV yield but relies on uptake. Community-based testing might address barriers to testing access. In the Bridging the 
Gap in HIV testing and care for children in Zimbabwe (B-GAP) study, we investigated the uptake and yield 
of index-linked testing in children and the uptake of community-based vs facility-based HIV testing in Zimbabwe.
Methods B-GAP was an interventional study done in the city of Bulawayo and the province of Matabeleland South 
between Jan 29 and Dec 12, 2018. All HIV-positive attendees (index patients) at six urban and three rural primary 
health-care clinics were offered facility-based or community-based HIV testing for children (age 2–18 years) living in 
their households who had never been tested or had tested as HIV-negative more than 6 months ago. Community-based 
options involved testing in the home by either a trained lay worker with a blood-based rapid diagnostic test (used in 
facility-based testing), or by the child’s caregiver with an oral HIV test. Among consenting individuals, the primary 
outcome was testing uptake in terms of the proportion of eligible children tested. Secondary outcomes were uptake of 
the different HIV testing methods, HIV yield (proportion of eligible children who tested positive), and HIV prevalence 
(proportion of HIV-positive children among those tested). Logistic regression adjusting for within-index clustering 
was used to investigate index patient and child characteristics associated with testing uptake, and the uptake 
of community-based versus facility-based testing.
Findings Overall, 2870 index patients were linked with 6062 eligible children (3115 [51·4%] girls [sex unknown in 
seven], median age 8 years [IQR 5–13]). Testing was accepted by index patients for 5326 (87·9%) children, and 
3638 were tested with a known test outcome, giving an overall testing uptake among 6062 eligible children 
of 60·0%. 39 children tested positive for HIV, giving an HIV prevalence among the 3638 children of 1·1% and an 
HIV yield among 6062 eligible children of 0·6%. Uptake was positively associated with female sex in the index 
patient (adjusted odds ratio [aOR] 1·56 [95% CI 1·38–1·77], p<0·0001) and child (aOR 1·10 [1·03–1·19], p=0·0080), 
and negatively associated with any financial cost of travel to a clinic (aOR 0·86 [0·83–0·88], p<0·0001), increased 
child age (6–9 years: aOR 0·99 (0·89–1·09); 10–15 years: aOR 0·91 [0·83–1·00]; and 16–18 years: aOR 0·75 
[0·66–0·85]; p=0·0001 vs 2–5 years), and unknown HIV status of the mother (aOR 0·81 [0·68–0·98], p=0·027 
vs HIV-positive status). Additionally, children had increased odds of being tested if community-based testing was 
chosen over facility-based testing at screening (1320 [73·9%] children tested of 1787 vs 2318 [65·5%] of 3539; aOR 1·49 
[1·22–1·81], p=0·0001).
Interpretation The HIV yield of index-linked testing was low compared with blanket testing approaches in similar 
settings. Index-linked HIV testing can improve testing uptake among children, although strategies that improve 
testing uptake in older children are needed. Community based testing by lay workers is a feasible strategy that can be 
used to improve uptake of HTS among children and adolescents.
Funding UK Medical Research Council, UK Department for International Development, Wellcome Trust.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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The scale-up of antiretroviral therapy (ART) globally in 
the past 20 years has substantially reduced HIV-
associated mortality across all age groups.1 However, 
glo bally the cov erage of ART in children (<15 years) was 
only 53% in 2019, largely due to delays in diagnosis.2 
Testing of HIV-exposed children within pre vention 
of mother-to-child trans mission (PMTCT) pro grammes 
remains sub optimal, and subsequently children with 
perinatally acq uired HIV are often diagnosed later 
in childhood when they present with HIV-associated 
seque lae.3,4 Late diag nosis is associated with chronic 
com pli cations such as growth failure, organ damage, 
and increased mortality.5–7 Effective strategies to address 
the barriers to HIV diagnosis in children are urgently 
needed.8
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Given the relatively low prevalence of HIV in children,2,3 
targeted HIV testing strategies, including the use of 
screening tools and index-linked testing, have been 
suggested to improve testing efficiency and potentially 
reduce costs.9 Index-linked testing, whereby an HIV test 
is offered to contacts of an index case (ie, an individual 
living with HIV), has been shown to increase HIV yield 
when used in children, but as with any other testing 
strategy, it relies on uptake by parents and carers.9,10 The 
test location (eg, health facilities vs community-based 
settings) might influence uptake.11 Barriers to facility-
based testing in children include inflexible facility 
working hours, user fees, distance to clinics, transport 
costs, and insufficient or overworked health-care pro-
viders.12 In view of these barriers, WHO recommended 
the use of lay workers in community settings in 2018 to 
reduce costs and increase uptake of HIV testing services 
(HTS).13 Index-linked testing of children, adolescents, 
and young adults (age 1–24 years) in community-based 
settings resulted in higher uptake than at health facilities 
in Malawi.14 In recent years, self-testing with oral mucosal 
transudate (OMT) has been implemented among adults 
in sub-Saharan Africa,15,16 and an extension of this 
approach whereby caregivers test their children might 
also improve accessibility.17 Offering indexes a choice 
of different HTS delivery models acknowledges different 
preferences, and providing flexi bility in the place and 
mode of HTS delivery might optimise uptake of index-
linked HIV testing.
Zimbabwe has an early-onset, sustained, severe 
HIV epi demic, with an adult HIV prevalence of 13% 
in 2018.3 HIV prevalence in child ren (age 0–14 years) 
was 1·6% and in young people (age 15–24 years) was 4·4% 
in 2016.3,18 Although PMTCT coverage in Zimbabwe is 
high, with 94% of HIV-positive pregnant women receiving 
ART, only 63% of infants born to HIV-positive mothers 
were tested within the first 2 months of birth in 2019.3
In the Bridging the Gap in HIV testing and care for 
chil dren in Zimbabwe (B-GAP) study, we evaluated 
index-linked testing provided in health facilities and via 
two community-based approaches (namely testing by a 
trained lay worker and HIV testing by the caregiver at 
home using OMT), for children aged 2–18 years in rural 
and urban Zimbabwe. The aim of this study was to 
investigate the uptake and yield of index-linked testing 
and factors associated with its acceptance. We also 
investigated the choice of testing methods (ie, com-
munity-based vs facility-based testing) and factors 
associated with acceptance of community-based over 
facility-based index-linked HIV testing. We hypothesised 
that offering HTS to chil dren living in households with 
an HIV-positive individual will result in a high yield 
Research in context
Evidence before this study
HIV testing rates in children exposed to HIV remains low 
in prevention of mother-to-child transmission programmes 
in sub-Saharan Africa, with many children being diagnosed 
late in childhood when they develop advanced disease. Due 
to the relatively low HIV prevalence among children and 
adolescents, targeted HIV testing services (HTS) approaches 
such as index-linked testing (HIV testing offered to children in 
the same household as people with HIV) might be most efficient 
and cost-effective. On April 1, 2020, we searched Medline for 
studies on index-linked HIV testing in children and adolescents, 
without restrictions on date, location, or language. Using the 
keywords “HIV testing”, “index”, “children”, and “adolescents”, 
we found five studies that had evaluated index-linked testing 
in children and adolescents (age 0–19 years). The studies were 
done in Cameroon, Kenya, Lesotho, and Malawi between 
2016 and 2019. All of the studies reported higher HIV yield with 
index-linked testing than that obtained via routine HTS. Only 
one of the studies offered index-linked HIV testing in both rural 
and urban settings and only two studies offered index patients 
a choice of test location (facility-based or community-based). 
None of the five studies evaluated factors associated with 
uptake of testing.
Added value of this study
Our study is the first to compare the uptake of index-linked 
testing in children via health facility testing versus 
community-based testing by lay workers or caregivers in 
an HIV-prevalent setting. We evaluated preferred choice 
of HIV testing modality, and index patient and child factors 
associated with choice and uptake of testing. Our study shows 
that, although facility-based methods are more commonly 
chosen when initially proposed, probably because this 
approach is well known to the public, actual uptake of 
HTS is higher with community-based approaches. 
Community-based approaches might address some of the 
key barriers to facility-based testing, such as travel costs, 
distance to a clinic, particularly in rural areas, and suboptimal 
access due to restrictive opening hours of health facilities. 
Our study also shows that community HTS provided by lay 
workers and caregivers is feasible.
Implications of all the available evidence
To reach the UNAIDS 95-95-95 targets (95% of HIV-positive 
people aware of status, ART for 95% of those diagnosed, 
and viral suppression for 95% of those treated by 2030), 
HTS strategies will need to focus on hard-to-reach populations 
and address barriers that existing approaches have not been 
able to overcome. Community-based approaches might 
address such barriers but will require sensitisation and 
education of communities, and support for caregivers who 
test their children. Quality control, monitoring, and linkage 
to care for children who test positive will need to accompany 
these approaches.
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of HIV diagnoses when compared with approaches that 
are not targeted, and that the option for community-
based HTS might increase uptake compared with 
facility-based HTS alone.
Methods
Study design and participants
The B-GAP study was an interventional study without a 
control group done in Bulawayo, the second largest city 
in Zimbabwe, and Matabeleland South province, between 
Jan 29 and Dec 12, 2018. Matabeleland South borders 
Botswana and has the highest HIV prevalence (20·4%) 
in the country.18 Three rural primary health-care clinics in 
Mangwe district in Matabeleland South and six urban 
primary health-care clinics in Bulawayo were purposively 
selected on the basis of the number of patients registered 
for HIV care and distance to another facility.18
At each facility, all individuals attending for HIV care, 
regardless of ART status and time since diagnosis, were 
screened over 3 months to identify index cases. The 
national HIV programme provides a 3 month drug 
supply, therefore the majority of clinic attendees were 
anticipated to have undergone eligibility screening for 
study inclusion by 3 months. After screening and inclu-
sion, a structured questionnaire collecting socio demo-
graphic data, the number of children in the house hold, 
and their HIV status was administered by research 
assistants to index patients and data was entered on 
electronic tablets into Open Data Kit (version 1.11.1). 
Index patients were defined as con senting HIV-positive 
individuals who had at least one child aged 2–18 years 
living in their household (regardless of whether or not 
they were a biological parent) who was eligible for HTS 
(ie, had never had an HIV test or had a negative HIV test 
more than 6 months before screening). Children who 
were reported to have had an HIV-negative test more 
than 6 months ago were eligible for testing as index 
patients could have over-reported testing of children, 
older adolescents might have been sexually active, and 
some children might have been victims of sexual abuse.
Written informed consent for participating in the study 
was obtained from all eligible index patients in either 
English, Shona, or Ndebele when they were approached 
at the health facility. Index individuals aged younger than 
18 years were included in the study if accompanied by an 
adult who could provide consent. At the point of testing 
of children either at the facility or in the community, 
verbal consent from the child’s parent or legal guardian 
and child assent (for children aged <16 years) or direct 
verbal consent from the child (for children aged ≥16 years) 
for HIV testing was sought.
Ethical approval for this study was obtained from the 
Medical Research Council of Zimbabwe, the institutional 
review board of the Bio medical Research and Training 
Institute of Zimbabwe, and the London School of 
Hygiene & Tropical Medicine ethics committee. The 
B-GAP study protocol has been published previously.19
Procedures
Index patients were offered three choices of HIV testing 
for eligible children living in their household: testing in 
the health facility; testing by a lay worker at home; or 
testing by the index caregiver at home. Testing in the 
facility was done by routine clinic staff or research 
assistants. Research assistants were the lay workers and 
in addition to training for the study had undergone 
a 2-week training course on rapid HIV testing and coun-
selling provided by a private training institution affiliated 
with the Zimbabwe Ministry of Health and Child Care. 
The lay workers were stationed at each clinic. Index 
patients could only elect for caregiver testing if they were 
a biological parent or the legal guardian to ensure 
safeguarding of children who would be tested in the 
absence of a health-care provider. Caregiver testing was 
done with OMT (OraQuick ADVANCE Rapid HIV-1/2; 
OraSure Technologies, Bethlehem, PA, USA). Caregivers 
were counselled and shown how to do the test by research 
assistants at each facility. If assessed by the research 
assistant to be competent to test, they were given an 
OMT HIV test for each eligible child and asked to do the 
test within 5 days. A helpline number for counselling 
and support was provided. Results of caregiver-provided 
testing were by self-report. Index patients who chose 
caregiver-pro vided testing were told to return to the 
facility for confirmatory HIV testing in the event of 
a reactive OMT test as per WHO guidelines.20
Index patients who chose community testing by a lay 
worker were visited at home on a scheduled date. Up to 
two further home visits were undertaken if the child was 
not present on the scheduled date. For facility and 
caregiver-provided testing, all index patients were con-
tacted by lay workers by phone on days 7, 14, and 21 post-
screening if their children had not yet been tested. If 
unreachable by phone, a maximum of two home visits 
were undertaken and HIV testing done at home by a lay 
worker if the index patient and child consented. There-
fore, index patients who initially chose facility-based 
testing could later consent to testing in the home. Simi-
larly, index patients who initially chose community-based 
testing could, at a later date, switch to testing at the 
facility. The test method chosen by the index patient at 
screening and the final test location for children was 
recorded. Testing at the facility or community-based 
testing by a lay worker was done according to the national 
HIV testing algorithm via a blood-based rapid diagnostic 
test, with results available on the same day.21 We defined 
community-based testing as either testing done by a lay 
worker at home or caregiver-provided testing.
Children were given age-appropriate explanations 
of the test results, determined by the age and maturity of 
the child and guided by the Zimbabwe Ministry of Health 
and Child Care guidelines for HIV testing and coun-
selling for children.22
For children who were not tested, the reason was 
recorded. Children who tested HIV-positive were referred 
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to their nearest facility or the preferred facility of the 
child or household for onward care.
Outcomes
The primary outcome of the study was the uptake 
of testing, defined as the proportion of eligible children 
having an HIV test during the study. Secondary outcomes 
were the uptake of the different HIV testing methods, 
HIV yield, and HIV prevalence. HIV yield was defined as 
the proportion of HIV-positive children among all eli gible 
children. HIV prevalence was defined as the proportion of 
HIV-positive children among those tested. Any children 
with an unknown test outcome were classed as not tested 
and therefore not included in the denominator for HIV 
prevalence.
Statistical analysis
Sample size estimations were based on precision of the 
estimated proportion taking up HIV testing. An average 
of 32 clients were anticipated to attend a clinic per day. 
A sample size of 6739 children would provide a 1% pre-
cision interval for an estimate of 80% of children taking 
up testing. An average of 32 clients were anticipated to 
attend a clinic per day based on routine data on attendance 
of each clinic in 2017. Therefore, during the 3 month study 
period at each clinic, in nine clinics assuming 5 working 
days per week, this visit rate would provide sufficient 
numbers of index patients assuming 30–40% of index 
patients had eligible children and accepted participation. 
Within-index clus tering was not taken into account when 
calculating sample size due to the small numbers of 
children expected in each household.
All analyses were done with Stata software (version 15.0). 
Continuous variables were summarised as means and 
SDs or medians and IQRs, and categorical variables as 
counts and percentages. We used univariable logistic 
regression to investigate the association bet ween index 
patient characteristics and at least one child in their 
household having an HIV test, and between child charac-
teristics and a child having an HIV test. Index charac-
teristics of interest were age, sex, health-care facility 
setting (rural or urban), highest level of education, time 
since HIV diagnosis, mode of transport to the facility, and 
cost of travel to the facility. Child charac teristics of interest 
were age, sex, HIV status, relationship to index patient, 
orphanhood status, mother’s HIV status, history of 
receiving ART for PMTCT, and any previous offer of 
HIV testing. For each model, significant index patient or 
child variables (at p<0·10) in univariable analysis were 
retained in multivariable logistic regression models 
(significance deemed at p<0·10). Using logistic regression 
we also evaluated the odds of having an HIV test by 
selected testing model adjusted for clustering by index. 
For models including child characteristics, robust stan-
dard errors or generalised estimating equations were 
used to allow for household-level clustering. Additionally, 
index patient and child characteristics associated with 
selection of community-based testing models versus 
facility-based testing at screening were evaluated in uni-
var iable and multivariable models. As sensitivity analyses, 
we investi gated factors associated with selection of testing 
by a lay worker versus facility-based testing, and with 
selection of testing provided by a caregiver versus facility-
based testing. Clustering by index patient was adjusted 
for in all models including child variables. An independent 
project steering committee met annually.
Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Between Jan 29 and Dec 12, 2018, 9927 individuals were 
screened in the nine primary health-care clinics 
(427–2005 per clinic), of whom 5164 reported no children 
aged 2–18 years in the household and 820 declined 
consent to provide information about children in their 
household. Of the remaining 3943 individuals, 2870 had 
at least one child eligible for HTS in their household and 
were therefore classed as index patients (figure 1). The 
median age of index patients was 39 years (IQR 32–46) 
and 2259 (78·8% of 2866 with available data) were 
women. 1622 (56·5%) of the 2870 index patients had 
been diagnosed with HIV in the past 5 years. The main 
means of transport to the clinic was by foot (for 
1874 [65·4%] of 2866 with available data; table 1). The 
median number of children living in the households of 
index patients was 1 (IQR 1–3).
8218 children (4147 [50·5%] girls [sex unknown in 
nine], median age 9 years [IQR 5–13]) living in the 
households of index patients (n=3943) were screened for 
eligibility (figure 1). Of these children, 6062 (73·8%) were 
eligible for index-linked testing (3115 [51·4%] girls [sex 
unknown in seven], median age 8 years [IQR 5–13]), with 
2837 (34·5%) having tested HIV-negative more than 
6 months ago, and 3225 (39·2%) having not previously 
tested. The range in eligibility prevalence by clinic 
was 54·4–98·6%. 500 (6·1%) children had a known 
HIV-positive status.
Of the 2870 index patients with at least one eligible child, 
1789 (62·3%) had at least one child in their household 
tested, including 1012 (35·3%) who had two or more 
children tested. Overall, 1476 (51·4%) index patients had all 
eligible child ren in their households tested. In terms of 
corresponding numbers in children, HIV testing was 
accepted for 5326 (87·9%) of 6062 eligible children (range 
by clinic 61·3–98·4%). The main reason for index patients 
refusing testing in 736 children was that the index patient 
was not the biological parent of the eligible child (304 
[41·3%] children). In the 5326 children with acceptance for 
testing, 3638 (68·3%) were subsequently tested (range by 
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clinic 53·5–92·0%), representing an overall uptake of HTS 
among 6062 eligible children of 60·0% (figure 1). Among 
1688 children not tested despite acceptance by the index 
patient, the main reasons for non-uptake were inability to 
contact chil dren (1101 [65·2%]) and no consent from 
guardians at the point of testing (161 [9·5%]).
Of the 3638 children with an HIV test outcome, 39 were 
positive, giving an HIV prevalence of 1·1%, and an HIV 
yield among 6062 eligible children of 0·6%. HIV 
prevalence was 1·0% (24 of 2322 children) in urban 
settings and 1·1% (15 of 1316) in rural settings. The 
median age of children diagnosed with HIV was 11 years 
(IQR 8–15; range 3–18) and 28 (71·8%) were girls. 
17 (43·6%) of the 39 children were single or double orp-
haned, 25 (64·1%) were biological children of the index 
patient, 28 (71·8%) had not been previously tested, and 
nine (23·1%) were linked to index patients who had been 
diagnosed within the past year. HIV was diagnosed in 
26 (prevalence 1·4%) of 1916 children tested in a health-
care facility and 13 (0·8%) of 1722 children tested in the 
community. In the com munity, HIV was diagnosed in 
12 (0·8%) of 1522 children tested by a lay worker, and one 
(0·5%) of 200 tested by their caregiver using OMT and 
confirmed HIV-positive at their health-care facility. Of 
the 39 children who tested HIV-posi tive and received 
a referral, 36 (92·3%) were registered with a facility.
The proportion of index patients who had at least one 
child tested was similar between urban (1286 [61·7%] of 
2084 index patients) and rural (504 [64·1%] of 786) sites 
(table 1). In our univariable analysis of index patient 
characteristics, female sex, cost to travel to the facility, and 
mode of transport were associated with HIV testing for at 
least one child in the household. In multivariable analysis, 
female sex of the index patient was associated with at least 
Figure 1: Screening and HIV testing flow for HIV-positive clinic attendees (green) and children living in their households (blue)
HTS=HIV testing services. *490 children registered in care and 10 not registered in care. †Test result slip or note in the child’s medical records.
9927 patients screened 
4763 with children (age 2–18 years) 
in the household
5164 without children in the household
3943 eligible patients with children 
in the household and consented 
to provide information about 
household 
820 declined consent 
2870 patients (index) living with 
at least one eligible child 
1073 without children eligible for testing
8218 children living in household
with eligible index patient
6062 children eligible for HTS
2837 HIV-negative >6 months
3225 not previously tested
2156 children ineligible for HTS
 500 HIV-positive*
 1656 HIV-negative <6 months
1081 without testing of children 
in the household
1789 index patients with at least one 
eligible child tested 
736 children for whom testing was 
refused by index patient
 304 not biological child of the 
index patient
 203 for whom testing not wanted
 47 for whom index did not have 
time for testing
 182 with other reasons
5326 eligible children whose index 
patient accepted testing
1688 children not tested
 1101 not found during tracing
 161 without parent or legal 
guardian consent 
 58 did not give assent
 31 with evidence† of a negative 
test within <6 months
 318 with other reasons
 19 with unknown test outcome
3638 children tested 
1751 index patients with children 
testing HIV-negative 
38 index patients with at least one 
child testing HIV-positive
39 children tested HIV-positive 3599 children tested HIV-negative
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one child in the household having an HIV test (adjusted 
odds ratio [aOR] 1·56 [95% CI 1·38–1·77], p<0·0001). 
Additionally, children were less likely to be tested if the 
index patient reported any financial cost for them to travel 
to the facility (aOR 0·86 [0·83–0·88], p<0·0001; table 1).
In our univariable analysis of child characteristics, 
having an HIV test was associated with sex, age, HIV 
status, relationship to the index patient, and mother’s 
HIV status. In multivariable analysis, female sex of the 
child was associated with having an HIV test (aOR 1·10 
[95% CI 1·03–1·19], p=0·0080). Increased age of the 
child (6–9 years: aOR 0·99 (0·89–1·09); 10–15 years: 
aOR 0·91 [0·83–1·00]; and 16–18 years: aOR 0·75 
[0·66–0·85]; p=0·0001 vs 2–5 years) and unknown 
HIV status of the mother (aOR 0·81 [0·68–0·98], 
p=0·027 vs HIV-positive status) were associated with 
reduced odds of having an HIV test (table 2).
Of the 5326 eligible children whose index patient 
accepted testing at screening, facility-based testing was 
chosen for 3539 (66·4%) children and community-based 
testing for 1787 (33·6%; figure 2). Per clinic, the pro portion 
of children whose index patients opted for community-
based testing ranged from 8·9% to 81·1%. In univariable 
analysis adjusting for clustering by index patient, the odds 
of the child being tested were higher if the index patient 
selected community-based testing versus facility-based 
testing (1320 [73·9%] children tested of 1787 vs 2318 [65·5%] 
of 3539; aOR 1·49 [95% CI 1·22–1·81], p=0·0001).
Regardless of initial choice, similar proportions of 
eligible children were tested by facility-based and 
community-based approaches (of 3638 children with a 
known test outcome overall, 1916 [52·7%] were tested at 
a facility vs 1722 [47·3%] in the community). 2318 children 
with ini tial acceptance for facility-based testing went on 
Index patient population Univariable analysis Multivariable analysis*
Patients with at least 
one eligible child 
(n=2870), n (%)
Patients with at least one child 
tested (n=1789), n (% of those 
with ≥1 eligible child)
OR (95% CI) p value aOR (95% CI) p value
Age, years
0–18 54 (1·9%) 36 (66·7%) 1·00 (ref) ·· ·· ··
19–34 892 (31·1%) 566 (63·5%) 0·87 (0·49–1·55) ·· ·· ··
35–59 1767 (61·6%) 1087 (61·5%) 0·80 (0·45–1·42) ·· ·· ··
≥60 157 (5·5%) 101 (64·3%) 0·90 (0·47–1·73) 0·63 ·· ··
Sex†
Male 607 (21·2%) 329 (54·2%) 1·00 (ref) ·· 1·00 (ref) ··
Female 2259 (78·8%) 1456 (64·5%) 1·53 (1·28–1·84) <0·0001 1·56 (1·38–1·77) <0·0001
Site
Rural 786 (27·4%) 504 (64·1%) 1·00 (ref) ·· ·· ··
Urban 2084 (72·6%) 1286 (61·7%) 0·90 (0·76–1·07) 0·24 ·· ··
Highest level of education completed†
None 45 (1·6%) 27 (60·0%) 1·00 (ref) ·· ·· ··
Primary 909 (31·7%) 571 (62·8%) 1·13 (0·61–2·08) ·· ·· ··
Secondary 1817 (63·4%) 1136 (62·5%) 1·11 (0·61–2·03) ·· ·· ··
Tertiary 95 (3·3%) 52 (54·7%) 0·77 (0·38–1·59) 0·36 ·· ··
Mode of transport to facility†‡
By foot 1874 (65·4%) 1259 (67·2%) 1·00 (ref) ·· ·· ··
Public transport 844 (29·4%) 442 (52·4%) 0·54 (0·46–0·64) <0·0001 ·· ··
By car 42 (1·5%) 20 (47·6%) 0·45 (0·24–0·82) 0·0097 ·· ··
Other 106 (3·7%) 65 (61·3%) 0·78 (0·52–1·16) 0·22 ·· ··
Cost of travel to facility‡
No cost (0 US$) 1998 (69·6%) 1332 (66·7%) 1·00 (ref) ·· 1·00 (ref) ··
Some cost (>0 US$) 872 (30·4%) 458 (52·5%) 0·86 (0·83–0·90) <0·0001 0·86 (0·83–0·88) <0·0001
Time since HIV diagnosis, years§
<1 290 (10·2%) 174 (60·0%) 1·00 (ref) ·· ·· ··
1–5 1332 (46·6%) 820 (61·6%) 1·06 (0·82–1·38) ·· ·· ··
6–10 990 (34·7%) 618 (62·4%) 1·10 (0·85–1·45) ·· ·· ··
>10 245 (8·6%) 168 (68·6%) 1·45 (1·02–2·08) 0·16 ·· ··
Tested children were classed as all those who received a test and had a known test outcome. OR=odds ratio. aOR=adjusted OR. *Significant index patient variables (at p <0·10) 
in univariable analysis were retained in multivariable logistic regression. †Missing data for four index patients. ‡Only cost of travel to facility included in multivariate analysis 
due to collinearity with mode of transport to facility. §Missing data for 13 index patients.
Table 1: Index patient characteristics associated with HIV testing in at least one child
Articles
www.thelancet.com/hiv   Published online November 13, 2020   https://doi.org/10.1016/S2352-3018(20)30267-8 7
to be tested, 473 (20·4%) of whom were tested in the 
com munity. By contrast, 1320 children with acceptance 
for community-based testing went on to be tested, of 
whom 71 (5·4%) were tested in a facility (figure 2).
In univariate analysis adjusted for clustering by index, 
factors associated with uptake of community-based HIV 
testing were site type (urban or rural), index patient age, 
cost of travel to a facility, time since diagnosis in the 
index patient, child age, child HIV status, PMTCT treat-
ment history, and a previous offer of HIV testing. On 
multivariable analysis, urban residence (aOR 2·29 [95% 
CI 1·80–2·91], p<0·0001), any travel cost to the facility 
(aOR 1·21 [1·15–1·28], p<0·0001), and time since HIV 
diagnosis in the index patient (1–5 years since diagnosis: 
aOR 1·58 [1·07–2·31]; and ≥6 years since diagnosis, 
aOR 1·59 [1·07–2·35]; p=0·070 vs diagnosis <1 year ago) 
were associated with selection of community-based 
testing compared with facility-based testing at screening 
(table 3). Increased child age (6–9 years: aOR 1·20 
[1·02–1·41]; and 10–15 years: aOR 1·35 [1·14–1·59]; 
p=0·0020 vs 2–5 years) and unknown HIV status in the 
child (aOR 1·33 [1·12–1·59], p=0·0013) were also 
associated with selection of community-based testing at 
screening. Results were similar in our sensitivity analysis, 
in which the outcome was defined as testing delivered by 
a community lay worker (n=1487 children) compared with 




(n=3638), n (% of those 
eligible)
aOR (95% CI) p value aOR (95% CI) p value
Sex‡
Male 2940 (48·6%) 1720 (58·5%) 1·00 (ref) ·· 1·00 (ref) ··
Female 3115 (51·4%) 1911 (61·3%) 1·07 (1·01–1·15) 0·032 1·10 (1·03–1·19) 0·0080
Age, years‡
2–5 1801 (29·7%) 1159 (64·4%) 1·00 (ref) ·· 1·00 (ref) ··
6–9 1586 (26·2%) 956 (60·3%) 0·97 (0·89–1·06) ·· 0·99 (0·89–1·09)
10–15 1981 (32·7%) 1174 (59·3%) 0·89 (0·82–0·97) ·· 0·91 (0·83–1·00)
16–18 687 (11·3%) 342 (49·8%) 0·73 (0·65–0·82) <0·0001 0·75 (0·66–0·85) 0·0001
HIV status§
Never tested 3224 (53·2%) 1930 (59·9%) 1·00 (ref) ·· 1·00 (ref) ··
Known negative 
>6 months
2837 (46·8%) 1708 (60·2%) 1·10 (1·02–1·20) 0·021 1·06 (0·96–1·17) 0·28
Relationship to index patient‡
Non-biological child 2482 (41·0%) 1466 (59·1%) 1·00 (ref) ·· 1·00 (ref) ··
Biological child 3573 (59·0%) 2165 (60·6%) 1·22 (1·11–1·33) <0·0001 1·12 (0·96–1·32) 0·16
Orphanhood status‡
Not orphaned 4728 (78·1%) 2796 (59·1%) 1·00 (ref) ·· ·· ··
Paternal orphan 960 (15·9%) 613 (63·9%) 1·00 (0·90–1·12) 0·98 ·· ··
Maternal orphan 190 (3·1%) 101 (53·2%) 0·98 (0·79–1·23) 0·88 ·· ··
Double orphan 177 (2·9%) 121 (68·4%) 1·15 (0·91–1·46) 0·23 ·· ··
Mother’s HIV status¶
HIV-positive 3223 (63·9%) 2048 (63·5%) 1·00 (ref) ·· 1·00 (ref) ··
HIV-negative 901 (17·9%) 585 (64·9%) 0·83 (0·74–0·94) 0·0037 0·90 (0·76–1·07) 0·24
Unknown to index patient 920 (18·2%) 475 (51·6%) 0·73 (0·64–0·83) <0·0001 0·81 (0·68–0·98) 0·027
Prevention of mother-to-child transmission treatment history||
No 1839 (55·4%) 1147 (62·4%) 1·00 (ref) ·· ·· ··
Yes 1284 (38·7%) 758 (59·0%) 1·07 (0·97–1·18) 0·20 ·· ··
Unknown to index patient 196 (5·9%) 115 (58·7%) 1·05 (0·83–1·33) 0·67 ·· ··
Previous offer for HIV testing||
No 1191 (35·9%) 715 (60·0%) 1·00 (ref) ·· ·· ··
Yes 1999 (60·2%) 1216 (60·8%) 1·05 (0·95–1·17) 0·36 ·· ··
Unknown to index patient 136 (4·1%) 96 (70·6%) 1·10 (0·82–1·49) 0·52 ·· ··
Tested children were classed as all those who received a test and had a known test outcome. aOR=adjusted odds ratio (with adjustment for clustering by index patient). 
*Logistic regression with generalised estimating equations. †Significant child variables (at p <0·10) in univariable analysis were retained in multivariable logistic regression; 
n reflects children tested minus those with data missing on model variables. ‡Missing data for seven children. §Missing data for one child. ¶Missing data for 1018 children 
as question was introduced into the study after March 1, 2018. ||Question only asked if the child was the biological child of the index patient (n=3319).
Table 2: Child characteristics associated with having an HIV test
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facility-based testing (appendix pp 1, 2). Selection of 
caregiver-provided testing (n=300 chil dren) versus facility-
based testing at screening was associated with urban 
residence, the cost of transport, unknown HIV status 
in the child, and, additionally, female sex of the index 
patient (appendix pp 3, 4). No adverse events were reported 
in our study.
Discussion
We found an overall uptake of index-linked HIV testing 
of 60% after offering index patients a choice of 
facility-based or community-based HTS. A greater 
proportion of index patients chose facility-based testing 
over community-based testing; however, children were 
more likely to be tested if the index chose community-
based testing. Index patients who had to pay to get to the 
clinic were less likely to have children in their households 
tested, and older children were less likely to be tested. 
Some index patients refused testing for children because 
they were not the biological parents of children living in 
their households. This finding high lights the challenges 
of identifying children with HIV, who are dispro por-
tionately likely to be orphaned.23 Although being a bio-
logical child was associated with having a test in 
uni variable analysis, this effect was not significant in 
multivariate analysis. We also found that female index 
patients were more likely to have at least one child tested 
and female children were more likely to be tested than 
their male counterparts. Poor health-seeking behaviour 
is commonly reported among men and our study 
highlights the need for further work to engage men, to 
inform the development of acceptable HTS.24
The yield of HIV was lower than anticipated when 
compared with blanket approaches such as outpatient 
and inpatient provider-initiated testing and counselling 
in Zimbabwe and within sub-Saharan Africa, in which 
HIV yield among children and adolescents ranged from 
7·4% to 12·2%.11 This finding might be due to the scale-
up of the PMTCT programme in Zimbabwe, where 
coverage was 94% in 2018.3,25 Although index-linked 
testing implemented in Kenya and Malawi detected high 
prevalence of HIV (7·4% among children aged <12 years 
in Kenya and 4·0% among individuals aged 1–24 years in 
Malawi), their PMTCT coverage was similar at 91% and 
95%, indicating the possibility of missed diagnoses 
before the scale-up of PMTCT.3,14,26 Alternatively, low yield 
could also imply that even index-linked HTS is an 
insufficient strategy to address the gap in HIV testing for 
children in Zimbabwe. Some index patients refused 
testing or did not complete testing for eligible children in 
their house holds. Further studies evaluating reasons or 
risk factors for non-uptake of testing are therefore 
warranted. How ever, we do note that while 500 children 
living in households with an index patient were known to 
be HIV-positive before the study, 39 (7·2%) of 
539 children (500 who were known HI-positive and 
39 newly diagnosed in this study) had been missed by 
existing services.
The median age of children diagnosed with HIV in our 
study was 11 years. Older children are at particularly high 
risk of living with undiagnosed HIV as they have missed 
HIV testing within PMTCT programmes27 and were less 
likely to be tested in our study. A misplaced assumption 
might be that an older child who is not ill is unlikely to 
have perinatally acquired HIV infection, particularly 
when the mother’s status is not known. In addition, 
adolescents are a challenging group to engage within 
health services. In our study, older children and children 
whose mother’s HIV status was not known had lower 
odds of being tested. Our findings highlight the need for 
continued efforts to expand HTS particularly among 
older adolescents. Notably, this age group is also at risk of 
horizontal transmission and index-linked testing might 
need to be combined with other approaches.
Facility-based index-linked testing has been recom-
mended in WHO guidelines and in Zimbabwean 
national guidelines.19,28 Our study found that similar 
pro portions of children were tested by facility-based or 
community-based index-linked HIV testing, despite 
substantially more index patients choosing facility-
based testing at screening. Community-based testing 
poten tially addresses some of the barriers to HTS, such 
as costs of travel to health facilities and the time taken 
Figure 2: Selection of facility-based (blue) and community-based (green) HIV testing for eligible children 
whose index patient accepted testing
*1487 children with acceptance for testing by a lay worker and 300 for testing by a caregiver at screening.
1522 tested by community lay
worker
 1026 with acceptance for 
community lay worker testing
 26 switched from caregiver- 
provided testing
470 switched from facility-based 
testing 




3539 children with acceptance for
facility-based testing 
2318 tested
1916 tested at facility
 1845 originally on facility-based 
testing
 10 switched from 
caregiver-provided testing
 61 switched from 
community lay worker 
testing
1722 tested in the community
 1249 originally on 
community-based testing
 473 originally on facility-based 
testing
1221 not tested
200 tested by caregiver
 197 with acceptance for 
caregiver-provided testing
 3 switched from facility-based 
testing 
See Online for appendix
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by index patients to bring children to facilities. Children 
were less likely to be tested if the index patient had to 
pay for travel (eg, via public transport or a car) rather 
than walk to a health facility. In addition, paying for 
travel to a health facility was associated with selection of 
community-based rather than facility-based HIV testing 
by the index patient. Community-based index-linked 
testing might identify children who are particularly 
hard to reach with currently available approaches. 
Indeed, index patients who had been diag nosed with 
HIV for a long period of time, increased age of the child, 
and no history of previous testing of the child, all of 
which are indicators of a lack of engagement with HTS 
for children, were independently associated with selec-
tion of community-based HIV testing.
Although WHO has recommended community-based 
HIV testing by lay workers,13 in many countries including 
Zimbabwe, HTS in the community is done by nurses. In 
the B-GAP study, lay workers underwent 2 weeks of 
training on study processes and rapid HIV testing and 
caregivers were also able to test their children using an 
oral HIV test after brief demon strations within the health 
facility. Our study shows the feasibility of lay individuals 
with minimal training implementing community-based 
HTS. HIV self-testing for adults has had high uptake 
among groups such as men, older adolescents (age 
16–18 years), sex workers, and men who have sex with 
men.13,15,16 This high uptake is often attributed to ease, 
privacy, and confi dentiality, and the non-invasiveness of 
the test compared with blood-based testing.13,15,29 We 
identified a low uptake of caregiver-provided testing, 
probably due to poor awareness of self-testing among our 
study population, for whom HIV self-testing is not yet 
routinely or widely available. In our study, female index 
patients were more likely to take up caregiver-provided 
testing, which might reflect the potential useful ness of 
this strategy within PMTCT programmes.
Community-based testing by lay workers or caregivers 
could reduce workload for facility-based health workers 
and has potential to be cost-effective.30 Additionally, 
community-based testing could be used as a back-up 
mechanism for children who do not present for facility-
based index-linked testing. Many children in our study 
were subsequently tested in the community, as lay 
workers visited children at home who did not attend 
facilities for testing as per the protocol procedures.22 
Notably, 20% of children whose index patients initially 
opted for facility-based testing were subsequently tested 
by a community-based approach, but only 5% whose 
index patients opted for community-based testing were 
ultimately tested in a health facility.
The strengths of this study include a large sample size 
and comprehensive ascertainment of outcomes. The 
inclusion criteria were not restricted to biological children 
of index patients to ensure that children who might have 
been orphaned were not excluded. The study was done in 





Univariable analysis Multivariable analysis 
(n=5262)*
aOR (95% CI) p value aOR (95% CI) p value
Index patient variables
Age, years
0–18 29 (1·6%) 1·00 (ref) ·· 1·00 (ref) ··
19–34 480 (26·9%) 1·48 (0·63–3·47) ·· 1·07 (0·46–2·45) ··
35–59 1146 (64·1%) 1·99 (0·86–4·60) ·· 1·27 (0·56–2·89) ··
≥60 132 (7·4%) 2·32 (0·92–5·88) 0·02 1·64 (0·65–4·12) 0.22
Sex
Male 363 (20·3%) 1·00 (ref) ·· ·· ··
Female 1424 (79·7%) 1·00 (0·79–1·27) 0·98 ·· ··
Site
Rural 448 (25·1%) 1·00 (ref) ·· 1·00 (ref) ··
Urban 1339 (74·9%) 2·51 (1·99–3·17) <0·0001 2·29 (1·80–2·91) <0·0001
Highest level of education
None 33 (1·9%) 1·00 (ref) ·· ·· ··
Primary 538 (30·1%) 0·74 (0·33–1·63) 0·45 ·· ··
Secondary 1143 (64·0%) 1·19 (0·54–2·58) 0·67 ·· ··
Tertiary 73 (4·1%) 1·90 (0·76–4·70) 0·17 ·· ··
Mode of transport to facility†
By foot 1003 (56·1%) 1·00 (ref) ·· ·· ··
Public transport 691 (38·7%) 2·42 (1·95–3·00) <0·0001 ·· ··
By car 12 (0·7%) 0·64 (0·25–1·65) 0·35 ·· ··
Other 81 (4·5%) 1·01 (0·60–1·68) 0·98 ·· ··
Cost of travel to facility, US$†
No cost (0 US$) 1090 (61·0%) 1·00 (ref) ·· 1·00 (ref) ··
Some cost (>0 US$) 697 (39·0%) 1·24 (1·18–1·31) <0·0001 1·21 (1·15-1·28) <0·0001
Time since HIV diagnosis, years‡
<1 132 (7·5%) 1·00 (ref) ·· 1·00 (ref) ··
1–5 815 (46·5%) 1·53 (1·07–2·20) ·· 1·58 (1·07–2·31) ··
≥6 804 (45·9%) 1·48 (1·03–2·13) 0·066 1·59 (1·07–2·35) 0·070
Child variables
Sex§
Male 884 (49·5%) 1·00 (ref) ·· ·· ··
Female 902 (50·5%) 0·95 (0·84–1·07) 0·42 ·· ··
Age, years§
2–5 472 (26·4%) 1·00 (ref) ·· 1·00 (ref) ··
6–9 474 (26·5%) 1·26 (1·09–1·47) ·· 1·20 (1·02–1·41) ··
10–15 645 (36·1%) 1·41 (1·21–1·63) ·· 1·35 (1·14–1·59) ··





1028 (57·6%) 1·00 (ref) ·· 1·00 ··
Unknown 758 (42·4%) 1·32 (1·17–1·48) <0·0001 1·33 (1·12–1·59) 0·0013
Relationship to index§
Non-biological child 672 (37·6%) 1·00 (ref) ·· ·· ··
Biological child 1114 (62·4%) 1·09 (0·94–1·26) 0·24 ·· ··
(Table 3 continues on next page)
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making the findings generali sable to similar settings 
within Zimbabwe and the sub-Saharan Africa region. A 
limitation of our app roach, whereby the starting point of 
offering testing is at the facility level, is that it excludes 
index patients who are disengaged from care and whose 
children might be HIV-positive but without a confirmed 
diagnosis. Addi tionally, con tacting participants to ascer tain 
out comes might have indirectly increased uptake. Further-
 more, oral testing results were obtained by self-report. We 
did a substudy to investigate accuracy of care giver testing 
and findings will be reported separ ately. A further limi-
tation was that the study was not aimed or powered to 
investigate index patient factors associated with an 
HIV-positive child diagnosis. If completed, a study foc used 
on index factors associated with HIV-positive child status 
would allow health service providers to further target index-
linked testing in children and adolescents, and we there-
fore recom mend future studies on this aspect.
Evaluation of the affordability of index-linked app-
roaches is crucial to inform scalability. Previous studies 
have shown that community-based HTS stra tegies 
among adults, including HIV self-testing, are cost-effec-
tive compared with facility based HTS in South Africa 
and Malawi.31,32 However, cost-effectiveness of any 
approach will depend on HIV yield and uptake of HTS. A 
cost evaluation of the HTS approaches in the B-GAP 
study is underway and will be reported separately.
Substantial progress has been made in reducing 
the incidence of HIV infection, due to the scale-up of 
PMTCT programmes and improved coverage of ART in 
children. However, implementing strategies to identify 
hard-to-reach groups of children is imperative if the 
UNAIDS 95-95-95 targets (95% of HIV-positive people 
aware of status, ART for 95% of those diagnosed, and viral 
suppression for 95% of those treated by 2030) are to be 
met. Increasing the reach of testing will require strategies 
that target residual barriers to accessing HIV testing, 
which approaches to date have not been able to overcome. 
Although a targeted approach such as index-linked testing 
is an efficient approach in children in whom HIV pre va -
lence is low, coverage to date has not been optimal. Our 
study provides evidence for the effectiveness of com-
munity-based approaches via lay health workers and 
caregivers for the testing of children at risk of HIV. 
Community-based testing might reduce burden on health 
facilities and address barriers to HTS access. Combined 
approaches and providing index patients with choice and 
flexibility might further improve uptake.
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5. The challenges and relational aspects of index-linked HIV 





5.1 Introduction  
Chapter 4 presented the uptake and yield of index-linked HIV testing for children 
and adolescents and found that HIV yield was low when compared to other 
studies in similar settings using the same index-linked strategy.22 The study 
showed that older adolescents were less likely to be tested when compared to 
younger children. Additionally, while most indexes chose facility-based HIV 
testing for their children, children were more likely to be tested if the indexes 
chose HIV testing in the community.  
 In this chapter the factors that influence and affect uptake of index-linked HIV 
testing for children and adolescents are evaluated.9 Using data from five focus 
group discussions, this manuscript builds on the findings from Chapter 4 by 
exploring the factors that affect uptake of HIV testing, from both the health 
providers and caregivers’ perspectives.  
The study found that caregivers viewed HIV testing of children not as a “one-off” 
event but as a process with potential consequences on multiple people and 
relationships. Hence, as well as providing information about the need to test 
children for HIV, discussions about HIV testing with caregivers should be tailored 
to enable caregivers to engage with HIV testing in their individual context.  
While programmes often adopt a broad policy based on improving “health 
outcomes”, this study highlights the importance of considering the context of the 
individuals targeted in public health programmes.  The findings from this study 
inform how implementation of index-linked HIV testing for children and 
adolescents can be strengthened to optimise the success of this approach. 
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Introduction
Globally, 2.8 million children aged 0–19 years were liv-
ing with HIV in 2018 [1, 2]. While coverage of preven-
tion of mother to child transmission programmes
(PMTCT) has increased (82% in 2018 compared to 43%
in 2013), corresponding coverage of early infant diagno-
sis of HIV remains low (59% in 2018) [3]. Therefore,
many children living with HIV are only diagnosed in
later childhood, with a consequent increased risk of
mortality and morbidity [4].
The World Health Organization (WHO) has recom-
mended targeted HIV testing strategies such as index-
linked HIV testing to improve efficiency and reduce
costs of HIV testing [5]. Index-linked HIV testing (i.e.
HIV testing offered to children or sexual contacts of in-
dividuals living with HIV) is anticipated to have higher
uptake and yield compared to universal HIV testing ap-
proaches. When implemented in Malawi, Kenya,
Lesotho and Cameroon, index-linked testing for children
did result in a higher yield of HIV (proportion of eligible
children who test positive) compared to universal test-
ing, but uptake of testing (proportion of eligible children
tested) remained suboptimal, ranging from 14 to 71%
[6–8].
Children and adolescents face specific barriers to
accessing HIV testing in facilities, including the require-
ment for parental consent, perceived low risk in this age
group by healthcare providers who then do not offer
testing, and lack of personal resources to independently
access HIV testing [9]. Index-linked HIV testing may
mitigate some of these barriers by targeting and follow
up of children and adolescents at risk of HIV. However,
index-linked testing initially requires uptake by a parent
or caregiver, and there are a number of factors that in-
fluence the decision-making process by individuals when
considering HIV testing for their children. HIV remains
a deeply stigmatised infection and therefore a diagnosis
of HIV is associated with risk of social harms [10]. HIV
infection also requires lifelong treatment which may
have a significant impact on children as well as their
caregivers’ lives [11]. Therefore, when implementing
index-linked HIV testing, it is important to understand
the lived experiences of indexes which will influence
their ability to engage with HIV testing and care services
[12].
The Bridging the Gap in HIV testing and care for chil-
dren in Zimbabwe (B-GAP) study evaluated uptake and
yield of index-linked HIV testing for children and ado-
lescents aged 2–18 years in rural and urban communities
in Zimbabwe [13]. Testing in facility and community-
based settings was offered to children of individuals liv-
ing with HIV already accessing treatment. In this paper,
we report on the lived experiences of caregivers who
went through index-linked HIV testing for children in
their households and providers who offered index-linked
testing to the caregivers in order to further understand
the decision-making process for testing. We aimed to
understand enabling and inhibiting factors for testing,
which are critical to inform how this testing strategy
should be implemented to optimise uptake.
Methods
Study setting
Zimbabwe has experienced an early onset, severe and
sustained HIV epidemic with antenatal HIV prevalence
peaking at 35% in 1998 [14] and current adult HIV
prevalence of 14% [2]. In 2016, an estimated 24% of
households had at least one HIV-positive household
member, and HIV prevalence among children aged 0–
14 years in Zimbabwe was 2% [1, 2]; 39% were undiag-
nosed and only 26% of children born to mothers with
HIV received an HIV test within 1 year of birth [2].
The B-GAP study was conducted in three rural and
six urban facilities from January to December 2018. Indi-
viduals attending for HIV care who had children aged
2–18 years of unknown HIV status in their households
(indexes) were offered three options for having their
children tested for HIV: health facility-based testing,
community-based testing by a provider or provision of
an oral HIV test kit to the index to test their child at a
location of their choice (Fig. 1). Indexes were followed
up by telephone or home visits at specified intervals over
21 days to ascertain test outcomes.
Qualitative study procedures
We conducted one focus group discussion (FGD) with
providers who offered index-linked HIV testing to in-
dexes in the health facility, and four FGDs with indexes
who had their children tested for HIV through B-GAP
(caregivers). No qualitative data collection was con-
ducted with indexes who did not take up HIV testing for
Contributions to the literature
 Although promoted and recommended by the World Health
Organization, index-linked HIV testing for children has not
been a standard practice in routine HIV care for many coun-
tries including Zimbabwe.
 Prior this study, no study has evaluated the factors that
influence and affect uptake of index-linked HIV testing for
children and adolescents as reported in our manuscript.
 Our findings have the potential to bridge the HIV testing
gap for children and optimise index-linked testing. This strat-
egy has been shown to result in higher yield of HIV when
compared to universal HIV testing; however, index-linked
testing uptake remains suboptimal.
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their children due to anticipated difficulties in engaging
this group. FGDs with caregivers were conducted up to
4 months after being approached to have their child(ren)
tested. The four caregiver FGDs were grouped according
to gender and site (Figure 1).
Caregivers were purposively selected from the study
sites to represent a mix of those who took up the differ-
ent test location options. Open invitations were made
via telephone call to selected B-GAP participants, and
those who were available on the scheduled day were re-
cruited. All the B-GAP providers participated in the pro-
vider FGD. All of the caregiver FGDs were conducted in
a private room at the health facility and the provider
FGD was conducted at the study office. They were facili-
tated by two Zimbabwean research assistants (one male
and one female) who were not involved in the recruit-
ment of caregivers for index-linked testing, in order to
minimise the risk of interviewer bias. The researchers
(NN and KS) were experienced in qualitative research
and had at least Bachelors level education. They both re-
ceived a 1-day refresher training in qualitative data col-
lection prior to conducting the FGDs. Neither NN nor
KS had prior relationships with the participants and in-
troduced themselves and the purpose of the research.
Caregivers selected for the FGDs were purposively se-
lected to represent an equal mix of caregivers who had
taken up each of the three testing approaches offered
through B-GAP. Facilitators used topic guides
(Additional files 1 and 2) to generate discussion focused
on understanding the caregiver’s experiences of testing
for their children, their preferences for how and where
index-linked testing should be conducted as well as to
gain insights from both the caregivers and the providers
about the enabling and inhibiting factors in the decision-
making process around index-linked testing. Given the
specificity of the sample inclusion criteria, the topic
guides were not piloted but in line with best qualitative
practice, iterative data collection and analyses allowed
for the guides to be refined after each FG D[15]. All
FGDs were face-to face and were conducted in either
English or one of the local languages (Ndebele and
Shona) depending on the participants preferences. Some
participants used the local languages interchangeably as
is common practice in this setting. NN and KS took field
notes during each FGD.
Data analysis
FGDs were audio recorded and translated from Shona
and Ndebele and transcribed into English by NN and
KS. Translation was a discursive process to allow for the
identification of correct English words for vernacular
terms or to decide on words with equivalent meanings
where this was not obvious. The translators provided
interview summaries to CDC and were involved in dis-
cussing the content of the interviews. Transcripts were
read by CDC for familiarisation and open coding.
Fig. 1 Participant recruitment flow
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Constant case comparisons were made between the
coded caregiver transcripts to identify overarching pat-
terns and differences. Caregiver and provider FGD tran-
scripts were analysed separately then compared for
similarity and contrast. Following initial coding, analyt-
ical memos were written to identify emerging key
themes. Content thematic analysis was done collabora-
tively by the first two authors (CDC and SB), and recur-
ring themes were noted in the later FGDs [15–17]. The
coded data was organised using Microsoft Word and
Excel. Refined coding was undertaken to further develop
thematic areas and to explore case comparisons across
the dataset, including considering the learning from any
deviant cases.
Ethics
Ethical approval was obtained from the Medical Re-
search Council of Zimbabwe, the Institutional Review
Board of the Biomedical Research and Training Institute,
and the London School of Hygiene and Tropical Medi-
cine ethics committee. Written informed consent was
obtained from all study participants (caregivers and pro-
viders). As part of the consent process and prior to com-
mencing the FGD, participants were made aware that
their HIV status would be implicitly disclosed to others
in the group and that they could withdraw participation
at any point. Participants were not incentivised for par-
ticipation but reimbursed transport costs. Due to confi-
dentiality concerns surrounding deductive disclosure in
the home, FGD transcripts were not given to partici-
pants. A dissemination meeting with participants is
scheduled at the end of the B-GAP study.
Results
We conducted five FGDs with 30 caregivers and seven
providers between December 2018 and February 2019.
The number of participants in each caregiver FGD
ranged from 4 to 11. The caregiver FGDs lasted over 2 h
on average, and the provider FGD was conducted over 5
h in two sessions. The median age of caregivers was 37
years (IQR 32–45) and 21 (70%) were female (Table 1).
Most caregivers (68%) interviewed were biological par-
ents of the children tested. In the main B-GAP study
(89%) of indexes offered testing for children in their
households had been diagnosed with HIV over a year
prior to being offered testing and only 9% had not initi-
ated antiretroviral therapy (ART).
Three key themes were identified that explain care-
givers’ uptake of testing and the decision-making process
around index-linked testing: (i) inadequate emphasis on
paediatric HIV information in routine adult care, (ii) the
relational nature of index-linked HIV testing of children
and (iii) limited access to facilities once the decision to
test has been made. Additional provider perspectives
that were unique to those voiced by the caregivers in-
cluded logistical challenges in locating homes for com-
munity testing, follow-up and indirect refusals through
the provision of wrong addresses and phone numbers.
Inadequate emphasis on paediatric HIV in routine adult
care
Caregivers felt confident about understanding the impli-
cations of their own HIV infection, but not how HIV in-
fection would affect their children. Although they had
children in their care, for some caregivers, literacy about
paediatric HIV was poor, particularly understanding of
perinatal HIV and testing for children. This information
was not given much emphasis in their routine care, and
some caregivers only became meaningfully aware of the
need for testing children and the possibility and benefits
of testing through their involvement in the B-GAP
study. Caregivers reported that the way information was




Age categorya 18–25 2 (6.7)
25–50 20 (99.7)
> 50 7 (23.3)
Sex Male 9 (30.0)
Female 21 (70.0)
Site Rural 15 (50.0)
Urban 15 (50.0%)
Test location Facility-based 11 (36.7)
Community-based by provider 15 (50.0)
Caregiver-provided self-test 4 (13.3)
Relation to child b
N = 78
Biological parent 53 (67.9)
Grandparent 18 (23.1)





Age category 18–25 1 (14.3)
25–50 6 (85.7)
> 50 0 (0.0)
Sex Male 2 (28.6)
Female 5 (71.4)
Site Urban 4 (57.1)
Rural 3 (4.3)
aMissing data for 1 caregiver
bCaregivers had different relationships to children that were tested in
their households
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provided in B-GAP enabled them to understand the
need to test.
We had only seen posters about free testing and if
you are infected, you start on your medication.
However, we had not heard about taking your chil-
dren for testing, we heard this for the first time
from B-GAP. (Caregiver #26, Male, 54)
Participants reported that while information about
paediatric HIV testing in routine care is an important
first step in encouraging the testing of children, informa-
tion alone is insufficient. A critical step to encourage
caregivers to take up testing was being able to apply the
pertinence of this information to one’s personal situ-
ation. This required more nuanced and individualised
information that would enable caregivers to accurately
assess their child’s risk.
With younger children, the ones that you are talking
about, maybe those who are 7 and below, their par-
ents were a bit hesitant because they would say;
‘Where would they have gotten the HIV from?’
(Provider#1, Female, 30)
Without adequately tailored information, testing is
often not taken up, with delays justified by an incorrect
assumption that it is unnecessary. In such situations,
testing tends to be done reactively only once illness has
developed.
As for me, I had never really heard it as such, that
children can get tested. But…. my child was con-
stantly sick. So, I thought to myself that it would be
best if I brought in my child for testing. (Caregiver
#13, Female, 31)
As such, the provision of tailored information provided
within the B-GAP intervention was influential in encour-
aging the uptake of testing. Many caregivers noted that
the B-GAP providers explaining the rationale for testing
reassured them and resulted in the caregivers having
courage to take up testing. Caregivers valued the time
that the providers took to convey information and to
help them apply it to their individual context. Caregivers
emphasised the benefits of allowing time to discuss and
listen to their concerns. For some, these conversations
extended over more than one encounter.
I would say that the B-GAP team were an experi-
enced team, who were well taught about their pro-
gram because they would approach you in a way
that make you feel free. One person will approach
you and explain what they are doing in a good way
that helps you to open up and tell them your status
and the team was well trained and open. (Caregiver
#22, Male, 52)
The relational nature of index-linked HIV testing of
children
Participants illuminated the complex relational webs that
HIV so perniciously affects. Caregivers viewed HIV test-
ing of children not as a “one-off” event but as a process
with potential consequences on multiple people and
relationships.
They described living with HIV as a lifelong burden
which the child experienced from a young age. Index-
linked testing would also inadvertently reveal their own
status to other family members, and they would have to
confront this both with the child and others. Many care-
givers who had kept their HIV status a secret from
others in their household feared that they might lose the
control they had exercised over disclosing their own
status.
I still remember, there was this case uh, of this par-
ticular lady who said; ‘Living with HIV is already a
burden to me. It’s quite difficult. So, if you come
into my home and test these children, and they
come out positive, the assumption will be that I am
the one who infected them and that will certainly
disturb my family; the makeup of my own particular
family’. (Provider #4, Male, 34)
Other reported concerns that would follow a positive
HIV test were having to support the medication-taking
throughout childhood and disruption of care for other
children. Caregivers were living with HIV themselves
and for many the potential additional responsibility in-
volved in managing their child’s HIV care alongside their
own was undesirable, but testing would at least facilitate
access to care. Often caregivers would take time to make
this decision and reach a point where they are willing
and ready.
This one lady; she had initially refused, then I had
shown her my office because I usually screen them
where she was. So, she came in later, she said; ‘I rea-
lised that in as much as I do not want my child to
be tested, but I am already on ART, and it is really
helping me. I have seen other people die when they
are not taking ART. So… I would rather have my
child tested so that we know the way forward than
to stay in the oblivion age where he/she doesn’t
know what is going on’. (Provider#6, Female, 24)
Caregivers stated that these factors would impede up-
take of HIV testing for children but, importantly, they
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emphasised that they needed both time and support to
work through these concerns and reported that feeling
under pressure to quickly move to testing was not con-
ducive to uptake.
The relational dynamics between caregivers were an
important determinant of uptake of index-linked HIV
testing for children. Caregivers demonstrated that index-
linked HIV testing for children requires negotiation
with, and the involvement of, different individuals. In
some instances, the decision to test had to be a joint de-
cision between two caregivers such as biological parents.
In the B-GAP study, most indexes were women, who
sometimes sought the permission of their husbands for
testing of their children. Beyond the relational nature of
the decision, there are extensive ramifications that could
follow a positive HIV test result, including who is
deemed responsible for HIV transmission as well as for
supporting treatment.
Where the father lives in South Africa, those
mothers may not accept the idea of testing the child
on their own in the absence of the father of the chil-
dren because when he returns, he may want an-
swers about where the child got HIV. (Caregiver
#11, Female, 37)
While indexes may have been the primary caregiver,
they were not always the biological parent of the chil-
dren living in their households. Caregivers, who were
not the biological parents, expressed concern about their
right to link a child to testing and care and the negative
impact that HIV testing of the child would have on their
relations with the biological parents.
If my brother receives a call from me telling him
that his child got tested and is now on ARVs, the
next time we meet he will certainly kill you. (Care-
giver #23, Male, 58)
Regardless of relation to the child, the issue of bearing
the additional emotional and financial cost of supporting
someone who was not their biological child was raised.
However, while acknowledging these issues, many care-
givers felt they were liable to make the final decision be-
cause they provided day to day care of children. There
was variation in how caregivers handled the decision-
making, a process which would likely take time to re-
solve sometimes together with biological parents.
If you are saying that if the children are under your
care you would first need to inform a parent in
South Africa, what if the child gets sick and needs
to be admitted in hospital? What would you do
then? In my view, whether the biological parent
wants or not I will get the child tested! (Caregiver
#19, Female, 42)
I live with my grandchildren; my child lives in South
Africa. If anything happens to those children, I am
responsible. But I am expected to first inform my
child, and if she refuses… I would rather tell her
after the fact that I did this and that. (Caregiver #14,
Female, 53)
Sometimes we have to take a stand and make the ef-
fort to have an open discussion with the biological
parents so that it does not become a problem in fu-
ture. Because it is also a burden to have this oppor-
tunity and yet decline to have those non-biological
children tested. It is also difficult. So, I need to dis-
cuss with the biological parents and inform them of
their children’s statuses. I need to be open about it.
(Caregiver #10, Female, 65)
In addition to needing to inform biological parents
about testing for their children, caregivers who were not
the biological parents of the children to be tested noted
that the inadvertent disclosure of the HIV status of bio-
logical parents was a critical factor to consider in the
testing process for non-biological children. Caregivers
had to weigh up the importance of testing the child ver-
sus the unwelcome risk of doing so potentially revealing
the mother’s HIV status, which she may not have
wanted to share.
I feared that if the child who isn’t mine biologically
tested HIV positive, I was going to struggle to in-
form the child’s real mother. Perhaps the mother is
positive, and she has not disclosed this to me. Ini-
tially it used to bother me, but I resolved that I
would tell her since she is my younger sister and I
tested the child because the child lives under my
care. (Caregiver #11, Female, 37)
Caregivers highlighted the need to engage children
themselves in the HIV testing process, particularly older
children who were often reluctant to go to the clinic. In
these cases, caregivers expressed a preference for com-
munity health workers to go to the household and speak
to older children directly about HIV testing.
This option (home based testing) was very helpful
to me because I have an older child who always
used to refuse to go with me to the clinic, every
time I would ask him to go and get tested at the
clinic he would refuse. However, when they arrived,
Dziva Chikwari et al. Implementation Science Communications            (2020) 1:99 Page 6 of 10
they summoned him, and he could not refuse. And
they spoke to him in their way and before I knew it,
they were holding hands and they seemed to really
click. (Caregiver #2, Female, 36)
For older adolescents, caregivers repeatedly mentioned
the need to consider sexual risk rather than solely the
perinatal HIV infection assumed by index-linked HIV
testing. Caregivers mentioned the fears that adolescents
may have about disclosing their sexual behaviour by
ways of an HIV test. Older adolescents were felt to be
old enough to consent independently.
It’s because they will be afraid, young people indulge
and experiment on a lot of things, then that brings
in the fear that leads one to decide not to accept
this kind of testing. (Caregiver #30, Male, Age-
unknown)
Addressing limited access: provision of community-based
HIV testing options
Once the decision to test has been made caregivers often
need to bring their children to a health facility. As has
been reported in other studies, this leads to out-of-
pocket expenditure and loss of income by taking time
off work to make the journey.
I had always wanted my children to get tested but I
didn’t have the time to take the children to the
clinic. (Caregiver #29, Male, 25)
To address these barriers, the B-GAP study provided
two options for testing in the community, which partici-
pants noted was helpful in increasing accessibility of
testing for their children.
We were happy that B-GAP would come home.
Taking the children to the clinic using a taxi will be
costly since I had 4 children that needed to be
tested, so it meant us filling the whole taxi as a fam-
ily to the clinic and back home, this was going to be
too costly and that money would be money that we
can use at home for a month, this is what was good
about B-GAP. (Caregiver #28, Male, 39)
Provider perspectives: follow-up, logistics and indirect
refusals
Explicit contributions from providers included chal-
lenges surrounding community testing by providers
and follow-up for caregivers who chose facility test-
ing. Providers noted that sometimes they had diffi-
culty locating households due to inaccurate or wrong
addresses and phone numbers provided by the
caregivers.
When you are asking about directions then some-
one says you turn to the left and in actual fact they
mean turn to the right, so until you are now in the
road and you call and you ask you said I should turn
left and they say yes turn to the left but you realize
the actual turn is to the right. (Provider#7, Female,
40)
The providers did highlight that in some instances
they felt these could be indirect refusals from caregivers
who did not want to have the children in their house-
holds tested. While the study protocol was that care-
givers be followed up at least 3 times in order to
complete testing, some caregivers would provide false
phone numbers and fake addresses.
I don’t know now because if the number doesn’t go
through at all, at all! And the number doesn’t go
through, you try for the whole month. You don’t
know if this number is some number that belongs
to him, but is no longer in use, you know? (Pro-
vider#3, Female, 33)
I don’t think there is anything that could have been
done, why I say so is because someone lies and tells
you that I stay at this address and they do not stay
there. (Provider#1, Female, 30)
Despite this, however, there were some caregivers who
appreciated the follow-up from providers to facilitate
testing for the children in their households. This follow-
up allowed caregivers who were indecisive more time to
make the decision to test as well as act as a reminder to
caregivers who may have forgotten.
It is very good to follow up because when you sign
up with B-GAP people, they will call you, I was
called, and they asked when they should come. And
I told them I was in the village, when I got back, I
never got back to them, but they called me again.
And they asked when they should come and I ap-
preciated that because I had forgotten about it, so I
think that the follow ups are good. If they had gone
stealth, I also would have forgotten about it. So, the
follow ups are good, some need scolding. (Caregiver
#14, Female, 53)
I think it is a good idea to follow up because at
times you just agree to be part of the program be-
cause you will in a certain state of mind then you
set an appointment but then that fear, on the
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appointment date you decide not to go to the clinic
and the clinic staff sees that someone missed their
appointment so I think it is good for them to phone
you and it will actually give you the confidence that
you are dealing with people who are genuine who
remembers to call you for a follow up and at times
you would just completed a form so that the person
does not continue to bother you and in actual es-
sence you were not serious about it, so if they call
you it’s now confirmation that whatever the results
these people might actually help since they would
have made that follow up. (Caregiver #29, Male, 25)
Discussion
Our study highlights inadequate emphasis on paediatric
HIV for adults living with HIV and accessing routine
care. Emphasis on testing children has traditionally been
confined to PMTCT in most programs and not part of
general adult care [18]. Additionally, in general, standard
of care focuses more on individual treatment and part-
ner testing rather than for children [19]. Clients receiv-
ing HIV care had not been given adequate information
about the need to test children in ways that they could
satisfactorily engage with. This results in missed oppor-
tunities for diagnosis of children who only present once
they develop HIV-associated illness. This can be re-
versed by directly addressing the issue of low-risk per-
ception [20]. B-GAP staff provided tailored information
so that caregivers grasped the pertinence of testing their
children, which increased uptake of testing.
While many caregivers may be aware of the benefits of
HIV testing, they are confronted with a myriad of issues
when offered index-linked HIV testing including the pro-
spect of lifelong treatment for their children and auto-
matic disclosure of the HIV status of the index and that of
biological parents (if the index is not the biological par-
ent). These issues may have enormous implications on the
relationships within a family unit and beyond.
Other studies have also highlighted the difficulties both
caregivers and health care providers face in discussing
parent-to-child HIV transmission with children, and this
can be a substantial barrier to children being tested for
HIV [21–24]. HIV status disclosure and potential social
harms, such as gender-based violence, are consistent con-
cerns for HIV testing [25, 26]. Support for disclosure to
both other family members and to children, where
wanted, should be an integral component of index-linked
testing. This is likely to have longer-term benefits in terms
of promoting psychological well-being and adherence to
treatment should the child test HIV-positive [27].
The multiple relationships which may be affected by
an HIV test result substantially influence decision-
making about testing of children. If uptake of paediatric
HIV testing is to be improved, providers need to
recognise and more actively engage with these relational
dimensions to HIV testing. Our findings illustrate the
centrality of relationships in decision-making, which can
potentially impede the uptake of testing for children as
well as prolonging the process of testing. However, up-
take can be improved if providers recognise and engage
with individual concerns regarding the complex and po-
tentially wide-ranging consequences of caregivers having
their children tested for HIV.
Testing programmes are often focused on the clinical
urgency of testing and on achieving targets such as the
UNAIDS 90-90-90 targets, without considering social
and relational issues [28]. Notably, there has been much
more attention paid to these issues for supporting adher-
ence to treatment in children and adolescents through
the provision of social and community-based psycho-
social support [29, 30]. We argue that a similar approach
must be adopted for improving uptake of HIV testing,
and HIV testing must be regarded as a process rather
than a discrete event [31].
Although recommended by WHO, index-linked test-
ing was not a standard practice in routine HIV care for
children in Zimbabwe when B-GAP started. The B-GAP
study implemented screening of individuals living with
HIV and rigorous follow-up by telephone and home
visits for caregivers who initially accepted testing for
their children. This facilitated tailored conversations be-
tween the caregivers and providers, often within the
household, with those who would not otherwise have
attended healthcare facilities with their children despite
agreeing to test [13]. This follow-up may have given
caregivers more time and support to make a decision
and subsequently led to increased uptake of testing. We
note that some participants only took up testing after
follow-up and after having received support from B-
GAP providers.
In B-GAP, we found that older adolescents (16–18
years) were less likely to be tested when compared to
children aged 2–5 years (under review). As highlighted
by this and previous studies, engaging adolescents is
challenging and index-linked testing may expose sexual
activity of adolescents to their caregivers [32, 33]. As
highlighted by caregivers, respecting adolescents’ auton-
omy and approaching them directly and then their care-
givers for consent may be more appropriate.
Our study shows that overcoming barriers to access is
vital to increase uptake of HIV testing. In B-GAP, the
provision of testing in community settings, such as test-
ing at home by a provider or the provision of an oral
HIV self-test kit to the caregiver, mitigated against bar-
riers such as transportation costs and loss of income
when caregivers have to take time off work to bring chil-
dren to health facilities. Offering alternative testing ap-
proaches can improve uptake of index-linked testing and
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this has also been demonstrated in Malawi where com-
munity testing had higher uptake than facility-based
testing [6]. These community-based strategies should be
included as part of routine care if we are to identify hard
to reach children and adolescents living with undiag-
nosed HIV. We did note, however, some logistical bar-
riers with uptake of community testing whereby some
caregivers gave inaccurate or false addresses or phone
numbers. In some instances, providers felt this was indi-
cative of indirect refusals which would be expected
where caregivers are not ready to test children in their
households.
A key strength of our study was the provision of
index-linked HIV testing by trained and dedicated staff.
Health facilities in low-income settings are often under-
staffed and have overworked personnel who may not
have the time to offer the support and detailed commu-
nication or information that was offered by providers in
this study. The B-GAP study facilities are run by nurses.
This highlights the limited ability for the study providers
and caregivers who are part of this system to influence
longstanding change. However, key learnings from this
study can be integrated into large-scale implementation.
A limitation of our study is that FGDs were held only
with caregivers who took up index-linked testing and
providers. While it may have been beneficial to include
caregivers who refused or did not take up testing for
children in their households, this group is difficult to en-
gage as it may be uncomfortable for individuals to justify
not acting on health recommendations. However, ex-
ploring the decision-making process of caregivers who
took up testing provides an insight into the enablers to
testing and the issues indexes struggle with. Providers
who offered testing to all caregivers (those that took up
testing and those that did not) were able to indirectly
provide perspectives on both groups through their
experiences.
We did not conduct in-depth interviews in our study.
FGDs aim to capture social norms around index-linked
HIV testing rather than focus on individual stories.
However, as participants in each FGD were aware that
everyone had engaged in the intervention, it was com-
mon for participants to choose to reflect on their own
experiences, as well as to consider more common trends
within the community. Both sexes and caregivers from
both rural and urban settings were represented to allow
for the breadth of contextual diversity to be explored.
Conclusion
In conclusion, this study provides a novel perspective
into the lived experiences of providers and caregivers
who have offered and accepted index-linked HIV testing
in rural and urban settings in Zimbabwe. It demon-
strates that the testing gap in children can be bridged by
improving paediatric HIV literacy, recognising the rela-
tional aspects of HIV testing that caregivers are con-
fronted with when offered HIV testing for their children,
and the need for providing time for caregivers to navi-
gate these aspects.
Panel of recommendations
 Paediatric HIV literacy should be strengthened as
part of standard HIV care.
 Discussions about paediatric HIV testing should be
individualised and include discussions on HIV risk
in children and the benefits of testing.
 Index-linked HIV testing should be coupled with
robust support for indexes.
 Offering community-based follow-up and/or an op-
tion for community-based HTC may improve access
and uptake.
 A family- and process-centred approach should also
be adopted to improve uptake of testing
 Adolescents should be directly engaged, and their
autonomy respected for HIV testing.
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One of the index-linked HIV testing strategies evaluated as part of the B-GAP 
project was HIV testing performed by caregivers using OMT tests.21 OMT tests 
have been shown to have high sensitivity and specificity for the diagnosis of HIV 
in adults but had not previously been validated against routinely used rapid 
blood-based HIV tests in children.112  
In this chapter performance of OMT tests was compared to that of blood-based 
rapid HIV tests that are currently used as standard of care in national algorithms. 
The validation was done in Kenya and Zimbabwe among ART naïve children aged 
18 months – 18 years. Children on ART were excluded from this study as among 
ART experienced individuals (including children) OMT tests have been shown to 
produce false negative results.143 
In this study the OMT test was 100% sensitive and 99.9% specific.  This 
manuscript is the first validation of OMT tests in ART naïve children and 
demonstrates that OMT tests can be used for HIV testing among children and 
adolescents, as in adults.9 For adults, currently, OMT tests are recommended for 
use as a screening tests with confirmatory HIV testing using blood-based tests.9 
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Diagnostic Accuracy of Oral Mucosal Transudate Tests
Compared with Blood-Based Rapid Tests for HIV Among
Children Aged 18 Months to 18 Years in Kenya and
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Background: Gaps persist in HIV testing for children who were
not tested in prevention of mother-to-child HIV transmission
programs. Oral mucosal transudate (OMT) rapid HIV tests have
been shown to be highly sensitive in adults, but their performance
has not been established in children.
Methods: Antiretroviral therapy-naive children aged 18 months to 18
years in Kenya and Zimbabwe were tested for HIV using rapid
OraQuick ADVANCE Rapid HIV-1/2 Antibody test on oral fluids
(OMT) and blood-based rapid diagnostic testing (BBT). BBT followed
Kenyan and Zimbabwean national algorithms. Sensitivity and specificity
were calculated using the national algorithms as the reference standard.
Results: A total of 1776 children were enrolled; median age was
7.3 years (interquartile range: 4.7–11.6). Among 71 children positive
by BBT, all 71 were positive by OMT (sensitivity: 100% [97.5%
confidence interval (CI): 94.9% to 100%]). Among the 1705
children negative by BBT, 1703 were negative by OMT
(specificity: 99.9% [95% CI: 99.6% to 100.0%]). Due to
discrepant BBT and OMT results, 2 children who initially tested
BBT-negative and OMT-positive were subsequently confirmed
positive within 1 week by further tests. Excluding these 2
children, the sensitivity and specificity of OMT compared with
those of BBT were each 100% (97.5% CI: 94.9% to 100% and
99.8% to 100%, respectively).
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Conclusions: Compared to national algorithms, OMT did not miss
any HIV-positive children. These data suggest that OMTs are valid
in this age range. Future research should explore the acceptability
and uptake of OMT by caregivers and health workers to increase
pediatric HIV testing coverage.
Key Words: HIV, children, pediatric, oral HIV testing, diagnostic,
saliva HIV testing
(J Acquir Immune Defic Syndr 2019;82:368–372)
INTRODUCTION
The HIV pandemic has heavily affected children with
over 1.8 million children (,15 years) living with HIV and
180,000 newly infected in 2017.1 Prompt diagnosis and
initiation on antiretroviral therapy (ART) is associated with
decreased morbidity and mortality2,3 and improved develop-
mental outcomes4,5; however, gaps remain in diagnosis,
particularly among older children and adolescents.6
World Health Organization (WHO) recommendations
endorse rapid antibody-based HIV tests for diagnosis of
individuals .18 months.7 Blood-based HIV tests (BBT) are
used globally. In addition, oral mucosal transudate (OMT)
rapid HIV tests allow for sample collection that is less
invasive, are more acceptable to clients, poses fewer risks to
health care workers (HCW), and may increase testing
uptake.8–10
The Food and Drug Administration approved the Ora-
Quick OMT in 2004 for testing by health providers for
individuals .12 years.11 In 2016, the OraQuick HIV Self-Test
received WHO prequalification and it is now recommended by
WHO as a screening test for HIV.12 OMT has high sensitivity
and specificity in detecting HIV antibodies in adults and older
adolescents.7,10 A meta-analysis comparing OMT with BBT in
adults reported a pooled sensitivity of 98.0% and specificity of
99.7% for OMT.10 OMT has not been validated in children.
We evaluated the diagnostic performance of OMT
compared with routine BBT in children and adolescents aged
18 months to 18 years in Kenya and Zimbabwe.
METHODS
Setting and Participants
This analysis includes pooled data from 2 studies in
Kenya and Zimbabwe that include parallel point-of-care diag-
nostic OMT and BBT to assess sensitivity and specificity of
OMT among children and adolescents. Data were combined to
increase precision of sensitivity and specificity estimates, as the
number of newly diagnosed HIV-positive children in both
settings has reduced with the scale-up of pediatric HIV
prevention and treatment programs.
Zimbabwe
This analysis was nested within the “Bridging the Gap
in HIV Testing and Care for Children in Zimbabwe” (B-GAP
Project) whose aim is to evaluate index-linked testing for
pediatric case detection. Study participants were children and
adolescents of unknown HIV status, aged 2–18 years,
attending any health services in the participating hospitals
and primary health care clinics.
Kenya
The “Saliva Testing and Video Information to Expand
Uptake of Pediatric HIV Testing” (STEP-UP) study enrolled
children aged 18 months to 12 years. Two recruitment
streams were used. First, children of HIV-positive adults
attending HIV clinics who were tested for HIV within
a randomized controlled trial of financial incentives for index
case testing (FIT trial; NCT0304991713) were recruited after
determining HIV status using BBT within the trial. Second,
children from outpatient clinics were recruited after HIV
testing using BBT within routine testing; here children who
tested BBT positive were oversampled.
Procedures
Zimbabwe
Testing followed the national algorithm14: first, BBT by
Determine (Alere Determine HIV-1/2 Ag/Ab Combo; Abbott,
Chicago, IL) (fourth generation), followed by First Response
(First Response HIV-1-2; Premier Medical Corporation Ltd,
Kachigam, India) (third generation), if Determine was
reactive. In the case of 2 reactive BBTs, the same 2 BBTs
were performed by a different provider to confirm a positive
diagnosis. In the case of discordant BBTs, both tests were
repeated. If discordance persisted, a third test, CHEMBIO
was performed (CHEMBIO HIV 1/2 STAT-PAK Assay;
CHEMBIO Diagnostic Systems, Inc., New York, NY). If this
third test was positive, the result was reported as inconclusive
and a retest conducted in 14 days. OMT was conducted by
clinic staff blinded to BBT results.
Kenya
The national algorithm mirrored that in Zimbabwe with
the following exceptions: the Determine HIV test was third
instead of fourth generation and DNA PCR from dry blood
spot specimens was the third test and was considered
conclusive.14–16 In addition BBT was conducted by research
staff for those enrolled in the FIT trial and non-research staff
for those enrolled from routine testing points. Research staff
performed OMT and were not blinded to BBT results.
The reference standard used for our study was the HIV
status as per the national algorithim of each country.
OMT
In Zimbabwe and Kenya, OMT sample collection and
processing was performed bedside by qualified HIV testing
lay providers who are typically lower than nurse level
providers and are responsible for HIV testing in both
countries. The qualification for these providers is a standard
national training for HIV services conducted over 2 weeks.
Testing was conducted according to manufacturer details
(OraQuick ADVANCE Rapid HIV-1/2 Antibody Test; Or-
aSure Technologies, Inc., Bethlehem, PA), whereby the
research staff collected an oral fluid sample from the
participants by running the test device between the lips and
outer gums of the client once on top and once at the bottom
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and then place the test device pad directly into the reaction
fluid immediately after collection.17 OMT results were read
once between 20 and 40 minutes in Zimbabwe, and twice
in Kenya at both 20 and 40 minutes to assess test performance
at the lower and upper recommended times. OMT results
were not shared with caregivers, because the test was
undergoing validation.
Statistical Analysis
Data were analyzed using STATA 14 (StataCorp,
College Station, TX). Sensitivity was calculated by dividing
the number of OMT and BBT-positive children by the
number of BBT-positive children. Specificity was calculated
by dividing the number of OMT and BBT-negative children
by the number of BBT-negative children. Positive predictive
value (PPV) and negative predictive value (NPV) were
calculated in the Zimbabwean cohort by dividing the number
with both positive OMT and BBT by all the positive OMT
tests (PPV) and by dividing the number with both negative
OMT and BBT results by the total negative by OMT (NPV).
PPV and NPV were not calculated in the Kenyan cohort,
because positive children were oversampled. Ninety-five
percent (95%) or 97.5% (when the estimate was 100%)
confidence intervals (CIs) were calculated using a binomial
distribution. Stability of the test results using result interpre-
tation pictures from the manufacturer was described in Kenya.
Ethics
Adolescents $16 gave independent written informed
consent without parental/guardian consent. Parents/guardians
of children aged 18 months–15 years provided written consent;
adolescents 13–15 years signed a paragraph within the parental
consent form to give their assent, whereas children 7–12 years
signed a separate assent document, which was optional in
Kenya. B-GAP received approval from the Biomedical
Research and Training Institute, the Medical Research Council
of Zimbabwe and institutional review boards at Duke Uni-
versity and the London School of Hygiene and Tropical
Medicine. The Kenyan study received approval from the
Kenyatta National Hospital Ethics and Research Committee
and the University of Washington Institutional Review Board.
RESULTS
Demographics
Overall, 1776 children were enrolled; 1570 (88%) from
Zimbabwe and 206 (12%) from Kenya. The median age was
7.3 years (IQR: 4.7–11.6); 2 (0.1%) were 18 months
22 years; 512 (29%) were .2–5 years; 845 (48%) were
.5–12 years; and 417 (23%) were .12–18 years. Overall,
918 (52%) were female. Among Kenyan children, 169 (82%)
were identified via index case testing and 37 (18%) in out-
patient clinics and inpatient wards (Table 1).
OMT Sensitivity and Specificity
Among 71 children positive by BBT, 71/71 (sensitivity:
100.0% [97.5% CI: 94.9% to 100.0%]) were positive by
OMT. Among 1705 children negative by BBT, 1703/1705
(specificity: 99.9% [95% CI: 99.6% to 100.0%]) were
negative by OMT. In the 1570 Zimbabwean participants,
the PPV was 93.3% (95% CI: 77.9% to 99.2%) and the NPV
was 100.0% (97.5% CI: 99.8% to 100.0%).
In Zimbabwe, 2 children who initially tested BBT-
negative and OMT-positive were retested within 1 week to
confirm HIV status because of suggestive clinical presentation
and history; both were confirmed positive. A 9-year-old was
confirmed positive by ELISA. A 2-year-old was confirmed
positive by First Response and CHEMBIO. Excluding these 2
children, the sensitivity and specificity of OMT compared with
those of BBT were each 100% (97.5% CI: 94.9% to 100% and
99.8% to 100%, respectively) (Table 2).
Stability of Visual Results (Kenya)
Among 43 children with positive OMT at 20 minutes,
43 (100%) had positive OMT at 40 minutes. Among the
163 children with negative OMT at 20 minutes, 163
(100%) had a negative OMT at 40 minutes. Using result
interpretation pictures from the manufacturer, among 43
positive OMT results, 26 (60%) and 29 (67%) were
strongly positive at 20 and 40 minutes, respectively. Three
reads that were weakly positive at 20 minutes were strongly
positive by 40 minutes; the remaining 14 (33%) were
weakly positive at both 20 and 40 minutes.
TABLE 1. Sociodemographic Characteristics
Child
characteristics
All, N = 1776
BBT HIV
Positive, n = 71
BBT HIV








18 mo–2 yrs 2 (0.1) 1 (1) 1 (0.1)
.2–5 yrs 512 (29) 21 (30) 491 (29)
.5–12 yrs 845 (48) 34 (48) 811 (48)
.12–18 yrs 417 (23) 15 (21) 402 (24)
Female 918 (52) 46 (65) 872 (51)
Recruitment
country
Zimbabwe 1570 (88) 28 (39) 1542 (90)
Kenya 206 (12) 43 (61) 163 (10)
Index case
testing
169 (82) 7 (16) 162 (99)
Inpatient/
outpatient
37 (18) 36 (84) 1 (1)
Child
characteristics
All, n = 189
BBT HIV
positive, n = 43
BBT HIV
negative, n = 146





8 (4) 5 (12) 3 (2)
Any maternal
ARVs
4 (50) 2 (40) 2 (67)
Any infant
prophylaxis
4 (50) 2 (40) 2 (67)
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DISCUSSION
In this cross-sectional study of children aged 18 months
to 18 years, we found that OMT had excellent sensitivity and
specificity. When compared to the Kenyan and Zimbabwean
national algorithms, OMT did not miss any positive children.
These data suggest that OMT is valid for HIV diagnosis in
this age range.
As with other antibody tests, OMT is inappropriate as
a diagnostic test for children under 18 months due to the
presence of maternal antibodies.18 In adults, antibody-based
tests have limitations due to a long window period, which
may lead to failure in detecting recent HIV infection.19
However, this is less of a concern among older children
and younger adolescents who, if infected, are likely to have
long-standing HIV, acquired perinatally.
Our results provide evidence for wider use of OMT for
pediatric testing. Current testing approaches to identify
children include index-linked testing, provider-initiated test-
ing and counseling, targeted testing in health facilities,
and community-based testing.6,7,20–26 Outpatient provider-
initiated testing and counseling can identify children earlier in
disease progression27; however, achieving high coverage is
challenging21 because of high client volume and workload for
limited numbers of HCWs.28 In resource-limited settings,
scaling up testing will require simultaneously increasing
coverage and minimizing costly components of testing,
including HCW time.29,30 The ease and safety of OMT
presents a potential opportunity for task-shifting from
HCWs to lay providers, as was done in this study, or to
caregivers to overcome human resource constraints. It is
also important to note that the time to perform OMT is also
similar to that required for BBT. Future research is needed
to explore the acceptability and feasibility of OMT by
caregivers and HCWs in facility and community settings.
A 2012 systematic review comparing OMT with whole
blood specimens reported a pooled sensitivity of 98.0% and
specificity of 99.7% for OMT.10 Despite this, the concentra-
tion of antibodies in oral fluid is lower than in blood and
typically wanes during HIV treatment.31,32 Previous studies in
Zimbabwe have confirmed that OMT has suboptimal sensi-
tivity in ART-experienced children.29,33 WHO has issued
warnings, advocating that rapid diagnostic tests not be used
among ART-experienced adults; similar warnings seem
warranted in children. Therefore, it is critical to avoid
use of OMT by ART-experienced patients, either to
confirm being “cured” of HIV or when reinitiating HIV
care.34 Our study included an entirely ART-naive pediatric
population and observed no false-negative results. In
2 cases, children were negative by BBT and positive by
OMT and were confirmed HIV-positive upon repeat
testing. This suggests slightly better detection by OMT
than BBT in our study; it is unclear why we observed this
counterintuitive finding.
Our study’s strengths include a large sample of ART-
naive, HIV-positive children to inform precise estimates of
sensitivity. In addition, data from Kenya and Zimbabwe
provided similar results. OMT results were compared with
routine, field-based BBT according to national algorithms,
which provides an apt comparison with standard-of-care tests
and provides useful public health information. Limitations
include that OMT result interpretation was not blinded in
Kenya, which may have influenced result interpretation.
National algorithms between the 2 countries differed slightly,
so the “reference standard” was not the same in both
countries. However, in both cases, the algorithms are those
used for national guidelines. Consequently, our findings
demonstrate the performance of OMT against the standard-
of-care and are therefore generalizable in these settings.
Although the BBT in this study was not ELISA or poly-
merase chain reaction (PCR) based, OMT has previously
been compared with these more sensitive lab-based tests to
inform Food and Drug Administration approval and WHO
TABLE 2. Performance of OMT vs BBT for HIV Diagnosis






Positive 71 2* 73
Negative 0 1703 1703
Total 71 1705 1776








100% (97.5% CI: 99.8 to 100)
Panel B: Zimbabwe
OMT
Positive 28 2* 30
Negative 0 1540 1540
Total 28 1542 1570








100% (97.5% CI: 99.8 to 100)
Panel C: Kenya
OMT
Positive 43 0 43
Negative 0 163 163
Total 43 163 206




100% (97.5% CI: 97.8 to 100)
*Subsequently confirmed as HIV-positive using additional tests within 1 week of
initial testing.
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endorsement for use in adults.11,31 An additional limitation is
that in our study we did not have any inconclusive test results.
Procedures on how to report and manage inconclusive test
results must be put in place.
CONCLUSIONS
OMT is highly sensitive and specific in children and
adolescents. This is consistent with findings from studies in
adult populations. Policymakers and regulators should con-
sider expanding the age at which OMT may be used to
include children over 18 months.
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7. Feasibility and accuracy of HIV testing of children by 





The study conducted in Chapter 6 showed that OMT tests were highly sensitive 
and specific in identifying HIV among children and adolescents.1 Several studies 
have shown that adults are able to accurately perform HIV self-testing using OMT 
tests and this approach has been endorsed by the WHO.2,3 However, the 
feasibility of testing of children by their adult caregivers has not previously been 
assessed. One of the three index-linked HIV testing approaches offered as part of 
the B-GAP study was HIV testing by caregivers using OMT tests in the community. 
This chapter is an evaluation of how well caregivers perform the OMT on their 
children and whether they can correctly interpret the test results. This is the first 
ever study to evaluate the feasibility of caregivers testing their children for HIV. 
In phase one of the study caregivers were shown how to perform the test on their 
children and subsequently observed by research assistants while performing the 
test on their children. In phase two of the study caregivers were not shown how 
to perform the test but were also observed by research assistants. The majority 
of caregivers could correctly perform OMT testing on their children and interpret 
HIV test results with or without prior demonstration.  
This study shows that this HIV testing strategy can be used by caregivers and 
could potentially increase access to HIV testing for children who have limited 
access to health facilities. In Chapter 4 where the uptake of the three HIV testing 
approaches is compared HIV testing by caregivers had the lowest uptake. 
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Feasibility and Accuracy of HIV Testing of Children by
Caregivers Using Oral Mucosal Transudate HIV Tests
Chido Dziva Chikwari, MSc,a,b Victoria Simms, PhD,b,c Katharina Kranzer, PhD,a,b,d
Stefanie Dringus, PhD,c Rudo Chikodzore, MBChB,e Edwin Sibanda, MBChB,f Karen Webb, MSc,g
Nicol Redzo, BA,b Hilda Mujuru, MMed,h Tsitsi Apollo, MBChB,i Getrude Ncube, MIH,i
Karin Hatzold, MD,j Sarah Bernays, PhD,k,l Helen A. Weiss, PhD,c and Rashida A. Ferrand, PhDa,b
Background: Children encounter multiple barriers in accessing
facilities. HIV self-testing using oral mucosal transudate (OMT) tests
has been shown to be effective in reaching hard-to-reach popula-
tions. We evaluated the feasibility and accuracy of caregivers
conducting HIV testing using OMTs in children in Zimbabwe.
Methods: We offered OMTs to caregivers (.18 years) living with
HIV to test children (2–18 years) living in their households. All
caregivers were provided with manufacturer instructions. In Phase 1
(January–December 2018, 9 clinics), caregivers additionally
received a demonstration by a provider using a test kit and video. In
Phase 2 (January–May 2019, 3 clinics), caregivers did not receive a
demonstration. We collected demographic data and assessed care-
giver’s ability to perform the test and interpret results. Caregiver
performance was assessed by direct observation and scored using a
predefined checklist. Factors associated with obtaining a full score
were analyzed using logistic regression.
Results: Overall 400 caregivers (83.0% female, median age 38
years) who were observed tested 786 children (54.6% female,
median age 8 years). For most tests, caregivers correctly collected
oral fluid [87.1% without provider demonstrations (n = 629) and
96.8% with demonstrations (n = 157), P = 0.002]. The majority
correctly used a timer (90.3% without demonstrations and 96.8%
with demonstrations, P = 0.02). In multivariate logistic regression
caregivers who obtained a full score for performance were more
likely to have received a demonstration (odds ratio 4.14, 95%
confidence interval: 2.01 to 8.50).
Conclusions: Caregiver-provided testing using OMTs is a feasible
and accurate HIV testing strategy for children. We recommend
operational research to support implementation at scale.
Key Words: HIV, self-testing, children, adolescents, caregiver
(J Acquir Immune Defic Syndr 2021;87:781–788)
INTRODUCTION
Globally, 1.8 million children (0–14 years) were
estimated to be living with HIV in 2019, but over 845,000
of these were either undiagnosed or diagnosed but not on
treatment.1 Although coverage of prevention of mother-to-
child transmission programs has risen substantially in the last
decade, only 50% of exposed infants underwent HIV testing
within the first 2 weeks of birth in 2019, and postnatal
transmission continues to occur.2 Thus, children continue to
be infected (150,000 infections in 2019), with many children
not presenting to health care until older childhood when they
have developed advanced HIV disease.1,3–5
Facility-based HIV testing is routinely implemented in
most high prevalence settings. However, children encounter
multiple unique barriers in accessing facility-based HIV
testing services including reliance on caregivers to take them,
guardian consent, distance to and costs incurred to access
facilities, and inconvenient opening times coinciding with
school hours.6,7
HIV self-testing (HIVST) using oral mucosal transudate
(OMT) tests has been shown to be effective in reaching
previously hard-to-reach populations including men, adoles-
cents, sex workers, and men who have sex with men.8–10
Benefits of HIVST include privacy and autonomy, decreased
workload for health care workers, and improved access
through community distribution.11
The World Health Organization12 (WHO) already
recommends community-based HIV testing using OMT tests
by lower cadre health care workers, and an extension of this
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would be HIV testing of children performed by caregivers
using OMT. HIV testing for children provided by a caregiver,
if feasible and acceptable, could address the barriers to testing
children,13 thus potentially increasing coverage of HIV
testing among children, and decrease the demands on health
care provider time and potentially be more cost-effective.14
Qualitative studies show that caregivers are willing to
perform HIV testing on their children and believe that this
form of testing has several advantages including privacy,
convenience, control over who knows the child’s status, and
lower costs.13,15 However, some caregivers expressed uncer-
tainty about their ability to test children without assistance
and support from a health care worker.13 Before recommend-
ing HIV testing by caregivers at scale, there is a need to
understand whether HIV testing by caregivers is
performed correctly.
In this study, we evaluated the feasibility and accuracy
of caregivers conducting HIV tests using OMT in children
aged 2–18 years in Zimbabwe.
METHODS
The study was embedded within the Bridging the Gap
in HIV Testing and Care for Children in Zimbabwe (B-GAP)
project conducted between January 2018–May 2019 in 12
primary care clinics: 9 in Bulawayo (urban) and 3 in
Matebeleland South province (rural).16 Adult (aged 15–64)
HIV prevalence is 18% in Bulawayo and 22% in Matebele-
land South.17
The B-GAP project aimed to investigate different
approaches for index-linked testing for children. Index-
linked HIV testing is a strategy whereby an HIV test is
offered to contacts of individuals living with HIV. B-GAP
evaluated 3 approaches for index-linked HIV testing for
children, namely, facility-based testing, home-based testing
performed by a lay worker, or testing performed by a
caregiver using an OMT test.18 This study evaluates testing
performed by caregivers.
Study Participants and Procedures
Study participants were consenting individuals (age $
18 years) living with HIV attending the study clinics for HIV
care who had children (2–18 years) in their household of
unknown HIV status and who selected the caregiver-provided
HIV testing option to test their children. Caregivers had to be
biological parents or caregivers (where parents were not
available). The unknown HIV status was defined as never
having had an HIV test or having a negative test result more
than 6 months previously. Caregivers were provided with
HIV self-test OMT kits (OraQuick ADVANCE Rapid HIV 1/
2, OraSure Technologies Inc.) for each eligible child.19 Each
kit included manufacturer’s instructions in English and the 2
main local languages, Shona and Ndebele. Caregivers were
explicitly told that the HIV OMT test is a screening test and
that a reactive result would require confirmation by a blood
test at the health care facility as per national guidelines.20
Caregivers were also provided with a hotline number to
contact should they have any questions or concerns during the
testing process. All caregivers who took up caregiver testing
were followed up (in person or by telephone).
The study was conducted in 2 phases initially as part of
the main B-GAP study in 2018 (Phase 1) and as an extension
of B-GAP in 2019 to evaluate caregiver testing without
demonstrations (Phase 2).
Phase 1: Caregivers Received Demonstrations
Recruitment in this phase was in 6 urban clinics and 3
rural clinics. From January–December 2018, caregivers who
consented to participate in the study and chose to test their
children using OMT received a demonstration by research
assistants in the clinic of how to perform the HIV self-test
(see Fig. 1, Supplemental Digital Content 1, http://links.lww.
com/QAI/B607). To demonstrate, the research assistants used
the OMT test instruction pamphlets, a dummy test kit, and a
4-minute video on a handheld mobile device. After the
demonstration, caregivers were asked to show the research
assistant how to perform the test using a dummy kit to check
their understanding.
A home visit was scheduled within 5 days for the first
15 caregivers enrolled in each of the 9 facilities. During the
home visit, a member of the research team observed the
caregiver performing the test (direct observation) on each
child. No further demonstrations were provided on the testing
day unless the caregiver asked for assistance. If requested to
do so, the research assistants could provide assistance to
caregivers. All other caregivers were followed up by tele-
phone on day 5 after they had been given the OMT tests to
ascertain the test outcome. If not reachable by telephone,
caregivers were followed up by home visit (up to 2
home visits).
Phase 2: Caregivers Did Not Receive Demonstrations
As most caregivers were able to correctly preform the
test in Phase 1; from January to May 2019, caregivers did not
receive a demonstration in person or by video in the clinic.
Direct observation of the caregiver conducting the test on
their child at home was scheduled for all caregivers. During
this phase, caregivers were discouraged from asking for
assistance from the research assistants but would be assisted
if they requested assistance. Recruitment was in 3 urban
clinics. No rural clinics were included because of
budget constraints.
Direct Observation
Direct observation of caregiver testing was performed
by research assistants during the scheduled home visits. Using
a tablet-based form, research assistants collected data on a
predefined checklist assessing the testing process. The
checklist evaluated caregiver performance for each step
including whether or not the caregiver looked at the
instruction pamphlet, collection of oral fluid from the child’s
mouth, and handling of test kit components such as the buffer
and use of a timer when performing the test. Caregivers were
asked to interpret the OMT test result. For all directly
observed tests, data on whether or not the caregivers
interpreted the test result correctly (according to the manu-
facturer’s guidance) were collected. The research assistants
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also collected data on whether or not the caregivers asked for
assistance, what the assistance was for, and when assistance
was provided.
After preliminarily data analysis, from March 2019, the
research team introduced a more detailed questions asking for
the OMT result interpretation by the caregiver and the OMT
result interpretation by the research assistant (see Fig. 1,
Supplemental Digital Content 1, http://links.lww.com/QAI/
B607). In the initial questionnaire, only the caregiver
interpretation was captured followed by a question about
whether or not this interpretation was correct according to the
research assistant. After March 2019, the questionnaire
captured caregivers’ interpretation of the OMT test result
and in addition the interpretation by the research assistant
(considered the gold standard). For the entire duration of the
study, all children of caregivers who were directly observed
when testing the children had a blood-based rapid HIV test
performed on the child by the research assistant to confirm the
OMT result. All children who tested HIV positive were
referred to their preferred health facility for onward care.
Caregiver performance of conducting the HIV test was
evaluated using 4 indicators which are part of the steps
described in the manufacturer’s instructions19: (1) Correct
collection of oral fluid from the child’s mouth ie, gently swab
completely around the outer gums, both upper and lower, one
time around, using the flat pad; (2) Complete insertion of the
flat pad into the buffer solution ie, making sure that the flat
pad touches the bottom of the vial; (3) Use of a timer during
the test; (4) Correct interpretation of the test result
Each indicator was given a score of 1 if conducted
correctly or 0 if incorrect, with a maximum score of 4. In both
phases, direct observations and data collection were con-
ducted for all tests conducted in the household that is for each
child in the household.
Data Analysis
Analyses were conducted using STATA v15$0 soft-
ware (StataCorp, TX). Categorical variables were summa-
rized as counts (percentages), and continuous variables were
summarized as medians (interquartile range: IQR). Only tests
performed by caregivers who received direct observation
were included in the analysis. These caregivers were grouped
as those who received a demonstration and those who did not
receive a demonstration. We compared 3 key caregiver
characteristics (sex, age, and education level) between those
who received a demonstration and those who did not, using
x2 tests. Similarly, we compared child characteristics (age,
sex, and relationship to the caregiver) by whether the
caregiver received a demonstration or not, using logistic
regression adjusting for clustering by caregiver with robust
standard errors.
Univariable and multivariable logistic regression at the
child level was used to assess factors associated with
obtaining a full score for performance. We adjusted for
clustering by caregiver using robust standard errors.
Ethical Considerations
Ethical approval for this study was obtained from the
Medical Research Council of Zimbabwe and the Institutional
Review Boards of the Biomedical Research and Training
Institute and the London School of Hygiene and Tropical
Medicine. Written informed consent was obtained from all
caregivers. Verbal assent was obtained from children aged
2–7 years. Written assent was obtained from children aged




Between January 2018 and May 2019, 867 children
(54.1% female, median age 8 years, IQR 5–12 years) were to
be tested by 443 caregivers (81.9% female, median age 38
years, IQR 32–45) (Fig. 1). Of the 443 caregivers, 30 (6.8%)
received a demonstration and were not directly observed, 77
(17.4%) received a demonstration and were directly observed,
and 336 (75.8%) did not receive a demonstration and were
directly observed (Fig. 1). Among the 107 caregivers in Phase
1, 10 (9.3%) were from the rural sites. As planned, all 336
caregivers in Phase 2 were from urban clinics, did not receive
demonstrations from the research assistants, and were all
directly observed. Overall, 413 caregivers received direct
observation, and 400 caregivers (96.9%) performed the test
on the children themselves (Fig. 1).
Most of the 400 caregivers who tested their children
were female (83.0%), had secondary level education (75.0%),
and were the biological parents of the children they tested
(70.8%) (Table 1). The median age of these caregivers was 38
years (IQR 32, 45). Receiving a demonstration was associated
with caregiver having less education (P = 0.06) and caregiver
age category (P = 0.06) (Table 1).
Among 808 tests where caregivers were observed,
caregivers performed 786 tests themselves (97.3%) (157
who received demonstration and 629 who did not receive
demonstrations) (Table 2).
The reasons for not performing the test on the remain-
ing 22 children included the child wanted to perform the test
themselves (n = 6), at the point of testing the caregiver said
they could not perform the test (n = 7), and that the child
wanted the research assistant to perform the test (n = 3). Most
of the caregivers who did not perform the test themselves (18/
22, 81.8%) had not received a demonstration. Of the 786
children tested, 54.6% were female, and the median age was 8
years (IQR 5, 12). No child characteristics were associated
with test demonstration (Table 1).
The subsequent analyses focus on the 786 tests
performed by caregivers who were directly observed and
performed the test themselves (Fig. 1).
Performance
For the 786 tests performed by caregivers, caregivers
correctly collected oral fluid for most tests, and this was
associated with receiving a demonstration (87.1% among
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those without a demonstration and 96.8% with a demonstra-
tion, P = 0.002). Among 86 caregivers who did not correctly
collect oral fluid, 35 (40.7%) swabbed either the lower or the
upper gum alone, scrubbed the gums rather than swabbing, or
swabbed both the upper and lower gums more than once.
Other caregiver inconsistencies included swabbing front
gums alone, brushing teeth rather than swabbing, and placing
the flat pad on the tongue or gums. Most caregivers inserted
FIGURE 1. Participant flow chart.
TABLE 1. Demographic Characteristics of Caregivers and Children Who Received Direct Observation and Performed the Test
Themselves, Comparing Caregivers Who Received Demonstrations and Those Who Did Not
Characteristics of Caregivers Who Performed the Test
Total,
N = 400 (%)
Received
Demonstration, N = 74 (%)
Did Not Receive
Demonstration, N = 326 (%) P*
Sex
Male 68 (17.0) 10 (13.5) 58 (17.9) 0.38
Female 332 (83.0) 64 (86.5) 268 (82.2)
Age
18–30 78 (19.5) 10 (13.5) 68 (20.9) 0.06
31–50 267 (66.8) 58 (78.3) 209 (64.1)
.50 55 (13.8) 6 (8.1) 49 (15.0)
Education†
Primary 59 (14.8) 17 (23.3) 42 (12.9) 0.06
Secondary 298 (74.7) 51 (69.9) 247 (75.8)
Tertiary 42 (10.5) 5 (6.9) 37 (11.4)
Characteristics of Children Tested by Caregivers
Total,
N = 786 (%)
Caregiver Received
Demonstration,N = 157 (%)
Caregiver Did Not Receive
Demonstration, N = 629 (%) P‡
Sex§
Male 356 (45.4) 70 (44.9) 286 (45.5) 0.89
Female 428 (54.6) 86 (55.1) 342 (54.5)
Age§
2–5 214 (27.3) 38 (24.4) 176 (28.0) 0.17
6–9 244 (31.1) 43 (27.6) 201 (32.0)
10–15 278 (34.2) 62 (39.7) 206 (32.8)
16–18 58 (7.4) 13 (8.3) 45 (7.2)
Relationship to index§
Biological child 556 (70.8) 99 (63.5) 457 (72.7) 0.12
Nonbiological child 228 (29.0) 57 (36.5) 171 (27.2)
*P-value obtained for x2 tests.
†Education data missing for 1 caregiver.
‡P-value for the child characteristics were obtained from logistic regression adjusting for clustering by a caregiver using robust standard errors.
§Missing data for 2 children.
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the flat pad all the way into the test fluid (97.3% without a
demonstration and 99.4% with a demonstration, P = 0.16).
Most caregivers used a timer during the test. Caregivers who
had received a demonstration were more likely to use a timer
(96.8% with and 90.3% without provider demonstrations, P =
0.02). Interpretation of the test result was correct in almost all
instances (97.3% without a demonstration and 97.5% with a
demonstration, P = 0.84) (Table 2).
Overall, 635/786 (80.8%) tests were performed cor-
rectly on all 4 indicators (490/629–77.9% among those
without a demonstration and 145/157–92.4% among those
with a demonstration) (Table 2). In univariate analysis
adjusting for clustering by a caregiver, having received a
demonstration was associated with performing all 4 indicators
correctly (Table 3). In multivariable analysis adjusting for
clustering by a caregiver, higher level of education when
compared with primary level [secondary odds ratio (OR)
2.51; 95% confidence interval (CI): 1.26 to 4.99 and tertiary
OR 2.82; 95% CI: 0.91 to 8.79; P = 0.06] and receiving a
demonstration (OR = 4.14; 95% CI: 2.01 to 8.50; P , 0.001)
was associated with a full score of 4. Because of their
association with having a demonstration, level of education
and caregiver age category were included in multivariable
analysis. Site (rural vs urban) was not included in this analysis
because no rural clinics were included in Phase 2 of the study.
Test Results and Caregiver Interpretation
All the caregivers with more detailed interpretation data
presented here had not received a demonstration, and
interpretation data were available for 587/786 tests. When
the 587 OMT tests were compared with blood-based test
results, the sensitivity and specificity of the OMT interpreta-
tion by research assistants was 100%. All invalid tests (n = 7)
were HIV negative using blood-based testing. Of the 567
OMT tests deemed nonreactive by the research assistant (ie,
the gold standard), all were identified as nonreactive by the
caregivers (specificity = 100%, 95% CI: 99.4% to 100%;
Table 4). Of the 13 OMT tests deemed reactive by the
caregiver, 4 OMT tests were identified as reactive by the
research assistant (sensitivity 30.8%, 95% CI: 9.1% to
61.4%). In addition, one caregiver read a nonreactive test
as invalid.
Most tests were performed with no assistance from the
research assistants, 608/647 (94.0%) among those who did
not receive any demonstration and 123/161 (76.4%) among
children whose caregiver received demonstrations (P ,
0.001). Most caregivers who asked for assistance did so
when collecting the swab on the child followed by how to
maneuver the packaging and test equipment then reading
the instructions.
All 30 caregivers who did not have direct observation
reported nonreactive results for the 59 children tested.
Ease of Performing the Test
When caregivers who did not receive a demonstration
were asked to score the ease of performing the test from 1 to 5
(1 = very easy to 5 = very difficult), most caregivers reported
that performing the test was very easy (41.2%) or easy
(34.1%). Only 1.6% of caregivers said that performing the
test was difficult. Most caregivers who performed the test
used the manufacturer’s instructions in vernacular (Shona or
Ndebele) (74.9%).
DISCUSSION
Our study findings show that caregivers can perform
oral HIV tests appropriately on their children. Most caregivers
in our study were able to accurately collect oral fluid,
maneuver test kit components, and correctly interpret test
results. We found that prior demonstration of OMT testing by
a provider did improve performance, particularly caregiver’s
ability to correctly swab the child’s mouth and also the use of
a timer while conducting the test. We also found that most
caregivers in our study, who did not receive prior demon-
stration from providers on how to perform the test, felt that
performing the test on their children was easy and usually did
not ask for assistance from a health care worker who was
present to observe them performing the test. Caregivers were
more likely to ask for assistance when they were explicitly
told they could ask for assistance. When discouraged from
asking for assistance most caregivers were able to perform the
test without asking for help. These findings are consistent
with other studies where individual’s ability to perform the
OMT test on themselves has been evaluated in different
settings including in South Africa and Zimbabwe, with over
90% of users being able to correctly interpret their HIV test
result.21,22
Although most caregivers could correctly interpret the
oral HIV test result, some caregivers incorrectly interpreted a
nonreactive OMT test result as reactive, and there were some
invalid test results, likely because of poor performance of the
caregivers in conducting the test. No caregivers incorrectly
interpreted a reactive OMT test result, although it is important
to note that the number of reactive OMT test results was low.
Most errors (incorrectly identifying a nonreactive test as
reactive) would have been picked up in subsequent
TABLE 2. Performance of Caregivers on Each Test Comparing











548 (87.1) 152 (96.8) 0.002
2. Caregiver inserted the
flat pad all the way
612 (97.3) 156 (99.4) 0.157
3. Caregiver used a timer 568 (90.3) 152 (96.8) 0.019
4. Caregiver correctly
interpreted the test result
612 (97.3) 153 (97.5) 0.843
5. Caregiver received a
score of 4/4
490 (77.9) 145 (92.4) ,0.001
*P-value obtained from logistic regression adjusting for clustering by a caregiver
using robust standard errors.
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confirmatory HIV testing at a health care facility according to
WHO HIVST guidelines.23 This, however, requires the
guardian and child to present to a health care facility for
confirmatory testing which may not always be the case. It is
also important to consider the emotional impact of believing
the test result is reactive on the caregiver and their child. This
can be investigated further in operational studies of caregiver-
provided HIV testing. We do note, however, that in Phase 1
of our study, we did have caregivers who took OMT kits
home to test their children and were not observed as would
happen in routine implementation.
OMT testing for HIV is accurate in children and is now
recommended by WHO and international implementing
partners, such as PEPFAR, as a screening test for individuals
aged 2 years and above.14,24 Caregiver-provided HIV testing,
such as self-testing, if rolled out is likely to be performed
independently at home without any providers present. In a
previous qualitative work from our group caregivers have
expressed fears about making a mistake while performing the
test and concerns about not having a health care provider
present to support them; however, all package inserts from the
OMT manufacturer do contain local hotline numbers for
remote assistance.13 This study shows that the most care-
givers can perform the test independently without support
from providers and also without prior demonstrations.
In our formative work, caregivers were also worried
about dealing with negative reactions to an HIV positive
result.13 As with HIVST in adults, concerns about social
harms in the form of intimate partner violence or gender-
based violence are warranted. In HIVST studies among
adults’ social harm reports were infrequent in Malawi.9,25
Our study had a very low HIV prevalence, however, among
TABLE 3. Factors Associated With Obtaining a Full Score for Caregiver-Provided Testing (N = 786)
Characteristic
Obtained a Full Score,
n = 635 Univariate Analysis* Multivariate Analysis†
n (%) OR (95% CI) P OR (95% CI) P
Index level variables
Caregiver’s age
18–30 118 (81.9) 1.42 (0.61 to 3.26) 0.63 1.06 (0.45 to 2.53) 0.81
31–50 424 (81.5) 1.37 (0.68 to 2.76) 0.93 (0.44 to 1.97)
.50 93 (76.2) 1 — 1 —
Caregiver’s sex
Male 101 (80.8) 1 —




Primary 82 (70.7) 1 — 1 —
Secondary 479 (82.3) 1.93 (1.00 to 3.71) 0.12 2.51 (1.26 to 4.99) 0.06
Tertiary 73 (83.9) 2.16 (0.70 to 6.66) 2.82 (0.91 to 8.79)
Received
demonstration
No 490 (77.9) 1 — 1 —
Yes 145 (92.4) 3.43 (1.79 to 6.58) ,0.001 4.14 (2.01 to 8.50) ,0.001
Child level variables
Child’ sex§
Male 288 (80.9) 1 —
Female 345 (80.6) 0.98 (0.69 to 1.40) 0.92
Child’s age,§ yrs
2–5 176 (82.2) 1 —
6–9 192 (78.7) 0.80 (0.51 to 1.23) 0.56
10–15 223 (83.2) 1.06 (0.66 to 1.74)






447 (80.4) 1 —
Biological child 186 (81.6) 0.93 (0.54 to 1.60) 0.78
*Univariate analysis adjusted for clustering by a caregiver.
†Multivariate analysis adjusting for clustering by a caregiver, caregiver level of education, and caregiver age category.
‡Missing data for 1 caregiver.
§Missing data for 2 children.
Dziva Chikwari et al J Acquir Immune Defic Syndr  Volume 87, Number 2, June 1, 2021
786 | www.jaids.com Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
the children tested and those who were diagnosed with HIV
no social harms were reported.
Key limitations of our study design are that demon-
stration was not allocated at random, and hence, the 2 groups
that received and did not receive test demonstration may not
have been comparable. This was due to the sampling strategy
whereby the study was conducted in 2 phases, and an urban
population was oversampled for the group that did not receive
demonstrations. Another limitation of our study is possible
observer bias. Caregivers may have performed the test better
or more confidently because they knew they were observed.
We also note the low number of HIV-positive children in our
study as a limitation precluding any firm conclusion of
interpretation of reactive results. Although our study does
provide the first evidence for this testing strategy, we
recommend further evaluations of caregiver-provided testing
to facilitate collection of good surveillance and operational
data to assess when, if, how, and where to roll out large scale
caregiver-provided testing.
This study shows that task shifting from highly skilled
health workers such as nurses in health facilities to caregiver
may be a feasible strategy for earlier diagnosis of HIV in
children.12 This is a timely approach in the context of the
ongoing COVID-19 pandemic where lockdowns have made it
more difficult to access health facilities for any service
including HIV testing.26 In addition to collection from health
facilities, OMT kits can be distributed in the community as
was piloted in another study in Malawi.27 Another key
consideration for caregiver-provided testing is rapid and
effective home linkage to HIV care for children who test
HIV positive. Concerns about linkage to care in the context of
adult HIVST programs have been raised; however, linkage to
care can be supported in multiple ways including telephone or
community follow-up and provision of incentives.27,28 Evi-
dence is limited, and further studies to assess linkage to and
retention in care for children diagnosed through caregiver
provider testing are warranted.
Acceptability of caregiver-provided testing must also be
assessed. This testing strategy may not be acceptable for all
caregivers because of its novelty which may require sensiti-
zation efforts before scale up. In addition, caregiver-provided
testing may not be suitable for testing older adolescents who
may not want to disclose their own sexual activity to
caregivers.18 Further evaluations of which user groups to
target such as female caregivers reiving antenatal care in
facilities, individuals already receiving care but with untested
children, or individuals newly diagnosed with HIV as is
performed with sexual partner testing may be useful.
The cost-effectiveness of caregiver-provided testing
should also be assessed and should include assessments of
the potential cost savings through reduced skilled health
care worker time in facilities. At scale, health worker time
may involve only distribution of OMT tests to caregivers
from facilities and time to demonstrate OMT test use as
was performed in Phase 1 of our study. In our study, lay
workers with 3 weeks training on HIV testing and HIV
self-testing through the Ministry of Health and Child Care
in Zimbabwe conducted the demonstration thus indicating
feasibility for this to be performed by lower cadre
health workers.
We conclude that caregiver-provided testing is a
feasible HIV testing strategy for children and recommend
further operational research to support implementation
at scale.
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8.1 Research aims and studies conducted  
The aim of this research was to evaluate the approaches for index-linked HIV 
testing for children and adolescents (aged 2-18 years). The following studies 
were undertaken:  
1. Investigation of the acceptability, uptake and yield of index-linked HIV 
testing for children and adolescents offered in facility and community-
based settings.  
2. Exploration of provider and caregiver perceptions and experiences of 
index-linked HIV testing for children.  
3. Evaluation of the diagnostic accuracy of the oral mucosal transudate HIV 
test for children and adolescents  
4. Assessment of the feasibility and accuracy of caregiver provided HIV 
testing for children and adolescents. 
In this chapter, the key findings, the strengths and limitations and the 
implications of the research findings are discussed. The chapter also includes a 
description of how the findings have been disseminated and opportunities for 
future research.  
8.2 Discussion of findings  
8.2.1 Index-linked HIV testing for children and adolescents  
This research showed that almost 40% of children living in the households of 
indexes had not previously been tested indicating an unmet need for HIV testing 
for children. Index-linked HIV testing was an acceptable HIV testing strategy with 
over 87% of indexes accepting HIV testing for their children. These findings are 
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comparable to a study conducted in Malawi in 2014 -2015 that showed that 
64.7% of indexes had a child or a young person (1-24 years) who had not been 
tested living in their household and uptake of HIV testing was also high at 93.5%.1 
Therefore, a targeted HIV testing strategy such as index-linked HIV testing is a 
suitable strategy to reach children living with individuals already in HIV care.  
Only 60% of eligible children were tested in this research; 2424 eligible children 
were not tested during the study for various reasons including refusals from 
indexes and children not found during tracing despite multiple attempts to follow 
up over 21 days from the day HIV testing was offered. As such despite targeted 
efforts, many children and adolescents in this study still remained untested 
possibly due to index fears about an HIV positive diagnosis for their child(ren), 
stigma or feeling that they are not yet ready for the child(ren) to test. It was 
difficult to trace some indexes during follow up as they had given false phone 
numbers and addresses which may have been indicative of indirect refusals for 
the reasons noted previously. It is likely that as HIV testing strategies are scaled 
up, the residual individuals who are not tested are likely to be those that are the 
“hardest to reach” and will require concerted and more resource-intensive 
efforts. One potential strategy is the use of incentives in tandem with index-
linked HIV testing whereby indexes can be offered incentives to bring their 
children for HIV testing. Incentivisation has been used to encourage uptake of 
other public health interventions e.g., immunisation, but does raise ethical 
concerns about coercion.2,3 The considerable risk of leaving a child undiagnosed 
vs the risk of coercion needs to be considered. Also, in the context, of HIV 
infection in children (most likely acquired perinatally and therefore no ongoing 
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risk via sexual transmission until they reach adulthood) incentivisation would be 
a one-off event. Two studies conducted in Kenya and Zimbabwe among children 
and adolescents showed higher HIV testing uptake in groups where an incentive 
for HIV testing was offered.4,5 In the study from Kenya the provision of USD5, 
USD10 and USD15 incentives to mothers for HIV testing of their children younger 
than 12 years of age increased uptake of HIV testing to 73% compared to 14% in 
similar settings with no incentives.5  
8.2.1.1 Facility vs community-based HIV testing approaches  
Facility-based HIV testing was the most preferred method (66% of indexes chose 
facility-based HIV testing) when compared to community-based HIV testing. 
However, many children were later tested in the community (in this study 
indexes who initially chose facility HIV testing but did not present at the facility 
were followed up in the community). 13% of children whose indexes had initially 
chosen facility-based HIV testing were later tested in the community. This 
highlights the benefits of flexibility in test location and offering both facility and 
community-based HIV testing to improve HIV testing uptake. Community-based 
strategies can bring HIV testing closer to the individual, and this study showed 
that this approach is feasible and could be used as a supplementary tool to help 
in improving completion of the HIV testing process. A review of studies 
evaluating index-linked HIV testing e showed there is variation in uptake of 
community vs facility-based HIV testing in different geographical contexts. In 
contrast to this research where the majority (66%) of indexes preferred for their 
children to be tested at the facility, over 95% of tests conducted in Malawi were 
done in the indexes home while in Cameroon 94% of indexes preferred facility-
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based HIV testing and subsequently 82% of children tested were tested in the 
facility.1,6  
This variation may be due to a number of factors including social, cultural and 
contextual factors unique to each country. These factors may include the stigma 
associated with HIV in the country and access barriers such as the distance to the 
nearest health facility in each study setting which were not captured by these 
studies. The quantitative and qualitative findings of this research show that the 
distance and costs an individual needs to travel to access a facility can influence 
test uptake and also their decision to either come to the facility to have their 
children tested or have a provider come to their household to provide HIV 
testing.7 In this study, indexes who had to pay anything to travel to access the 
health facilities were less likely to have a child in their home tested. Furthermore, 
indexes who lived in urban settings, those who had to pay to access a facility and 
those who had been on treatment for longer were more likely to choose 
community HIV testing for the children in their households. Individuals who have 
been on treatment for longer may have already disclosed their HIV status to 
others living in their households and were therefore more comfortable with 
having their child tested in their home. Furthermore, community-based HIV 
testing means that caregivers do not have to bear the additional cost of 
transporting their children to the health facility. An economic modelling analysis 
of the cost-effectiveness of community-based HIV testing in South Africa found 
home-based HIV testing could reduce HIV associated morbidity and HIV 
infections and was subsequently cost-effective.8 A modelling study among 
pregnant women and their male partners in Kenya, also found home based HIV 
  132
testing to be cost effective.9 However, none of these evaluations have included 
young children.  
The findings of this study and the variation observed in the uptake of community 
and facility-based HIV testing highlight both the potential of community-based 
HIV testing strategies to increase uptake of HIV testing for children and 
adolescents but also the need for flexibility and choice to be built into HIV testing 
approaches in relation to the local and individuals' context.  
8.2.1.2 Barriers and facilitators of index-linked HIV testing 
Costs to travel and distance to facilities remain barriers to HIV testing.  However, 
these can be mitigated by the provision of community-based HIV testing 
strategies which have also been shown to be effective in identifying some hard-
to-reach populations such as men in other settings.10 As noted above, offering a 
combination of HIV testing strategies such as facility and community-based HIV 
testing as was done in this research can further increase reach of HIV testing.  
This study showed that female indexes were more likely to have children tested, 
a finding similar to that from a Cameroonian study on index-linked HIV testing 
(60% in Cameroon and 56% in Zimbabwe).6,11 Generally, it is well-recognised 
that men have poorer engagement with health services than women, but they are 
often the gatekeepers in African contexts and have the ability to influence uptake 
of HIV testing for the household, and therefore engaging and targeting men is 
important if HIV testing rates in children are to be improved .12 
Public health programmes often undervalue the human context in which they are 
delivered. The research described in this thesis sought to explore ways through 
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which this targeted strategy can be enhanced to further improve the uptake of 
index-linked HIV testing for children and adolescents by gathering provider and 
index perspectives of the strategy. The findings show that HIV testing for children 
is not a one-off event and should be approached as a process using a family 
centred focus for it to be more acceptable.7 Many caregivers stressed the need to 
consult with other family members and often the adolescents themselves, a 
process which takes time, before having an HIV test. Several studies have 
previously shown that social factors such as the inadvertent disclosure of the 
parents’ HIV status when a child tests positive, concerns about disclosure of the 
child’s status to the wider family or to those outside the family or parental guilt 
about having infected their child impact the decisions of guardians to have their 
children tested. Active discussion and support to navigate these issues by 
providers is crucial to help individuals make a decision.12,13 Our study shows that 
an approach which incorporates support and counselling is important in the 
context of index-linked HIV testing for children. 
This study showed that there is a need to improve the quality and content of 
messaging currently provided on the importance of HIV testing for children and 
adolescents. This research showed that in routine HIV care, indexes are not 
aware of the need for testing their children despite constant exposure to facilities 
and being in care themselves. Often HIV testing for children is not offered. Many 
caregivers in care were not aware that HIV testing for children was available and 
important. Messaging about HIV testing provided in health facilities was not 
specific to children and adolescents and as such caregivers did not engage with 
HIV testing for their children. As such HIV testing for children is not emphasised 
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as an integral part of HIV care for indexes, although it should be. Once caregivers 
became aware of the need for having their children tested, they stressed that the 
“way” in which the providers (study staff) engaged with them and provided 
support to caregivers and their families facilitated them to take up HIV testing 
for their children. In busy HIV programmes, frequent training of health workers 
to focus on the HIV testing of children and facilitate this by supporting caregivers 
needs to be emphasised if index-linked HIV testing is to be effective. Although 
index-linked HIV testing has been recommended in the Zimbabwe National HIV 
Testing Guidelines since 2014 and the procedures defined in the 2015 Zimbabwe 
Operational and Service Delivery Manual for HIV, over 40% of children living 
with an index had not previously been tested.14,15  
8.2.1.3 HIV Testing in older children and adolescents 
Notably, older children and adolescents were also less likely to be tested when 
compared to the younger age groups.6,11 Qualitative research highlighted HIV 
testing barriers specific to older adolescents. Indexes noted that older 
adolescents are also at risk of horizontal HIV transmission but may not have 
disclosed their own sexual activity to their parents or caregivers.  As such an 
index-linked HIV testing strategy, whose premise is that the children of 
individuals who are HIV-infected will be at higher risk of perinatal HIV (due to 
MTCT), indirectly excludes the isosexual sexual risk and is not an ideal strategy 
for identifying adolescents who are at risk of also being infected horizontally. 
This study however adopted a broader approach to the traditional index-linked 
HIV testing in that any child aged between 2-18 years living in the household but 
not necessarily the biological child of an index was eligible.  The rationale for this 
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approach was that there may be a clustering of factors that go beyond biological 
risk (i.e. risk of mother-to-child transmission) that may put children living in 
households with individuals who have HIV at greater risk such as poverty, level 
of education and lack of social capital which have previously been identified as 
determinants of health in the context of HIV.16,17 In addition, testing all children 
in the household circumvents the potential stigma and issues such as inadvertent 
disclosure of HIV status of parents when using a strategy that doesn’t completely 
rely on HIV testing of biological children of individuals with HIV.  
In this research some indexes felt that adolescents should be approached directly 
rather than through their caregivers, in order to respect their autonomy.18 As 
noted above some adolescents may not be disclosing their sexual activity to their 
parents and may fear indirect disclosure of this through the HIV testing process. 
Additional strategies tailored specifically for adolescents, who may be at risk of 
both sexually and perinatally acquired HIV infection, should be evaluated. A 
study conducted in Malawi in 2012 showed that adolescents aged 16-18 years 
where more likely to self-test in the community when compared to older age 
groups which may highlight the adolescent needs and desire for autonomy in the 
HIV testing process.19 The PopART study in Zambia found that community-based 
HIV testing using a door to door approach improved knowledge of HIV status 
from 27.6% to 88.5% among adolescents aged 15-19 years at the end of the 
intervention.20 There is significant social, biological, cognitive heterogeneity 
across childhood and no one size fits all strategy for HIV testing for different age 
groups. HIV testing strategies developed for adults may not be suitable for testing 
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children. Similarly, HIV testing strategies effective for younger adolescents may 
not be effective for older adolescents.  
8.2.1.4 Yield of HIV testing 
The HIV yield was low (0.6%) when compared to other studies of index-linked 
HIV testing in SSA. In Kenya, the HIV yield among children aged 0-14 years who 
had undergone index-linked HIV testing in 2015/2016 was 4.5% and 
significantly higher than that from children tested through PITC (1.6% yield).21  
Similarly in Lesotho index-linked HIV testing yield for children aged 2-14 years 
was 1.4%, again much higher than that observed in other HIV testing models 
(0.4%).22 The findings from Kenya and Lesotho are similar to those from studies 
on index-linked HIV testing in children in Malawi and Cameroon.1,6 The lower 
than anticipated yield among children and adolescents in this study may be due 
to the high coverage of PMTCT programmes in Zimbabwe. In 2018 the proportion 
of pregnant women with HIV accessing ART in Zimbabwe was 94%, compared to 
80% in Cameroon and 77% in Lesotho, which may mean there is a higher 
prevalence of children with HIV, including those who may not have been 
identified by EID in the PMTCT programmes, in those settings.23  Additionally, 
the low HIV yield may potentially be indicative of further barriers in the index-
linked HIV testing approach .  
8.2.1.5 Linkage to care and treatment 
While HIV testing is the first step in the HIV care cascade it is followed by the 
important requisite of linkage to care, retention in care and also viral suppression 
for those who test HIV positive.24 Although my thesis was focused specifically on 
HIV testing I evaluated the rest of the HIV care cascade as part of the main B-GAP 
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study. Among the 39 children who tested HIV positive in this research, 36 
(92.3%) were registered with a facility and initiated on treatment within 12 
months of diagnosis. According to UNAIDS,  globally only 53% of children (0-14 
years) living with HIV were accessing ART in 2019.25 Therefore, linkage to care 
in this study was much higher than global estimates for ART among children. This 
may be due to a home visit intervention delivered to children who tested HIV 
positive as part of the B-GAP study. 
8.2.2 Caregiver provided HIV testing using OMT tests  
This research showed that the OMT test had high sensitivity and specificity 
(100% and 99.9% respectively) when compared to national HIV testing 
algorithms in children aged 2-18 years. This head-to-head comparison of the 
OMT test with rapid blood-based tests used in routine care in ART-naïve children 
had not previously been conducted. Preceding studies evaluating OMT tests use 
were conducted among children on ART or used an enzyme-linked 
immunosorbent assay (ELISA) as the gold standard against which OMT tests 
were compared, which is not used for routine HIV testing.  While comparison 
with the ELISA test can evaluate internal validity, comparison of the OMT tests 
with the rapid blood-based tests that are used for routine HIV testing enables 
evaluation in operational settings. A 2011 study compared the performance of 
oral specimens  to direct blood spot specimens in 1274 children of unknown HIV 
status using ELISA tests; the sensitivity of the oral specimens was only 48.8% and 
the specificity was 98.5%.26 Since 2011, improved OMT tests have been 
developed with better performance and with results available within 20 minutes 
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and subsequently received WHO prequalification as rapid HIV testing device in 
2017. 
Several studies have shown that false negative tests can occur if the OMT test is 
used in those taking ART. A 2016 study from Zimbabwe in 126 children aged 7-
18 years who were known HIV positive and on ART and underwent OMT testing 
found that there was a negative result in 11 (8.5%) of children and was 
indeterminant result for 2 (1.6%) children while the blood-based test was 
negative for only one child.27 Thus further highlighting the potential for false 
negative results in children that are already on ART.  
By July 2017 there was only one OMT test that had received WHO 
prequalification, and only for individuals >12 years.28,29 OMT testing is less 
invasive than blood-based testing and therefore may be more acceptable for 
testing children. It is also easier to administer in community-based settings by 
lay individuals including caregivers.30 
Validation of the OMT test meant this was an additional tool which could be used 
for the diagnosis of HIV in children and younger adolescents. However, the 
performance of the OMT test is also dependent on correct sample collection, 
following correct test procedures and correct test interpretation. The research 
(described in chapter 7) showed that caregivers were able to accurately collect 
the sample and perform the OMT test on their children. Additionally, most 
caregivers were able to correctly interpret the OMT test result although eight 
caregivers incorrectly interpreted non-reactive tests as reactive. These findings 
build on findings from studies which show that adults can reliably and accurately 
self-test for HIV.31 In addition, this research showed that prior demonstrations 
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from providers of how to perform the test can improve performance of HIV 
testing by caregivers. It is important to note that if rolled out at scale, 
demonstrations by providers may not be possible.  
Potential benefits of caregiver provided HIV testing for children and adolescents 
include the privacy and autonomy for caregivers to find out the HIV status of their 
child(ren) first as well as the added convenience whereby HIV testing can be 
conducted in the home and caregivers do not have to travel long distances or pay 
for transportation costs to get their children to a health facility for HIV testing. 
Possible harms include the lack of provider support in the HIV testing process 
particularly if a child has a reactive OMT test in the home.32 A qualitative study 
conducted in Zimbabwe found that caregivers had concerns about their ability to 
perform the test without assistance and were anxious about having a reactive 
test alone. However, they felt counselling and assistance from health providers 
would help in alleviating these concerns.32  
There have been concerns about possible social harms should children be tested 
outside facilities where caregivers (who are often women) do not have the 
additional support during the HIV testing process from health providers.33 
Gender-based violence is well documented and often blame for a child testing 
HIV-positive may be placed on the mother.34,35 In this research no adverse events 
were reported. This is similar to other studies of HIV self-testing among adults 
where minimal adverse events nor major social harms were associated with HIV 
self-testing.33,36 There is a possibility that subtle harms, which may not be easy 
to detect, could occur. These include inadvertent disclosure of the status of the 
parent to a partner or other household/family members who may not know, 
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matrimonial disharmony where either parent can be blamed for the positive HIV 
status of the child, feelings of isolation and stigma within households to the HIV 
positive child.33 
As with any other HIV testing methods, there is also a need to consider the 
onward linkage to care for children who may have reactive OMT results and 
require confirmatory HIV testing and subsequent linkage to care if HIV positive. 
It was not possible to evaluate this in this research due to the low number of 
children who tested HIV positive using this testing strategy. However, as 
discussed above onward linkage to care is an important part of the HIV cascade 
and caregiver testing leaves the responsibility of linkage to care in the hands of 
the caregiver who at the point of HIV testing would not have any provider 
support. Factors such as time to linkage in comparison to facility-based HIV 
testing or any of the other community-based HIV testing approaches needs to be 
assesses as timely linkage to care and ART initiation has significant treatment 
benefits.37  
Another consideration for the scale up of this HIV testing method is the cost 
effectiveness of OMT testing in comparison to routinely used blood-based HIV 
testing. A study from 2016 in Malawi reported that the costs of the OMT test 
makes HIV self-testing a more costly intervention when compared to blood-
based HIV testing.38,39 No cost effectiveness evaluations have been done in the 
context of caregiver provided testing for children and adolescents. This strategy 
may reduce the HIV testing burden on health providers and also reduce costs to 
caregivers who do would not need to incur costs to access health facilities. 
Research on the costs and cost effectiveness of caregiver provided testing in 
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comparison to routinely provided facility and community-based HIV is in 
progress. 
8.3 Strengths and limitations of this research  
The key strengths were that the study was conducted in public sector settings, 
had large sample sizes and included both rural and urban populations. For the 
validation of the OMT test in children data was combined from both Zimbabwe 
and Kenya to increase the power of the study. The research used both 
quantitative and qualitative methods which enabled exploration of context, 
caregiver and provider perceptions of index-linked HIV testing and exploration 
of individual experiences with the HIV testing strategies. 
Limitations of this study were that although all the research was carried out in 
routine healthcare settings, the intervention was implemented by research staff. 
These staff were trained and dedicated to implementing study procedures and 
protocols. It is likely that this would not be the case in real life settings in 
Zimbabwe where health facilities are often understaffed and the staff that are 
present have a heavy workload and multiple roles. This could potentially affect 
their ability to offer index-linked HIV testing or to provide demonstrations of 
OMT tests to caregivers. At protocol design stage, it was proposed that screening 
and HIV testing be provided by clinic staff as well as partner organizations 
working in the community. However, during the formative work it became 
apparent that there were competing priorities for clinic staff and partner 
organizations who were driven by funders’ targets to achieve high HIV yields and 
therefore HIV testing of children was not a priority, with greater efforts being 
towards actively seeking sexual partners of indexes due to the much higher yields 
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of HIV. These operational challenges are likely to persist in routine settings and 
highlight a potential limitation of generalising research findings that evaluate 
public health interventions to routine settings.   
This research was conducted in the Matebeleland region of Zimbabwe which in 
addition to having the highest HIV prevalence nationally in also predominantly 
of the Ndebele tribal group, with distinct sociocultural norms from the Shona 
tribe which may have an impact on health-seeking behaviours and subsequently 
uptake of index-linked HIV testing.40 Factors, such as the highly mobile 
population in the Matebeleland region could have affected uptake of HIV testing 
with many of the biological parents of children living and working in South Africa 
and Botswana, two countries bordering this region where better economic 
opportunities are available. This means that children in this region are often left 
in the care of grandparents or other relatives who sometimes felt they could not 
provide consent for these children to be tested. This is reflected in the 
quantitative data in Research Paper 3 and reiterated in the qualitative findings in 
Research Paper 4.  
Other factors that could limit generalizability include structural factors such as 
configuration of health systems including availability of systems to deliver 
healthcare in community-based settings. Other cultural and social factors such as 
the HIV stigma and discrimination in different settings may affect acceptability 
of these HIV testing strategies.  
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8.4 Contribution of the thesis to improving HIV testing for 
children and adolescents  
This study provides evidence that HIV testing for children in community settings 
can improve HIV testing uptake and that there is an added benefit from the 
provision of both facility and community-based HIV testing strategies. The 
editors of Lancet HIV commissioned an article (Appendix 1) based on Research 
Paper 3 titled, “Rethinking the challenges of paediatric HIV diagnosis”. The article 
highlighted that significant progress should have been made for the diagnosis of 
HIV in infants and children by now but continued efforts are still required to 
improve HIV testing for children and adolescents.41 
The findings from this research show that in this setting facility-based HIV testing 
strategies are preferred but among other groups the provision of and availability 
of community-based HIV testing can improve access and remove cost barriers. 
While HIV testing by lay workers is recommended by WHO, many programmes 
have continued to use only nurses. This study shows that HIV testing by lay 
workers in community-based settings is feasible. Facility-based HIV testing 
should be strengthened as should the provision of index-linked HIV testing for 
children as part of routine HIV care. This will require investment in human 
resource capacity, improved messaging about the importance of HIV testing for 
children as part of routine HIV service provision and prioritisation of HIV testing 
for children as well as training and retraining of providers.  
The finding of the robust performance of OMT tests in children resulted in WHO 
prequalification of OMT tests for HIV screening of children aged 2 -12 years by 
health providers in 2019 (Appendix 2). Findings from Chapter 7 demonstrate the 
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potential for of caregiver-provided HIV testing.42 The Covid-19 pandemic has 
increased the load on health providers, shifted healthcare priorities and made 
access to health facilities for services such as HIV testing difficult due to 
prolonged and restrictive lockdowns.43,44 In this context, the use of OMT  tests by 
caregivers to test their children may help maintain and potentially improve HIV 
testing for children. In April 2020, in response to the COVID-19 pandemic, the 
President’s Emergency Plan for AIDS Relief (PEPFAR) released guidance for 
countries to implement caregiver provided testing so that HIV testing for 
children could continue to be provided in the context of disruptions in health 
service delivery during the pandemic (Appendix 3).  
This research shows that while index-linked HIV testing had high uptake, a 
proportion of children and adolescents still remained untested. There is need for 
ongoing and concerted efforts to ensure that children and adolescents with HIV, 
a vulnerable and hard to reach group, are not left behind if we are to realise our 
collective vision of an “AIDS-free” world. 
8.5 Dissemination  
The findings of this research have been disseminated at local and international 
platforms that included various stakeholders including researchers, study 
participants, national and international policy makers, programmers and donor 
organisations. Summarized below are key fora where I have presented the 
research findings. 
8.5.1 Academic conferences and meetings 
I presented oral and poster presentations during the course of my PhD at the 
following academic conferences and meetings:  
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1. Royal Society of Tropical Medicine and Hygiene, Research in Progress 
Meeting: London 2017 
2. Institute of Continuing Health Education and University of Zimbabwe 
Medical Research Day: Harare 2018 
3. International AIDS Society, HIV Adolescence Workshop: Cape Town 2018 
4. Wellcome Trust Bloomsbury Centre for Global Health Research Scientific 
Meeting: Gambia 2019 
5. International Conference on AIDS and STIs in AFRICA: Rwanda 2019 
6. Conference on Retroviruses and Opportunistic Infections: Seattle 2019 
7. Research Council of Zimbabwe International Symposium: Harare 2019  
8. INTEREST Conference: (Virtual) 2020  
9. London School of Hygiene and Tropical Medicine MRC International 
Statistics and Epidemiology Group (ISEG) meeting: (Virtual) 2021 
 
8.5.2 Dissemination meetings 
During the course of my PhD, I disseminated the preliminary and final research 
findings at the following meetings and directly to the following organizations:  
1. Matebeleland South Provincial Health Team Meeting: Masvingo 2017 
2. Harare Research Group Meeting: Harare 2017 
3. National AIDS Council HIV research meeting: Harare 2018   
4. Médecins Sans Frontières International : (Virtual) 2019  
5. B-GAP Dissemination Meeting: Bulawayo 2020 
6. Zimbabwe – LSHTM Research Partnership Dissemination Meeting:  
Harare 2020  
  146
7. Organization for Public Health Interventions and Development:  
(Virtual) 2020 
8. World Health Organization, Catholic Relief Services, PEPFAR:  
(Virtual) 2020  
In addition, I shared my PhD experiences on the University of London blog and 
the social media platforms of the British Embassy in Zimbabwe where this work 
was spotlighted.  
The findings of my PhD have all been published in peer -reviewed journals 
(which form the basis of this thesis) and a policy brief has also been developed 
(Appendix 4). The policy brief on the topic of caregiver assisted oral HIV 
screening for children will be shared with the Ministry of Health and Child Care 
in Zimbabwe, WHO, CDC, USAID, the Office of the US Global AIDS Coordinator 
(OGAC), and Catholic Relief Services among others.  
8.6 Opportunities for future research  
Opportunities for future research include evaluation of the implementation of 
caregiver provided HIV testing in routine settings. Operational research to assess 
acceptability, feasibility and uptake of this strategy in routine settings and also in 
the absence of a provider will be useful in order to better inform implementation 
at scale and to understand how this strategy can be further targeted, adapted or 
improved.  Potential adaptations could include targeting caregiver provided HIV 
testing to mothers receiving antenatal or postnatal care or targeting this strategy 
only for indexes who are newly diagnosed in settings where index-linked HIV 
testing has already been provided over long periods of time. Furthermore, when 
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implemented as part of future research, components such as linkage to care 
among children who test HIV positive and the rate of social harms through 
community testing by caregivers should be evaluated.  
Studies that evaluate which HIV testing strategies are most acceptable to older 
adolescents as well as studies evaluating how to optimize the current HIV testing 
strategies for adolescents are warranted.   
While index-linked HIV testing can improve uptake of HIV testing the costs of HIV 
testing are a critical consideration for developing policy and programmes. The 
cost implications of using oral HIV test kits which are more expensive when 
compared to rapid blood-based tests, need to be weighed against the cost of 
health provider time.38,39 The costs and cost effectiveness of caregiver provided 
HIV testing for children and adolescents in comparison to routinely provided 
facility and community-based HIV testing by health providers should be 
evaluated.  
8.7 Conclusion  
This thesis has provided evidence for the uptake and yield of index-linked HIV 
testing for children and adolescents in facility and community-based settings in 
Zimbabwe. It has also provided evidence of the diagnostic accuracy of OMT tests 
for children as well a novel HIV testing approach whereby caregivers can 
accurately test their own children for HIV and interpret test results. Additionally, 
this thesis provided an in-depth exploration of some of the barriers and 
facilitators of index linked HIV testing for children which can be used to further 
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improve HIV testing uptake for children and adolescents using this HIV testing 
strategy.  
The research provides timely evidence to guide HIV testing policy makers as well 
as implementers of index-linked HIV testing for a group which currently lags 
behind in terms of HIV testing uptake and where a concerted effort to target and 
improve HIV testing is required.  
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Rethinking the challenges of paediatric HIV diagnosis
Diagnosing infants and children with HIV was supposed 
to have been made easier. Several contact points now 
exist that create opportunities to complete the pae­
diatric diagnosis process, including routine postnatal 
care visits and childhood vaccinations. However, achie­
ving early infant diagnosis in the first few months 
of life has remained one of the lowest global HIV 
programme metrics. In 2019, antiretrovirals were 
delivered to 85% of pregnant women living with 
HIV worldwide, but only 60% of their infants were diag­
nosed at an age early enough to reduce the high rates 
of morbidity and mortality from perinatally acquired 
HIV.1 Chido Dziva Chikwari and colleagues2 sought 
to address this perennial challenge in their study, 
Bridging the Gap in HIV testing and care for children 
in Zimbabwe (B­GAP), on the uptake of facility­based 
and community­based index­linked HIV testing.
The research team developed the study after an 
extensive formal stakeholder engagement process to 
optimise the identification and testing of children and 
adolescents (age 2–18 years) at risk of having undiag­
nosed HIV.3 Their strategy was to focus on households 
with caregivers living with HIV and in HIV care in both 
urban and rural settings, as the index patients of the 
programme. Families were offered three ways for 
their children to be tested: at a formal primary health­
care facility by a health­care provider; in their homes 
by a community health worker; or in their homes by 
the caregivers themselves using an oral fluid test. The 
option to change the method of testing was available 
throughout the study.
Even in the context of this thoughtfully imple mented 
study with a well resourced and experienced research 
team, only 1789 (62·3%) of the 2870 eligible index 
patients had at least one child in their household tested 
for HIV. The main challenge in two­thirds of cases was 
not being able to make contact with the children and 
adolescents, regardless of where or how the testing 
was to take place. The investigators identified factors 
associated with increased rates of acceptance and 
completion of testing that will be useful in guiding 
future efforts. Most notably, families were more likely 
to have their child tested if they chose a community­
based option. However, their 0·6% testing yield 
(39 children testing positive of 6062 eligible children) 
by index­linked testing was lower than expected 
in comparison with other studies. This outcome 
might reflect bias in their tested population or the 
cumulative effect of increasingly successful maternal 
HIV prevention interventions in the country. However, 
these results should not take away from the linkage 
of 36 (92%) children who tested positive for HIV in 
the study to HIV care, representing a triple dividend 
of healthier adolescents who will become adults and 
future parents. Furthermore, we should take note 
that the median age of children testing positive was 
11 years (IQR 8–15), which shows that the majority 
were adolescents with perinatally acquired HIV who 
were previously missed by the health care system.4
The B­GAP study shows that a differentiated HIV 
testing approach and task­shifting model (between 
health­care providers, lay health workers, and care­
givers) can be successfully used to diagnose children 
and adolescents who were lost in the traditional health­
care system. In addition, to reach UNAIDS targets for 
paediatric HIV testing and care,5 we can and should 
allow for increased patient­driven flexibilities at several 
decision points. As informed by the study findings, we 
must become more comfortable as health­care pro­
viders, implementers, and policy makers with what 
is essentially self­testing in the context of paediatric HIV, 
in which a caregiver can administer a HIV test to their 
child in their home. The findings of Dziva Chikwari and 
colleagues are valuable clues to closing the gaps in the 
global paediatric prevention and treatment cascade.
Untested HIV­exposed children and adolescents 
represent some of the hardest to reach at­risk popu­
lations in low­income and middle­income country 
settings.6 The B­GAP study reminds us that any 
intervention to improve paediatric HIV testing needs 
to appreciate the complex dynamics around parent­
to­child HIV transmission, the consequences of 
orphanhood, and the financial burdens associated with 
accessing health care. To achieve an AIDS­free future for 
children, we must work from both ends of the paediatric 
age spectrum; by focusing on early infant diagnosis 
around the perinatal period, and by redoubling our 
efforts to find older children and adolescents who have 
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9.4 Appendix 4: Accuracy, Acceptability, Feasibility, and Safety 
of Caregiver-Administered HIV Testing of Children Using 




 !"#$%&%#'  ()$&*+$,-./(.+,*%0$."$,1$%.234.",-5%67,8!$2"%9,*%.%:$",4%&.!.$",;"$!4!9,<%"%=%,>!/9,?$.%"9,?%&2(%,8!%9.,(.9.,%2$%(1,!(,*#2$,6"%$%&!%0()@%A$,?%&"%((,B./%,0%-$%9!,$$",%%,:%&.@7,;$%%@%$,.%;%,6$."+$,;.1$%9%%!%@$&%'
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